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vThesis Summary
Bipolar disorder (BD) is a fairly common, highly heritable psychiatric disorder 
which can be highly disabling to those who suffer from it. There is a limited 
understanding of early precursors to BD that might be helpful to inform 
prediction models and knowledge of aetiology. Few population-based 
longitudinal studies have examined associations between measures of 
childhood psychopathology/cognitive functioning and BD, or phenotypic 
manifestations of increased genetic risk for BD in childhood. 
I investigated whether childhood psychopathology and cognitive domains 
examined from ages 8-11 years were associated with hypomania examined at 
ages 22-23 years. I then conducted a systematic review to identify phenotypes 
associated with genetic risk for BD, measured using a polygenic risk score 
(PRS) approach. Finally, I investigated whether increased genetic risk for BD, 
using a BD-PRS, was associated with various psychopathology and cognitive 
domains in childhood and hypomania in young adulthood.
Findings from Chapter 4 suggest that borderline personality disorder (BPD) 
traits in childhood are strongly associated with hypomania, particularly the ‘risk-
taking/irritable’ factor. Better performance in the domains of working memory, 
problem solving ability, verbal learning and emotion recognition are also 
associated with hypomania, with stronger association with the ‘active/elated’ 
factor (Chapter 5). Findings from Chapter 6 highlight a limited literature on 
phenotypic manifestations of increased genetic risk for BD in 
childhood/adolescence. Individuals with increased genetic risk for BD are more 
likely to have ADHD, and have poorer executive functioning, processing speed 
and performance IQ in childhood (Chapters 7 and 8). 
This thesis adds to a limited literature examining associations between 
measures of childhood psychopathology/cognition and hypomania in the 
general population, and about how increased genetic risk for BD is manifest in 
childhood/adolescence. Further work to examine the robustness of these 
vi
findings in other populations at various stages of development are required, and 
to elucidate the mechanisms that underlie the associations observed.
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1Chapter 1: General Introduction
This thesis aims to inform understanding of the aetiology of bipolar disorder 
(BD) and the manifestations of BD genetic risk during childhood/early 
adulthood. This will be done using the population-based birth cohort the Avon 
Longitudinal Study of Parents and Children (ALSPAC). This first chapter will 
introduce the history of BD, its current nosology, known risk factors and the 
evolution of genetic studies of BD. 
1.1 A short history of BD
The origins of BD can often be linked back to Hippocrates who is credited as 
the first person to systematically describe mania and melancholia, though it was 
Aretaeus of Cappadocia who began meticulously detailing symptoms in the 
medical field, particularly emphasizing the biological origin of melancholia. Up to 
the 19th century, mania and melancholia were considered as two separate 
disorders that encompassed a variety of syndromes. It was not until the 1850s 
when both Jean-Pierre Falret and Jules Baillarger described states of mania 
and melancholia as “la foile circulaire” meaning the circular insanity and “folie à 
double forme” (double insanity) respectively, in which the two mood states were
linked. However, it is Emil Kraepelin, often labelled as the “father of modern 
psychiatry”, who detailed the differences between manic-depressive insanity
and dementia praecox (now termed schizophrenia (SZ)). He made a clear 
distinction between the features of manic-depressive insanity and dementia 
praecox, namely that manic-depressive insanity had an episodic nature, more 
benign prognosis and often presented in individuals with a history of manic-
depressive illness. Dementia praecox on the other hand was characterized by 
disordered intellectual functioning, constant deterioration and poor prognosis 
(Angst and Marneros 2001; Angst 2002).
The term BD was first used by Karl Leonhard in 1957. He proposed a system 
which extended beyond a clinical description. As an example, he observed that 
within manic-depressive illness, some individuals had a history of both 
depression and mania, whilst others had a history of depression only. He also 
2reported that those with a history of mania had a higher incidence of mania in 
their families compared to those with recurrent depression only. He classified 
phasic psychoses into pure and polymorphous forms. The pure forms included: 
pure melancholia, pure mania, pure depressions and pure euphorias whilst
polymorphous forms included: manic-depressive psychosis and the cycloid 
psychoses: anxiety-happiness psychosis, excited-inhibited confusion psychosis 
and hyperkinetic-akinetic mobility psychosis (Teichmann 1990). 
1.2 Classification of BD 
BD is a neuropsychiatric disorder characterised by recurrent changes in mood 
(mania, hypomania, depression or mixed episodes), energy and activity levels. 
The clinical presentation of BD is heterogeneous and differs from person to 
person, though there are nevertheless 4 main types of BD in the Diagnostic and 
Statistical Manual 5 (DSM 5): i) BD type I (BD-I) is characterised by 
experiencing a single episode of mania (lasting at least 1 week, or any duration 
if hospitalisation is required), ii) BD type II (BD-II) is characterised by 
experiencing at least one episode of hypomania (lasting at least 4 consecutive 
days, and present most of the day, nearly every day) and at least one episode 
of depression, iii) cyclothymia which is characterised by symptoms of 
hypomania and depression occurring for at least 2 years but these symptoms 
do not meet diagnostic criteria for a full episode of hypomania and/or 
depression, and  iv) BD not otherwise specified (American Psychiatric 
Association 2013). It is therefore likely that there is a continuum of experiences 
ranging from normal mood to elevated mood but not meeting criteria for 
hypomania, hypomania and then mania being the most extreme experience. A 
number of studies have examined the underlying factor structure of hypomania, 
with suggestions of a dual structure (Hantouche et al. 2003; Angst et al. 2005a; 
Hantouche and Akiskal 2006; Brand et al. 2011). On the one hand, there are 
those who predominantly experience increased euphoria and energy-related 
symptoms (termed as “sunny-side” hypomania), and on the other hand those 
who predominantly experience more risk-taking and irritablity symptoms 
(termed as “dark-side” hypomania) (Hantouche et al. 2003; Brand et al. 2011).
In this thesis, one of my main outcomes is hypomania which will be examined 
dimensionally (in line with Research Domain Criteria (RDoC) guidelines (see 
3section 1.2.2), and categorically (conforming more to the International 
Classification of Diseases-10 (ICD-10) criteria for bipolar affective disorder, 
current episode hypomanic (World-Health-Organisation 1993). 
1.2.1 Issues with the current classification systems
The Kraepelin view of a clear distinction between SZ (dementia praecox) and 
BD (manic-depressive insanity) is still present in the modern classification 
systems (DSM-5 and ICD-10), despite some obvious overlap in symptom profile 
(e.g. presence of psychotic symptoms) between both disorders. A major 
criticism of current classification systems for diagnosing BD is that they rely 
exclusively on behavioural observations of the pattern and type of symptoms 
(i.e. they are a subjective and not objective way of defining someone as 
experiencing BD). This means there are often patients who do not “fit” into the 
clearly defined categories of BD or SZ, and often end up either classified under 
the “not-otherwise specified” category, or within other diagnostic groups e.g. 
schizoaffective disorder (Vieta and Phillips 2007; Phillips and Kupfer 2013). 
Using a categorical clinical diagnosis approach has its merits to inform 
communication between clinicians and appropriate treatment, however, their 
use in research, aimed at understanding the biological basis of psychiatric 
disorders and informing classification is more limited. Therefore, an alternative 
approach is to focus on dimensional measures of psychopathology, in which 
clinical diagnoses would be the extreme end of a distribution of traits in the 
general population (Craddock and Owen 2010). By adopting a dimensional 
approach, the sharp boundaries between meeting criteria for the disorder or not 
are removed, under the assumption that the dimensional approach also 
captures severity of impairment and chronicity. This may lead to addressing a 
common weakness of categorical clinical diagnosis and could help with the 
under-recognition, and therefore under-diagnosis, of bipolar disorders more 
generally (Angst et al. 2010; Angst et al. 2011). 
1.2.2 The Research Domain Criteria (RDoC)
In an attempt to further progress in research on pathophysiology in the areas of 
Genomics and Neuroscience, the National Institute for Mental Health proposed 
4a framework, the RDoC (Insel et al. 2010). In a commentary piece clarifying the 
goal of the RDoC, the author wrote: “RDoC’s ultimate goal is precision medicine 
for psychiatry – a diagnostic system based on a deeper understanding of the 
biological and psychosocial basis of a group of disorders that is unambiguously  
among the most disabling disorders in medicine” (Insel 2014).
The RDoC framework has three assumptions: i) mental illnesses are brain 
disorders, which unlike neurological disorders, can be identified as disorders of 
brain circuitry, ii) abnormal neural circuitry can be identified using various 
clinical neuroscience methodology e.g. functional neuroimaging, and iii) data 
produced from research using the RDoC will identify “biosignatures” (Insel et al. 
2010). At the most basic level, the RDoC is a 2-dimensional matrix, in which, 
each row represents a given behavioural/neurobiological domain (negative (e.g. 
response to adverse fear such as anxiety), positive (e.g. response to positive
scenarios such as reward-seeking behaviour), cognitive (e.g. all cognitive 
processes), social processing (e.g. how you relate to other people including 
perception and interpretation) and arousal/regulatory system (e.g. regulation of 
systems for energy balance and sleep)), and each column the unit or 
measurement used to assess that domain (genes, molecules, cells, circuits,
physiology, behaviour, self-report measure and paradigms). A completed 
version of this is shown in Table 1, with generic examples of units of analysis 
provided for each of the RDoC constructs (Morris and Cuthbert 2012). For a full 
list of potential units of analysis which can be used to investigate each of the 
constructs, the reader is directed to:
https://www.nimh.nih.gov/research/research-funded-by-
nimh/rdoc/constructs/rdoc-constructs-with-units-of-analysis.shtml
5Table 1 Research Domain Criteria Matrix
a Research Domain Criteria guidelines as of May 2017 have guarded against referencing to specific genes within the RDoC matrix, hence this column being left 
blank; Examples provided in the respective columns are generic and taken from the RDoC website https://www.nimh.nih.gov/research/research-funded-by-
nimh/rdoc/constructs/rdoc-constructs-with-units-of-analysis.shtml; BDNF: Brain Derived Neurotrophic Factor; GABA: Gamma aminobutyric acid; FMRP: Fragile X 
Mental Retardation Protein; SCN: Suprachiasmatic Nucleus
Unit of analysis
Domain/construct Genesa Molecules Cells Circuits Physiology Behaviour Self-report Paradigms
Negative BDNF GABAergic cells
Autonomic 
nervous system Context startle Avoidance
Fear survey 
schedule
Fear 
conditioning
Positive Dopamine Dopaminergic neurons Amygdala
Cortical slow 
waves
Reward-
related 
speeding
Affective 
forecasting
Drifting Double 
Bandit
Cognitive Acetylcholine Pyramidal cells
Posterior parietal 
cortex Pupillometry
Impulsive 
behaviour
Conner’s 
impulsivity 
scale
Antisaccade
Social processing FMRP Mirror neurons
Amygdala-
brainstem
Local cerebral 
blood flow
Implicit 
mimicry
Face 
dimensional 
ratings 
scales
Penn emotion 
recognition
Arousal/regulatory 
systems Serotonin
SCN “clock” 
cells SCN core/shell Neural activity
Sleep-related 
and waking 
behaviours
Sleep diary Longitudinal actigraphy
6Naturally, as with any tool, there are also criticisms with using the RDoC which 
are broken down into 4 key points: i) The RDoC places an overemphasis on 
biological units and measures, ii) there appears to be a neglect of consideration 
of measurement error, iii) the limitations of biological and psychometric 
endophenotypes, and iv) the distinction between biological predisposition to 
psychopathology and the behavioural manifestations of that psychopathology 
(Lilienfeld 2014). The ideal scenario is one in which categorical diagnoses 
incorporate information from dimensional measures of psychopathology. One 
such model has been proposed by Owen and colleagues, in which the clinical 
syndromes of mental retardation, Autism Spectrum Disorder (ASD), SZ, 
schizoaffective disorder and BD exist on a continuum. These clinical syndromes 
also lie on the neurodevelopmental impairment gradient, depending on the 
relative contributions of genetic and environmental risk (Owen 2014).
1.2.3 Impact of BD and pharmacological treatment  
BD has a substantial impact on both the individual and society, with evidence 
from several studies reporting that unemployment, impaired friendships/social 
withdrawal and impaired functional recovery were common in those with BD up 
to 15 years after initial onset of symptoms (MacQueen et al. 2001; Dean et al. 
2004; Conus et al. 2006). More broadly, these impairments also affect overall 
quality of life. Two systematic reviews on health related quality of life have 
reported those with BD (including during euthymia), when compared to the 
general population, have lower quality of life (Dean et al. 2004; Pascual-
Sanchez et al. 2019). 
A study in 2010 used data from the World Health Organisation’s 2004 Global 
Burden of Disease study and reported that BD was the 4th highest leading 
cause of disability adjusted life years (DALYs), accounting for 3.8% of the total 
DALYs globally in the 10-24 years age group. This study also reported that 
neuropsychiatric disorders more generally accounted for 45% of years lost to 
premature mortality in the 10-24 years age group (Gore et al. 2011). In 2013, 
using data from the Global Burden of Diseases, Injuries, and Risk Factors 
Study, BD accounted for 7% of DALYs for all mental and substance use 
disorders, and was greatest between the age ranges 25 to 29 years of age 
7(Whiteford et al. 2013). A study using a further 3 years of data reported that 
amongst all mental and substance use disorders, BD was the 5th leading cause 
of DALYS, and accounted for 5.7% of the burden due to a mental or substance 
use disorder (Ferrari et al. 2016). 
Current pharmacological treatment options tend to involve a combination of 
mood stabilisers, antipsychotics and antidepressants (Lopez-Munoz et al. 
2018). When treating acute mania, antipsychotics are particularly effective, with 
evidence from meta-analysis suggesting haloperidol, risperidone and 
olanzapine being the most effective (Cipriani et al. 2011). When considering the 
most effective long term pharmacological treatment, evidence suggests the use 
of lithium carbonate, or lithium carbonate in combination with valproate 
(Goodwin et al. 2016). Unfortunately, even with treatment, up to one third of 
patients relapse into depression or mania within a year, with that figure rising to 
as high as 60% within 2 years (Gitlin et al. 1995). Effective treatments for the 
depressive phases of BD illness are under-researched, in spite of depression 
occurring more frequently than episodes of (hypo)mania (Solomon et al. 2010). 
Antidepressant monotherapy has the potential to cause a reverse in mood i.e. 
switch from depressed mood to (hypo)manic mood. However, as highlighted by 
the International Society for BD, this risk of mood switching appears to be 
higher in those with BD-I than with BD-II (Pacchiarotti et al. 2013). There is 
some evidence to suggest treatment using fluoxetine in combination with 
olanzapine being an efficacious option (Tohen et al. 2003; Taylor et al. 2014), 
though the Food and Drug Administration also suggest that Quetiapine or 
Lurasidone (monotherapy or in combination with lithium or valproate) may be 
used to treat bipolar depression (Shen 2018). Nevertheless, there are concerns 
over the limited efficacy of antidepressant use in the treatment of bipolar 
depression, with evidence from meta-analysis indicating its efficacy is no 
different from placebo (Sidor and MacQueen 2012; McGirr et al. 2016).
The episodic nature of BD can make its treatment difficult, especially in its early 
phases. It is clear that even though approved pharmacological treatments have 
efficacy, a substantial proportion of individuals will experience relapse in mood 
even with drug adherence. 
81.3 Epidemiology of BD 
A large-scale study of 61,392 community adults from 11 countries reported 
lifetime risk estimates for BD-I (0-1.0%), BD-II (0-1.1%), sub-threshold BD (0.1-
2.4%) and bipolar spectrum (0.1-4.4%). The highest lifetime risk estimates 
irrespective of which BD type are in the United States, with lowest estimates in 
India (Merikangas et al. 2011). It is possible that international variations in 
lifetime risk might be attributed to differences in diagnostic criteria, cultural 
factors, ethnicity and study methodology (Rowland and Marwaha 2018). 
A review (Diflorio and Jones 2010) reported little evidence of differences in 12-
month prevalence of BD-I between males and females in 9 studies using data 
from Canada (Bland et al. 1988a; Bland et al. 1988b), the USA (Weissman et al. 
1988; Weissman et al. 1996; Grant et al. 2005), Taiwan (Hwu et al. 1989), 
Korea (Lee et al. 1990), Australia (Mitchell et al. 2004), and New Zealand (Wells 
et al. 2006), but that 3 studies found higher 12 month prevalence of BD-II in 
women (Cassano et al. 1992; Baldassano et al. 2005; Schneck et al. 2008). A 
systematic review reported inconsistent evidence of differences in prevalence of 
BD based on ethnicity, which the authors proposed might be attributed to 
different levels of misdiagnosis as having SZ among different ethnicities, or that 
variations relate to different levels of migration across ethnic groups (Tsuchiya 
et al. 2003). 
There is substantial clinical heterogeneity in those with BD, and one method to 
reduce this heterogeneity is to study individuals who share specific 
characteristics. One characteristic that has received substantial attention is age 
at onset of BD symptoms. Determining an accurate age of onset of first 
symptoms of BD can be difficult, particularly as patients are more likely to seek 
help when experiencing symptoms of depression than symptoms of 
(hypo)mania (Angst et al. 2005b; Fritz et al. 2017). This means an accurate 
diagnosis can be delayed by as much as 10 years after first presentation of 
symptoms of BD (Ghaemi et al. 2002; Baethge et al. 2003). Studies reporting 
data on age of onset of BD often base this on the age at which the BD patient 
accessed appropriate clinical services e.g. age when they were admitted to 
hospital, age at when they received a diagnosis, or age when they first received
9treatment for BD, rather than the age the individual was when they first 
experienced BD symptoms (see Table 2).
A number of studies have examined age at onset of BD, with some studies 
reporting a two-peak, and others a three-peak distribution for age at onset. In 
those reporting a bimodal distribution, findings from large population-based 
cohorts report the peak age of onset ranges are: early (between ages 15-24 
years) and late (between 35-54 years) (Schurhoff et al. 2000; Carter et al. 2003; 
Kroon et al. 2013; Manchia et al. 2017). For studies that have used admixture 
analysis, 3 peaks for age at onset for BD-I have been reported: early (mean age 
of ~17 years), intermediate (mean age of ~26 years) and late (mean age of ~ 
35-46 years) (Bellivier et al. 2001; Bellivier et al. 2003; Lin et al. 2006; Manchia 
et al. 2008; Hamshere et al. 2009; Tozzi et al. 2011). It is yet to be determined 
as to whether a bimodal or trimodal distribution best fits data on age at onset of 
BD symptoms, and which threshold(s) are optimal for investigating clinical and 
genetic differences between subgroups based on age at onset. As shown in 
Table 2, sample sizes have been relatively small, and therefore potential 
differences between age at onset estimates may be due to chance attributed to 
low statistical power as opposed to true effects (Depp and Jeste 2004; Chu et 
al. 2010). Nevertheless, there is some evidence, albeit inconsistent, that 
compared to late-onset BD patients, early-onset BD patients have: i) more 
psychotic features (hallucinations and/or delusions), ii) higher familial loading for 
BD, iii) a longer time to accurate diagnosis, iv) more hospital admissions, v) a 
greater number of suicide attempts, and vi) a greater comorbidity with 
substance abuse and panic disorder (Schurhoff et al. 2000; Leboyer et al. 2005; 
Azorin et al. 2013).
10
Table 2 Summary of studies examining age at onset of BD
Study Diagnosis Country Sample size
How age at 
onset was 
defined
Age at
onset 
(years)
Schurhoff et 
al. 2000
DSM-IV BD-I 
and BD-II, 
and RDC BD
France 211
Age at 
diagnosis, 
age at 
treatment and 
age at first 
hospitalisation
Early (15.5); 
Late (48.5)
Bellivier et al. 
2001 DSM-IV BD-I France 211
Age at 
diagnosis
Early (16.9); 
Mid (26.9); 
Late (46.2)
Bellivier et al. 
2003 DSM-IV BD-I 
France, 
Switzerland, 
Germany and 
Ireland
368 Age at diagnosis
Early (17.6); 
Mid (24.6); 
Late (38.2)
Carter et al. 
2003
DSM-IV BD-I 
and BD-II Canada 319
Age at 
diagnosis
Early (14.6); 
Late (26.1)
Perlis et al. 
2004
DSM-IV BD-
I, BD-II and 
BDNOS
USA 983 Age at diagnosis
Early (<12); 
Mid (13-18); 
Late (>18)
Lin et al. 
2006
DSM-III-R 
BD-I, SZA 
and RDC 
BD-II
USA 211
Self-report of 
onset of first 
symptoms
Early (16.6); 
Mid (26.0); 
Late (34.7)
Kessing et al. 
2006 ICD BAD Denmark 1,719
Age at 
contact with 
clinical 
services
Early (<50); 
Late (>50)
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Table 2 continued
DSM-IV: Diagnostic and Statistical Manual-IV; DSM-III-R: Diagnostic and Statistical Manual-III-
Revised; BD-I: Bipolar Disorder type I; BD-II: Bipolar Disorder type II; SZA: Schizoaffective 
Disorder; BDNOS: Bipolar Disorder Not Otherwise Specified; BAD: Bipolar Affective Disorder 
RDC: Research Diagnostic Criteria; ICD: International Classification of Diseases
1.4 Aetiology of BD 
BD is a complex multifactorial disease whereby neither genetic nor 
environmental risk alone determine whether someone develops BD or not. In 
the next few sections, I will be describing evidence pertaining to the role of 
genetics, environment (pre, peri and post-natal), psychopathology and 
cognition. 
Study Diagnosis Country Sample size
How age 
at onset 
was 
defined
Reported 
mean age of 
onset/age at 
first episode 
(years)
Subramaniam 
et al. 2007 ICD 10 BAD UK 50
Age at 
diagnosis
Early (31.0); 
Late (72.0)
Manchia et al. 
2008 RDC BD-I Sardinia 181
Age at 
diagnosis
Early (18.1); 
Mid (24.3); 
Late (41.0)
Hamshere et 
al. 2009 DSM-IV BD-I UK 1,369
Age of first 
impairment 
due to 
mood 
episode
Early (18.7); 
Mid (28.3); 
Late (43.4)
Tozzi et al. 
2011
DSM-IV BD-I 
and BD-II or 
ICD-10 BD
Canada and 
the UK 964
Self-report 
of onset of 
first 
symptoms
Early (16.1); 
Mid (25.4); 
Late (32.2)
Kroon et al. 
2013
DSM-IV BD-I 
or BD-II
The 
Netherlands 649
GP 
records
Early (15-24); 
Late (45-54)
Manchia et al. 
2017
DSM-IV-TR 
BD I, BD-II or 
BDNOS
Italy 515 Age at diagnosis
Early (21.9);
Late (37.6)
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1.4.1 Genetic studies of BD
Family, twin and adoption studies are different approaches used to estimate the 
effect of environment and genetic influences on a particular disorder/trait in 
individuals who differ in their degree of biological relatedness. 
1.4.1.1 Family studies
Family studies aim to answer a simple question: Does the prevalence of the 
disorder among first degree relatives (FDRs) of affected probands differ from 
the prevalence in the general population or amongst relatives of unaffected 
probands? If this is true, the question arises as to whether this is due to genetic 
or environmental factors, or both. 
Family studies prior to 1960 did not distinguish unipolar from BD, instead 
following the Kraepelinian definition of manic-depressive illness. Nevertheless, 
these studies were consistently reporting an excess risk (4.8-15.8%) of manic-
depressive disorder in the FDRs of manic-depressive probands (Tsuang and 
Farone 1990). Post 1960, with collaborations between centres, a series of 
standardised instruments for assessing affective disorders was developed 
(Feighner et al. 1972; Spitzer et al. 1978). Following this refinement, numerous 
family studies were consistently reporting excess risk of BD among FDRs of 
affected BD probands compared to either FDRs of controls or the population 
baseline risk of 1% (Tsuang et al. 1980; Weissman et al. 1984; Maier et al. 
1993; Craddock and Jones 1999). The lifetime risk of BD in FDRs of BD 
probands has been reported to be between 7-10, which is 7-10 times that of the 
general population of 1-2% (Barnett and Smoller 2009). There is also some 
evidence to suggest both the BD-I and BD-II subtypes might be partly, but not 
entirely genetically distinct. Several studies have reported the risk of BD-II is 
higher in the FDRs of BD-II probands than FDRs of BD-I probands, and risk of 
BD-I is higher in FDRs of BD-I probands than FDRs of BD-II probands (Gershon 
et al. 1982; Andreasen et al. 1987; Heun and Maier 1993; Song et al. 2018). 
Several of these studies also suggest that FDRs of BD probands are also at 
increased risk of depression when compared to FDRs of controls (Gershon et 
al. 1982; Heun and Maier 1993).
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Whilst initial family studies used clinically-ascertained samples, these often had 
relatively small sample sizes. A shift towards using national registers and linking 
with hospital records provided larger sample sizes and validated earlier findings. 
A study using data from two Swedish national registers from 1947 reported the 
relative risk (RR) for BD when the proband had BD or SZ for a number of 
different possible relationships. Increased risk of BD to FDRs was strongest for 
parent-offspring (RR = 6.4) and full sibling relationships (RR = 7.9), a result 
which is similar for SZ if the proband has SZ (RR = 9.9 for parent-offspring and 
RR = 9.0 full sibling relationships) (Lichtenstein et al. 2009). Later studies also 
using the same Swedish data as that from Lichtenstein and colleagues but 
longer follow-up have also reported excess risk of BD among FDRs for BD 
(Song et al. 2015; Chen et al. 2019), Attention Deficit Hyperactivity Disorder 
(ADHD) (Larsson et al. 2013) and ASD (Sullivan et al. 2012). 
Other studies have examined risk for other psychiatric disorders in FDRs of BD 
probands and reported increased RR and/or odds of disease for SZ, MDD, 
ASD, ADHD, personality disorders and drug abuse (Song et al. 2015; Song et 
al. 2018; Chen et al. 2019), as well as the possibility of a dose-dependent 
relationship between risk for psychiatric illness and number of BD probands in 
FDRs. In brief, the greater the number of probands with a BD diagnosis a FDR 
has, the greater the increase in risk of psychiatric illness in the FDR  
(Gottesman et al. 2010; Chen et al. 2019). 
1.4.1.2 Twin studies 
Though family studies are consistent with a genetic component to BD, it is not 
possible to distinguish this from environmental contributions to BD. To try 
estimate this, classical twin research comparing concordance rates between 
monozygotic (MZ) and dizygotic twins (DZ) is used. MZ twins are assumed to 
share 100% of their genome, whilst DZ twins share on average 50%. It would 
be expected that there is a greater concordance rate for the genetic component 
in MZ twins compared to DZ twins. However, this is based on the equal 
environment assumption. The assumption is that shared environmental 
influences on MZ twins are not different from the shared environmental 
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influences on DZ twins i.e. MZ twins are not treated more similar than DZ twins 
throughout the life course (Fosse et al. 2015). 
In a similar fashion to early family studies, early twin studies (pre-1960) also 
had a number of methodological shortcomings including lack of blinded study 
design, small sample sizes, non-specific structured assessments in diagnostic 
procedures and not distinguishing between unipolar disorder and BD (Tsuang 
and Farone 1990). Nevertheless, there was consistent evidence of higher 
concordance rates in MZ twins compared to DZ twins. 
Much like with family studies, there was a shift towards using large population-
based registers from the 1970s onwards (Allen et al. 1974; Bertelsen et al. 
1977; Torgersen 1986; Kendler et al. 1995; Cardno et al. 1999; McGuffin et al. 
2003; Kieseppa et al. 2004). There was also a shift towards using operational 
diagnostic criteria as opposed to the narrow Kraepelinian definition of manic-
depressive illness. Concordance rates for studies published post 1970 range 
from 20-75% for MZ twins and 0-20% for DZ twins. From the available 
evidence, it is clear that genetics plays a substantial role in determining whether 
someone goes on to develop BD. Heritability estimates based on a recent twin 
study using data from the Swedish Twin Registry suggest heritability to be 
between 50-70% (Johansson et al. 2019). 
1.4.1.3 Adoption studies 
Adoption studies seek to estimate the extent to which variation in a given trait is 
due to environmental and genetic influences. Unlike the situation for SZ
(Ingraham and Kety 2000), adoption studies for BD are few and with small 
sample sizes (Smoller and Finn 2003). One method that has been used is the 
adoptees’ relative method which compares rates of BD between biological and 
adoptive relatives of adoptees with BD (probands). Rates of affective illness 
(BD, unipolar, schizoaffective disorder and cyclothymic disorder) in the 
biological parents of probands was higher (31.6%) than rates in the adopted 
parents (12.2%) (Mendlewicz and Rainer 1977). Similar findings were reported 
in another study examining rates of affective disorders (unipolar and BD) in 
which biological parents had higher rates (5.2%) than adopted parents (2.8%)
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(Wender et al. 1986). More recently, two studies have used the adoptee’s 
method, as opposed to earlier studies using the adoptee’s relative method 
described above. In the adoptee’s method, the proband is the parent who has
BD as opposed to adoptee having BD. Using data from Swedish national 
registries, the RR in adopted away offspring of BD probands was higher (RR = 
4.3) than for adoptees whose adoptive parent had BD (RR = 1.3) (Lichtenstein 
et al. 2009). Similarly, another study using the same registry but with a longer 
follow-up reported that RR in adopted away offspring of a BD parent was higher 
(RR = 5.0) than for adoptees whose adoptive parent had BD (RR = 3.1) (Song 
et al. 2015). 
1.4.2 Molecular genetic studies of BD
Given that concordance rates for BD in MZ twins are not 100%, one can 
conclude that genetic risk factors alone cannot be sufficient causes of BD, 
though they are likely necessary (Barnett and Smoller 2009). A complete 
understanding of the genetic aetiology of BD still eludes researchers to this day, 
but it is likely there are multiple genetic and environmental influences, which 
can be different in different people, and which could help account for a 
heterogeneous phenotype. Similar to other complex psychiatric and non-
psychiatric disorders, relatives of patients with BD likely carry an excess of risk 
alleles for BD which can be passed on to the offspring. To progress the 
understanding of the aetiology of BD, the search for chromosomal loci and 
specific genes conferring risk for BD has been aided by several technological 
changes. These have allowed the transition from linkage studies to association 
methods and from candidate gene studies to more genome-wide approaches. 
1.4.2.1 Linkage studies
The purpose of linkage studies is to examine several hundred to thousand 
markers which are spread across the genome in an attempt to identify 
chromosomal regions where susceptibility genes may be found. By examining 
these markers, it is possible to determine which loci found near to one another 
appear to be co-inherited together more often than by chance. 
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Though individual studies themselves may provide suggestive evidence of 
potential chromosomal regions implicated in BD at both genome-wide and 
suggestive significance, meta-analyses pool this data together allowing greater 
statistical power using larger samples. Evidence from a number of meta-
analyses highlight the following chromosomal regions as potentially implicated 
in BD: 13q, and 22q (Badner and Gershon 2002), 9p21.1-p22.3, 10q11.2-q22.1, 
14q24.1-q32.12 and 18p11-q22.1 (Segurado et al. 2003), 6q, 8q, 9p and 20p 
(McQueen et al. 2005). 
Though linkage studies for single gene Mendelian disorders such as 
Huntington’s disease have been successful, the success for BD and other 
psychiatric disorders more generally has not mirrored this (Sklar 2002). As is 
evident from the numerous meta-analyses, there appears to be a lack of 
consistency in determining which chromosomal regions are implicated in the 
aetiology of BD.
1.4.2.2 Candidate gene association studies
Unlike linkage studies, the candidate gene study approach tests genetic 
markers with a presumed functional relevance to a particular disorder using 
either a case-control (unrelated cases vs population-based controls) or family 
study (using the trio design with the affected child having the disease and the 
unaffected parents acting as controls) design. Whilst linkage is a property of 
genes or loci within families, association is a property of alleles which can be 
studied across a population.
There are a number of promising candidate genes, most of which are 
neurotransmitter genes, particularly serotonin, dopamine and noradrenaline 
given their apparent pharmacological role in regulating mood (particularly 
depression). A recent meta-analysis of 487 candidate gene association studies 
of BD found the most widely studied gene was the SL6A4 gene which is a 
serotonin transporter gene (n = 41). The second most studied gene was the 
serotonin receptor 2A (HTR2A) examined in 21 studies. The authors ran a 
random effects meta-analysis on 18 genes and reported significant associations 
for single polymorphisms in four different genes: Brain-derived neurotrophic 
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factor (BDNF) (p = 0.05), dopamine receptor 4 (DRD4) (p = 0.037), d-amino 
acid oxidase activator (DAOA) (p = 0.05) and tryptophan hydroxylase 1 (TPH1) 
(p = 0.001). However, these associations did not survive correction for multiple 
testing (Seifuddin et al. 2012). Despite a large number of potential candidate 
genes being reported as associated with BD, there are substantial limitations to 
the candidate gene approach (and a lack of replication across studies), 
including: i) selecting genes a priori depends on an accurate understanding 
about the aetiology of BD, which is not well understood, ii) individual studies 
using a candidate gene approach had sample sizes which would likely be 
underpowered to detect a small effect size, and iii) poorly matched cases and 
controls (including population stratification) can lead to spurious findings, likely 
overestimates of the true effect (Hirschhorn et al. 2002; Sullivan 2007; Button et 
al. 2013).
1.4.2.3 Genome-Wide Association Study (GWAS) findings for BD
GWAS offer a more powerful atheoretical alternative to both linkage and 
candidate gene studies. Linkage studies do not have the sample sizes to be 
sufficiently powerful enough to detect small to moderate effect sizes (OR = 1.1-
1.5) for common diseases (Spencer et al. 2009), whilst candidate gene studies 
have a very low a priori likelihood of identifying any novel single nucleotide 
polymorphisms (SNPs). Using GWAS, variants across the whole genome can 
be examined in a hypothesis-free manner. Current GWAS chips are able to 
genotype between 500,000-1,000,000 SNPs simultaneously.
1.4.2.3.1 Methodological considerations 
As with any method of analysis, there are also a number of considerations 
which must be adhered to when interpreting findings. Firstly, many genotype 
markers are often highly correlated and are inherited together more often than
by chance. This occurrence is known as linkage disequilibrium (LD) and refers 
to the non-random occurrence of alleles at multiple loci in the genome. To 
account for this, SNPs can be clumped whereby the most significant p-value is 
retained per LD block. Another consideration is that testing so many SNPs 
simultaneously for association with a particular phenotype may lead to false 
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positive results i.e. increased type 1 error. There are several methods 
researchers can use to correct for multiple testing such as the Bonferroni 
correction, false discovery rate, positive false discovery rate and permutations. 
At the time of writing this thesis, a SNP is considered genome-wide significant if 
its p-value is equal to or lower than 5 x 10-8 which equates to (0.05/1,000,000 
tests). Adjusting the threshold required to be considered as a significant finding 
reduces the type I error. 
1.4.2.3.2 Early GWAS findings (before large-scale Psychiatric Genomics 
Consortium (PGC) work)
Several studies have used individual or pooled genotyped data to conduct 
GWAS to identify loci associated with BD. The first GWAS of BD was conducted 
by the Wellcome Trust Case-Control Consortium (WTCCC) and contained 
individual genotype data on 2000 BD cases and 3000 controls from the 1958 
British Birth Cohort. Only one SNP (rs420259) on chromosome 16p12, in the 
Partner and Localiser of BRCA2 (PALB2) gene (heterozygous OR = 2.08; 
homozygous OR = 2.07, both p = 6.29x10-8) was reported as genome-wide 
significant (Wellcome Trust Case Consortium et al. 2007). 
Subsequent studies prior to the first PGC BD GWAS publication often used
overlapping samples for meta or mega analysis but were not always able to 
replicate the most strongly associated SNP(s) (Baum et al. 2008a; Baum et al. 
2008b; Ferreira et al. 2008; Sklar et al. 2008; Hattori et al. 2009; Schulze et al. 
2009; Scott et al. 2009; Smith et al. 2009; Djurovic et al. 2010; Cichon et al. 
2011; Jiang and Zhang 2011; Lee et al. 2011; Smith et al. 2011; Yosifova et al. 
2011) (see Table 3 for order in which these GWAS were conducted). It is 
possible that inconsistencies and lack of replication were due to relatively small 
sample sizes, thus leading to underpowered analyses.  
1.4.2.3.3 The PGC GWAS findings for BD
The PGC group was set up in 2007 with the aim of uniting researchers from 
around the world. This was to combine primary genotype data from studies with 
overlapping samples, for both meta and mega analysis, both within and across 
various psychiatric disorders. 
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To date, results from the PGC schizophrenia group have highlighted the 
necessity of larger sample sizes to detect loci of small effect size that reach 
genome-wide significance. Evidence supporting this comes from examining the 
updated PGC-2 schizophrenia sample (Ripke et al. 2014), which identified 108 
loci at genome-wide significance, in stark contrast to using the original PGC-1 
schizophrenia sample which identified around 7 loci, five of which were novel 
(Purcell et al. 2009).
The first paper published by the PGC BD group was in 2011 and had 7481 
unique cases and 9,250 unique controls of European ancestry from 11 case-
control GWASs of BD. Cases had the following diagnoses: BD-I, n = 6,289 
(84%); BD-II, n = 824 (11%); schizoaffective disorder, n = 263 (4%) and bipolar 
disorder not otherwise specified, n = 104 (1%). The authors reported 38 SNPs 
reached genome-wide suggestive (p<5x10-5) evidence, though only 4 regions 
contained SNPs which had a raw p-value at genome-wide significance; SNP 
rs1099437 located in the ANK3 gene on chromosome 10q21 
(p = 5.5x10-10; OR = 1.15), SNP rs9371601 located in synaptic nuclear 
envelope protein 1 (SYNE1) on chromosome 6q25 (p = 4.3x10-9; OR = 1.15), 
the intergenic SNP rs7296288 found in a region of linkage disequilibrium (LD) of 
~100 kb on chromosome 12q13 containing 7 genes (p = 9.4x10-9; OR = 1.15) 
and a novel SNP, SNP rs12576775 in the first intron of ODZ4 on chromosome 
11q14 (p = 2.7x10-7; OR = 1.18). ODZ4 is the human homolog of the Drosophila 
pair-rule gene ten-m (odz). However, only 2 SNPs, SNP rs1099437 (ANK3) and
SNP rs9371601 (SYNE1) had a genomic control p-value at genome-wide 
significance (p = 7.1x10-9 and p = 4.3x10-8) respectively (Sklar et al. 2011). 
In a replication analysis using an independent data set containing a further 
4,493 BD cases and 42,542 controls, a fixed effects meta-analysis found 2 
SNPs at genome-wide significance after correction for multiple testing: SNP 
rs4765913 on chromosome 12p13.33 in the CACNA1C gene encoding the 
subunit of the L-type voltage-gated calcium channel (OR = 1.14; p=1.82x10-9) 
and SNP rs12576775 in ODZ4 (OR = 0.89; p = 2.77x10-8) (Sklar et al. 2011).
Subsequent meta-analyses published which included PGC-1-BD data (but have 
not included the recent PGC-2BD GWAS) have identified 7 novel SNPs: 
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rs9834970, rs2271893 and rs4650608 located near the genes TRANK1 (LBA1),
LMAN2L and PTGFR respectively (Chen et al. 2013), rs17826816 in the gene 
Adenylate cyclase 2 (ADCY2) and rs12202969 found in a region between 
microRNA 2113 (MIR2113) and POU class 3 homeobox 2 (POU3F2) 
(Muhleisen et al. 2014), and finally rs174576 in the Fatty Acid Desaturase 2 
gene (FADS2) and rs4926298 near Nuclear Family I/X (NFIX) (Ikeda et al. 
2018).
At present, using the second PGC BD GWAS containing 20,352 BD cases (n = 
14,879 BD-I; n = 3,421 BD-II, n = 977 schizoaffective disorder and n = 1,075 
with BD unspecified) and 31,358 controls of European ancestry from 32 
cohorts, 30 genome-wide significant loci have been identified, 20 of which were 
novel (Stahl et al. 2019). 
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Table 3 Comparison of findings between studies conducting GWAS of BD
Author and 
year
Population i.e.
ancestry Diagnoses
Genotyping 
platform(s) used N Top SNP(s) Nearest gene
P value 
reported
WTCCC 2007 European
BD-I, BD-II, SZA 
and manic 
disorder
Affymetrix 500K 
1,838 cases 
and 2,938 
controls
rs420259 PALB2 6.3x10-8 
Baum et al. 
2008a
European (NIMH 
waves 1-4) BD-I Illumina 550
1,233 cases 
and 1,439 
controls
rs1012053 DGKH 1.5x10-8 
Sklar et al. 
2008 European BD-I 
Affymetrix 500K or 
5.0 
1,461 cases 
and 2,008 
controls
rs4939921 
MYO5B, 
TSPAN8 and 
EGFR
1.7x10-7, 
6.1x10-7 and 
8.4x10-8 
Ferreira et al. 
2008a European BD-I and BD-II Affymetrix 5.0 or 6.0 
1,098 cases 
and 1,267 
controls
rs7221510 SKAP1 1.4x10-6 
Baum et al. 
2008b
Meta-analysis combining data from WTCCC sample and Baum et 
al. 2008a
3,101 cases 
and 4,377 
controls
rs10791345 and 
rs4806874
JAM3
and SLC39A3
1x10-6
and
5x10-6
Ferreira et al. 
2008b
Meta-analysis combining data from WTCCC sample, Sklar et al. 
2008 and Ferreira et al. 2008a samples
4,387 cases 
and 6,209 
controls
rs10994336 and 
rs1006737
ANK3 
and CACNA1C
9.1x10-9 and 
7.0x10-8 
Hattori et al. 
2009
East Asian
(Japanese) BD-I, SZA and SAD
Affymetrix 100K 
and Illumina 
107 cases 
and 107 
controls
rs10994336 ANK3 3x10-6 
22
Table 3 continued
Author and 
year
Population 
(ancestry) Diagnoses
Genotyping 
platform(s) used N Top SNP Nearest gene
P value 
reported
Scott et al. 
2009
European (meta-analysis containing samples from WTCCC 
sample, Baum et al. 2008a and Ferreira et al 2008b
3,683 cases 
and 14,507 
controls
rs17418283;
rs1042779; 
rs472913
Intron of MCTP1; 
NEK4; NF1A
1.3x10-7; 
1.8x10-7; 
2.0x10-7 
Smith et al. 
2009
European and 
African (contains 
overlapping samples 
with Baum et al. 
2008a, Sklar et al. 
2008 and Scott et al. 
2009)
BD-I or SZA Affymetrix 6.0
European 
(1,001 cases 
and 1,033 
controls); 
African (345 
cases and 
670 controls)
European: 
rs5907577; 
African: rs2111504
European: 
Intergenic region 
at Xq27.1; 
African: 
DPY19L3
European: 
1.6x10-6; 
African: 
1.5x10-6 
Djurovic et al. 
2010
European (Norway 
and Iceland) BD
Affymetrix 6.0 and 
HumanHap300
194 cases 
and 336 
controls
rs4377455 RBMS3 RNA binding motif 5.39x10
-7 
Cichon et al. 
2011
European (WTCCC 
sample), USA (Smith 
et al. 2009 sample) 
and Australia
BD-I, BD-II, SZA, 
BDNOS or MD
HumanHap550 
(Illumina)
8,441 cases 
and 35,362 
controls
rs1064395 NCAN
Meta-analysis
P value:
2.14x10-9 
Lee et al. 
2011 East Asia (Taiwan) BD-I 
Illumina HapMap 
550
1000 cases 
and 1000 
controls
rs2709736 SP8 4.87x10-7 
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Table 3 continued
GWAS: Genome Wide Association Study; BD: Bipolar Disorder; WTCCC: Wellcome Trust Case Control Consortium; BD-I: Bipolar Disorder type I; BD-II: Bipolar 
Disorder type II; SZA: Schizoaffective Disorder; BDNOS: Bipolar Disorder Not Otherwise Specified; MD: Manic Disorder SNP: Single Nucleotide Polymorphism; 
ANK3: Ankyrin 3; CACNA1C: Calcium Voltage-Gated Channel Subunit Alpha1 C; JAM3: Junctional Adhesion Molecule 3; SLC39A3: Solute Carrier Family 39 
Member 3; SKAP1: Src Kinase Associated Phosphoprotein 1; EGFR: Epidermal Growth Factor Receptor; TSPAN8: Tetraspanin 8; MYO5B: Myosin 5B; DGKH: 
Diacylglycerol Kinase eta; PALB2: Partner and Localiser of BRCA2; MooDS: Systematic Investigation of the Molecular Causes of Major Mood Disorders and 
Schizophrenia; GRIK5: Glutamate Ionotropic Receptor Kainate type subunit 4; PARD6B: Par-6 Family Cell Polarity Regulator Beta; CTSH: Cathepsin H; ANK3: 
Ankyrin 3;  SYNE1: Spectrin Repeat Containing Nuclear Envelope Protein 1; TRANK4: Tetratricopeptide Repeat and Ankyrin repeat containing 4; LMAN2L: Lectin 
Author and 
year
Population 
(ancestry) Diagnoses
Genotyping 
platform(s) used N Top SNP Nearest gene
P value 
reported
Yosifova et al. 
2011
European 
(Bulgarian) BD Illumina Hap550v3
188 cases 
and 376 
controls
rs8099939; 
rs6122972; 
rs2289700
GRIK5, PARD6B 
and CTSH
9.86x10-8,
3.11x10-6 and 
9.14x10-6 
PGC-1-BD European (received primary genotypes from 11 previously reported samples of European ancestry)
7,481 cases 
and 9,250 
controls
rs10994397; 
rs9371601; 
rs7296288; 
rs12576775
ANK3; SYNE1; 
Intergenic 
(many); ODZ4
7.1X10-9; 
4.3X10-8; 
8.4X10-8; 
2.1X10-7 
Chen et al. 
2013
Meta-analysis of European (PGC-1-BD) and East Asian (Lee et 
al. 2011) samples
6,658 cases 
and 7,155 
controls
rs9834970; 
rs2271893; 
rs4650608
TRANK; 
LMAN2L; PTGFR
2.4x10-11; 
1.1x10-8;
1.2x10-7 
Muhleisen et 
al. 2014
Meta-analysis combining PGC-1-BD and data from MooDS 
(European, Australian and Canadian)
9,747 cases 
and 14,278 
controls
rs17826816; 
rs12202969
ADCY2; between 
MIR2113 and 
POU3F2
9.9x10-9; 
1.1x10-8 
Ikeda et al. 
2018
Meta-analysis combining European (PGC-
1-BD) and East Asian (Japanese) sample
Illumina Human 
Omni Express 
Exome
10,445 
cases and 
71,137 
controls
rs174576; 
rs4926298 FADS2; NFIX
1.3x10-10; 
5.8x10-10
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Mannose binding 2 Like; PTGFR: Prostaglandin F receptor; ADCY2: Adenylate Cyclase 2; MIR2113: MicroRNA 2113; RNA: Ribonucleic Acid; POU3F2:  POU class 
3 homeobox; FADS2: Fatty Acid Desaturase 2; NFIX: Nuclear Family I/X; MCTP1: Multiple C2 and Transmembrane Domain Containing 1; NEK4: Never in mitosis 
gene A Kinase 4; NF1A: Nuclear Factor 1A; DPY19L3: DPY-19 Like C-Mannosyltransferase 3; RBMS3: RNA Binding Motif Single Stranded Interacting Protein 3; 
RNA: Ribonucleic Acid; NCAN: Neurocan; SP8: SP8 Transcription factor
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1.4.2.4 Polygenic Risk Score (PRS)
It is clear that through GWAS, a number of SNPs occurring more frequently in 
BD cases compared to controls have been identified (Sklar et al. 2011; Ruderfer 
et al. 2018; Stahl et al. 2019), though the effect each of these SNPs has 
individually on disease risk is small and limits predictive power (Dudbridge 
2013). A newer statistical technique, the PRS, combines trait-associated SNPs 
into a single score, with the aim of explaining a greater proportion of the 
variation in the trait of interest. The basic principles of PRS analyses involve 
using two datasets. The first is the discovery (or training) dataset which is 
selected as the largest available GWAS for the trait being investigated. For PRS 
analyses, summary statistics of the genotype-phenotype associations are used, 
and for the major psychiatric disorders, are freely available online from the PGC 
downloads page (https://www.med.unc.edu/pgc/results-and-downloads/). The 
second is the target dataset, in which, raw genotype and phenotype data are 
available for each individual within the dataset. The PRS is calculated as the 
sum of risk-associated alleles weighted by the effect size (usually an OR) from 
the largest and most powerful GWAS (Wray et al. 2014). A summary diagram of 
the basic stages involved in generating a PRS is shown in Figure 1. A more 
detailed overview of the steps involved in generating the PRS, including quality 
control measures can be found in Chapter 3, section 3.5.  
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Figure 1 Summary diagram for performing PRS analyses
Adapted from Choi et al. (2018); GWAS: Genome Wide Association Study; OR: Odds Ratio; 
PRS: Polygenic Risk Score; SNPs: Single Nucleotide Polymorphisms; LD: Linkage 
Disequilibrium; PT: P-value threshold cut off score
The first study to use the PRS approach to investigate associations with any 
phenotype was that by the International Schizophrenia Consortium (ISC). The 
authors of the study investigated the extent to which common genetic variants 
i.e. SNPs occurring more frequently in SZ cases compared to controls 
contribute to risk of both SZ and BD. The authors found consistent evidence of 
association between the SZ-PRS and SZ, as well as evidence of association 
with BD. Their findings also highlighted that the inclusion of SNPs below 
Discovery dataset i.e. GWAS
Use summary statistics (Beta/ORs for 
PRS calculation)
Target dataset
Use raw genotype and 
phenotype data
Quality control
Both datasets require quality control measures as standard in GWAS
Keep overlapping SNPs in both datasets
LD adjustment e.g. 
clumping/pruning
Beta shrinkage e.g. 
lasso/ridge
Generate Multiple 
PRSs at various PT
Generate PRS and perform association testing
27
genome-wide significance in the derivation of the PRS increased the proportion 
of variance explained in both disorders (Purcell et al. 2009). 
Some years later, using the same principles as the ISC, the PGC group collated 
information from 11 sites globally and conducted a GWAS to identify SNPs 
occurring more frequently in BD cases compared to controls. When performing 
PRS analyses, the authors tested multiple p-value threshold cut off scores 
(PT’s) and determined the threshold which explained the greatest proportion of 
variance in BD was a PT≤0.5 (R2 = ~3% on the observed scale and ~1% on the 
liability scale) (Sklar et al. 2011). More recently, using data from the 2nd PGC 
BD GWAS, the threshold which is now considered optimal to maximally capture 
variance in BD is a PT≤0.01 (R2 = ~8% on the observed scale and ~4% on the 
liability scale) (Stahl et al. 2019).
Originally, PRS analyses were used to examine the proportion of variance in 
disorder explained by common genetic variants. However, as shown by the ISC 
(Purcell et al. 2009), the PRS approach can also be used to investigate 
associations with non-discovery sample phenotypes. Therefore, using the PRS 
approach, it is possible to examine potential phenotypic manifestations of 
increased genetic risk in various populations across the lifespan. Chapter 6 of 
this thesis will examine the current known phenotypic manifestations of 
increased genetic risk for BD, though the published article contains information 
on phenotypic manifestations of genetic risk for depression as well as BD
(Mistry et al. 2018a).
1.4.3 Environmental risk factors 
As highlighted in the previous section, genetics plays an important role in 
determining whether an individual goes on to develop BD. However, it is likely 
that other non-genetic factors also play a role given concordance rates for BD in 
MZ twins is not 100%. Environmental risk factors can occur pre, peri and 
postnatally, and can be categorised into neurodevelopmental, substance abuse 
related and physical/psychological stress (Marangoni et al. 2016).
Data on studies investigating various environmental risk factors is limited. There 
has been inconsistent evidence for an association between: i) smoking during 
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pregnancy and risk of BD in the offspring (Talati et al. 2013; Chudal et al. 2015; 
Marangoni et al. 2016; Quinn et al. 2017), ii) birth complications and risk of BD 
(Bain et al. 2000; Chudal et al. 2014; O'Neill et al. 2016), iii) lower gestational 
age and risk of BD (Ogendahl et al. 2006; Nosarti et al. 2012) and iv) being 
exposed to infectious agents during pregnancy and BD in the offspring 
(Barichello et al. 2016). In contrast, there are some consistent findings across 
studies such as: i) little evidence of association between low birth weight 
(<2,500g) and BD (Ogendahl et al. 2006; Nosarti et al. 2012), ii) increased 
frequency of experiencing some form of childhood maltreatment, particularly 
emotional abuse (Palmier-Claus et al. 2016) and iii) increased risk of BD due to 
substance abuse (Marangoni et al. 2016).  
Overall, data regarding perinatal and prenatal risk factors and associations with 
future risk of BD is weak and inconsistent. This is in contrast to much more 
consistent and stronger evidence of associations between perinatal and 
prenatal risk factors and risk of developing SZ (Davies et al. 2020). Postnatal 
risk factors for BD tend to be rather non-specific i.e. are also risk factors 
associated with increased risk of other psychiatric conditions, and in some 
instances is difficult to establish the temporal relationship.
1.4.4 Psychopathology and BD
As mentioned in section 1.3, the time taken for a patient to receive an accurate 
diagnosis of BD can be up to 10 years (Ghaemi et al. 2002; Baethge et al. 
2003). This delay is associated with substantial impairment to the individual, 
increased number of hospitalisations, medical comorbidity and increased 
frequency of suicide attempts (Goldberg and Ernst 2002; Altamura et al. 2010; 
Forty et al. 2014). Given the negative consequences associated with BD, 
studying its aetiology may help to better characterise the early presentation of 
the disorder and minimise negative impacts for the patient.
1.4.4.1 Comorbidity in BD
When investigating possible aetiological mechanisms underlying BD, one 
possible way of examining this might be to examine those who already have the 
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disorder. There are high levels of comorbidity in those with BD, with a 
suggestion that “comorbidity is the rule rather than an exception” (Sartorious 
2013). Comorbidities could develop after onset or be present prior to onset. 
Establishing an accurate temporal relationship between comorbidities and BD 
might aid earlier recognition and appropriate intervention, particularly because 
comorbidities are associated with poorer prognosis and can lead to reduced 
efficacy of treatment. 
1.4.4.1.1 Psychiatric comorbidity with Axis I disorders 
Evidence from international surveys have highlighted that 57-76% of individuals 
with BD have at least one other lifetime DSM-IV Axis I disorder, and that 16-
44% have three or more lifetime DSM-IV Axis I disorders (McElroy et al. 2001; 
Grant et al. 2005; Merikangas et al. 2011). The most common comorbid Axis I 
disorders from meta analyses are reported to be: anxiety disorders, with panic 
disorder being the most common (20-64%), substance abuse disorders, most 
notably alcohol abuse (22-48%), eating disorders, particularly bulimia nervosa 
(3-33%), and behavioural disorders such as oppositional defiant disorder (25-
29%) and intermittent explosive disorder (34%) (Merikangas et al. 2011; Hunt et 
al. 2016; Eser et al. 2018; Thiebaut et al. 2019).
1.4.4.1.2 Psychiatric comorbidity with Axis II disorders 
In addition to a number of Axis I disorders, there is also evidence to suggest 
that comorbidity with Axis II personality disorders is common. Evidence from 
meta-analyses and systematic reviews suggest that 23-31% have a ‘Cluster B’ 
personality disorder (antisocial, borderline, histrionic, narcissistic), 15-26% have 
a ‘Cluster C’ personality disorder (avoidant, dependent, obsessive compulsive), 
and 7-13% have a ‘Cluster A’ personality disorder (paranoid, schizoid, 
schizotypal). The most frequent personality disorders are borderline personality 
disorder (BPD) and obsessive compulsive disorder (OCD) (Friborg et al. 2014; 
Bezerra et al. 2015), although these findings were based on data from three 
studies of European populations and cannot be generalised to other populations 
such as those from Asia, Africa and America.
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1.4.4.1.3 Summary and limitations of work on psychiatric comorbidities  
Findings from studies examining both Axis I and Axis II comorbidities with BD 
suggest that comorbidities are common in individuals with BD. When pooling 
data together to increase sample size, a more accurate account of the true 
lifetime risk for comorbid conditions is possible from meta-analysis. 
Nevertheless, the studies included in these meta-analyses are cross-sectional, 
and are based on recollection of symptoms being present. This can lead to 
recall bias, particularly when in a mood episode (depressed, (hypo)manic or 
mixed). Although these studies are useful in informing current clinical practice 
with regards to appropriate treatment options, they say nothing about the 
temporal relationship between the comorbidity and BD: it is not possible to 
determine whether there may be causal effects (i.e. the comorbidity causes 
BD), whether comorbidities may arise secondary to the effects of medication 
used to treat BD, or whether the presence of BD symptoms causes comorbidity 
(reverse causality). They also do not answer the question “what is the initial 
symptom presentation of BD in childhood/adolescence?” To answer this 
question, studies of psychopathology in the premorbid phase of BD are 
necessary.
1.4.4.1.4 Premorbid psychopathology 
To better understand the manifestations of BD in childhood/adolescence, one 
approach is to follow high-risk offspring of BD parents longitudinally. It should 
then be possible to observe any potential psychopathology present at higher 
rates in offspring of BD parents compared to the offspring of control parents. 
Findings from prospective studies of high-risk offspring of BD parents suggest 
that prior to the first (hypo)manic episode, most patients with BD have one or 
more depressive episodes occurring in adolescence (Henin et al. 2005; Duffy et 
al. 2007; Mesman et al. 2016), and that presence of other psychopathologies 
such as childhood anxiety disorder and behavioural disorders such as ADHD 
may be present prior to puberty (Egeland et al. 2012; Duffy et al. 2013,2014). 
Evidence from two meta-analyses of high-risk offspring of BD parents highlight 
a number of Axis I disorders being more common compared to controls. Anxiety 
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disorder are the most prevalent psychopathology reported (lifetime risk 7-32%).
Lifetime risk of other non-bipolar diagnoses include depression (14-24%),
ADHD (14-16%), at least one substance use disorder (12-15%), SZ (4%) and 
any behavioural disorder (12-14%) (Rasic et al. 2014; Lau et al. 2018).
From the findings of high-risk offspring studies, one group have proposed a 
model of clinical trajectory for emerging BD based on evidence spanning over 
20 years. The model itself has 4 stages: 0 (well but at high familial risk); 1 (non-
mood disorders e.g. sleep disorders or ADHD); 3 (minor mood disorders e.g. 
depression not otherwise specified or cyclothymia) and 4 (BD). This is 
summarised in Figure 2 (Duffy et al. 2019). 
Figure 2 Clinical staging model for emerging bipolar disorder
Figure adapted from Duffy et al. (2019)
BD: Bipolar Disorder; ADHD: Attention Deficit Hyperactivity Disorder; NOS: Not Otherwise 
Specified; SZA: Schizoaffective Disorder
To date, and to the best of my knowledge, there are no studies that have used 
birth cohort data to examine associations between measures of 
childhood/adolescent psychopathology and subsequent BD in the general 
population. This is in contrast to a large literature reporting associations 
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between a number of different psychopathology measures and schizophrenia 
(Welham et al. 2009).
1.4.5 Cognition and BD
Approximately 40-60% of people with BD have cognitive impairment in at least 
one cognitive domain, and this is present independent of mood state (Arts et al. 
2008; Bora et al. 2009). Findings from several meta-analyses (Robinson et al. 
2006; Arts et al. 2008; Bora et al. 2009) have suggested premorbid deficits in 
processing speed, executive functioning, verbal learning, visual learning and 
attention (reported Cohen’s d effect sizes ranged from 0.28 to 1.09). Overall, 
there is consistency in reporting the most (executive functioning and verbal 
learning) and least (forward digit span test and sustained attention) affected 
cognitive domains across these studies (Robinson et al. 2006; Arts et al. 2008; 
Bora et al. 2009). The notable exception is the findings of one meta-analysis 
that reported large effect size for deficits in sustained and/or selective attention 
using the Continuous Performance Task (Torres et al. 2007). This finding 
should be interpreted with caution as the task itself often suffers from the 
“ceiling effect”, which can lead to low false positive scores (Kahn et al. 2012).
1.4.5.1 Cognition in BD subtypes
When considering associations between cognition and BD, most studies have 
focused on those with a BD-I diagnosis. However, there are now a number of 
studies that have examined associations in those with BD-II and these might 
help to identify differences in the severity or type of the deficits between BD 
subtypes. Two meta-analyses examining cognitive performance in BD subtypes 
(BD-I vs BD-II) have reported consistent findings, that BD-I compared to BD-II 
cases have poorer global cognition, verbal memory, processing speed, 
executive functioning speed, and executive functioning accuracy (reported 
Cohen’s d range from 0.16 to 0.26, in which the greatest deficits are for verbal 
memory), but no differences in social cognition or working memory (Bora et al. 
2011; Bora 2018). 
A recent meta-analysis investigated differences in cognitive functioning between 
psychotic BD cases vs non-psychotic BD cases. Psychotic BD cases had 
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poorer: global cognition, verbal memory, processing speed, executive 
functioning speed, executive functioning accuracy, working memory, and social 
cognition (reported Cohen’s d range from 0.12 to 0.28, with more pronounced 
deficits in verbal memory), but no difference was observed in visual memory or 
attention cognitive domains (Bora 2018).
1.4.5.2 Cognition in youth at familial high risk for BD 
It is well documented that there are neuropsychological impairments in youth 
who are at high genetic risk for schizophrenia (Hameed and Lewis 2016), and 
findings from one meta-analysis suggests this may also be the case for those at 
high genetic risk for BD. The authors included 18 studies, in which the offspring 
were aged 10-25. Overall, there was evidence of deficits in multiple domains: 
general cognition, visual memory, verbal memory, sustained attention, 
processing speed and social cognition (Cohen’s d range from 0.21 to 0.36), 
though there was little evidence to support differences in cognitive domains of 
planning and working memory (Bora and Ozerdem 2017a). A major limitation of 
studies of high-risk offspring is that it is not possible to know whether cognitive 
deficits present in high-risk offspring are due to genetics or family environment 
given they likely have more risk genes since they have parent(s) with BD and 
are brought up in an environment in which the parent(s) BD might affect their 
cognitive abilities. The authors of the systematic review highlighted a lack of 
sufficient information available on factors such as potential comorbid conditions, 
or whether the youths had misused substances which would likely affect 
performance on completing the cognitive tasks assessed.
1.4.5.3 Cognition in the premorbid phase
A number of studies have examined associations between premorbid cognitive 
functioning and subsequent development of BD/(hypo)mania using a cohort 
study design and report inconsistent findings. Using data from the Swedish and 
Danish National registries, two studies found no difference in premorbid IQ 
(ages 16-25 years) between those who did and those who did not go on to be 
hospitalised with BD (Zammit et al. 2004; Mortensen et al. 2005). Others using 
Swedish (Gale et al. 2010) and Dutch data (Vreeker et al. 2016) have reported 
that lower premorbid IQ (ages 16-25 years) is associated with increased risk of 
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hospitalisation with BD and that lower premorbid IQ was reported in those who 
had a BD-I diagnosis respectively. The findings of the latter study are unusual 
as these individuals (with lower premorbid IQ) also had higher educational 
attainment compared to controls (Vreeker et al. 2016). Evidence from three 
studies, one using data from Dunedin in New Zealand (Koenen et al. 2009), 
another using data from Bristol in the UK (Smith et al. 2015), and a final study 
using data from Sweden (MacCabe et al. 2013) all reported that higher 
childhood IQ is associated with increased risk of adult mania, higher scores on 
the Hypomania Checklist-32 and increased risk of BD respectively. Finally, two 
studies have reported associations between both better and poorer premorbid 
IQ (ages 16-25 years) and risk of hospitalisation with BD using Swedish 
national registry data (MacCabe et al. 2010; Gale et al. 2013). It is therefore 
possible that the relationship between premorbid IQ and BD is non-linear, in 
which those with better and those with poorer IQ compared to average IQ are at 
increased risk of BD. 
1.4.5.4 Summary of cognitive studies
Studies examining associations between cognitive performance (specifically IQ) 
in the premorbid phase and subsequent BD suggest that those with both lower 
and those with higher than average IQ may be at increased risk of developing 
BD. Evidence from studies examining clinical subtypes of BD suggest global 
impairments across multiple domains, with severity being greater in those with a 
BD-I (compared to BD-II) diagnosis and those with a psychotic BD (compared to 
non-psychotic BD) diagnosis. In youth at high genetic risk of BD because their 
parent(s) have BD, there are cognitive deficits similar to those observed in 
adults with BD who are in a euthymic state. It is therefore possible that certain 
cognitive deficits represent non-specific endophenotypes for BD (Kim et al. 
2015). 
1.5 Summary
The aetiology of BD is complex, with both genetic and environmental factors 
playing a role in determining whether someone develops the disorder. Whilst 
categorical diagnoses are necessary for guiding appropriate treatment, 
dimensional approaches such as the RDoC may be more useful for progressing 
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understanding of the aetiology BD. The use of GWAS has revolutionised the 
way we now interpret the genetic architecture of BD, and using polygenic risk 
scores it is now possible to investigate phenotypic manifestations of increased 
genetic risk for BD in different populations. Furthermore, whilst comorbid 
psychopathology and cognitive deficits are frequently described in people with 
BD, it is unclear whether these are present prior to illness onset, or are a 
consequence of having the illness itself. One way of studying this is to use 
general population samples of healthy children and follow them longitudinally 
over an extended period. The most consistently reported measures of 
psychopathology/cognition associated with hypomania have not yet been 
investigated, and even for studies examining this in BD, there is uncertainty as 
to the most reliable measures (Faedda et al. 2014; Faedda et al. 2015). 
Furthermore, most studies examining cognition in BD, particularly using general 
population samples, focus on IQ despite evidence from studies of adults with 
BD and youth at high familial risk of BD suggesting presence of deficits in 
multiple cognitive domains. Another limitation of a number of studies examining 
IQ and BD is not testing for the presence of non-linear effects of cognitive 
performance on risk. Therefore, it will be important to investigate the possibility 
of non-linear relationships between cognitive functioning and subsequent 
hypomania. Understanding the early (childhood) manifestations of BD genetic 
risk, and the childhood psychopathological and cognitive precursors of 
hypomania can help facilitate earlier identification of persons most at risk of 
developing BD, and perhaps provide suitable support mechanisms for these 
individuals and their families. The next chapter, Chapter 2 will outline the 
specific aims and objectives of this thesis.
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Chapter 2: Aims and Objectives of this Thesis
This chapter outlines the aims and specific objectives of this thesis. 
2.1 Aim 1
The first aim of this thesis is to identify childhood psychopathology and cognitive 
domains associated with hypomania in young adulthood.
2.1.1 Psychopathology in childhood 
Behavioural/emotional difficulties and presence of psychopathology in childhood 
are reported in up to 60% of adults with bipolar disorder (BD). Most studies that 
have examined childhood precursors/risk factors for BD have used small 
samples of high-risk offspring of parents with BD and compared these to 
controls. There have been few population-based studies that have examined 
childhood psychopathology as a precursor/risk factor for BD/hypomania, or 
examined whether associations exist across the continuum or only at clinical 
levels of BD psychopathology, or with specific aspects of hypomania. Therefore, 
the first set of objectives within this aim of the thesis are:
1. To investigate whether childhood psychopathology (borderline 
personality disorder (BPD) traits, attention deficit hyperactivity 
disorder (ADHD), emotional/behavioural problems and depressive 
symptoms) in childhood are associated with a dimensional measure 
of hypomania assessed in early adulthood.
2. To investigate whether childhood psychopathology is associated 
more specifically with “sunny-side” or “dark-side” features of 
hypomania, or with clinically-defined hypomania in young adulthood.
3. To investigate whether any associations are likely to be due to 
confounding or selection bias. 
Results for objectives 1-3 can be found in Chapter 4 of the thesis.
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2.1.2 Cognition in childhood 
Between 40-60% of adults with BD have cognitive deficits (Sole et al. 2017). 
However, the relationship between premorbid cognitive functioning in childhood 
and subsequent development of BD is unclear. As noted in Chapter 1, studies 
using large longitudinal national registry data, particularly from Scandinavian 
countries, have reported both better and worse childhood cognitive functioning
(namely IQ) in the premorbid phase in those who eventually go on to develop 
BD. There are few studies examining the relationship between premorbid 
cognitive functioning and dimensional measures of hypomania in young 
adulthood. Furthermore, there are few studies examining whether associations 
with cognitive deficits exist across the continuum or only at clinical levels of 
psychopathology, or with specific aspects of hypomania. Therefore, the second 
set of objectives within this aim of the thesis are: 
4. To investigate whether cognitive functioning (specifically the cognitive 
domains of processing speed, working memory, problem solving, 
executive functioning, attention, verbal learning and social cognition 
(emotion recognition)) in childhood is associated with a dimensional 
measure of hypomania in early adulthood.
5. To investigate whether a non-linear relationship exists, whereby both 
better and worse cognitive functioning in childhood is associated with 
higher scores on a dimensional measure of hypomania in young 
adulthood.
6. To investigate whether cognitive functioning is associated with 
“sunny-side” or “dark-side” features of hypomania, or clinically-
defined hypomania in young adulthood.
7. To investigate whether any associations are likely to be due to 
confounding or selection bias. 
Results for objectives 4-7 can be found in Chapter 5 of the thesis.
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2.2 Aim 2
The second part of this thesis aims to understand how genetic risk for BD is 
manifest by reviewing the literature of studies that have used a polygenic risk 
score (PRS) approach to examine this.
In the last 10 years, there have been an increasing number of studies which 
have used a PRS approach to determine possible phenotypes associated with 
increased genetic risk for BD. Most notably, large genome-wide association 
studies (GWAS) of BD cases and controls show the ability of the PRS to 
distinguish BD cases from controls at the group level (Sklar et al. 2011; 
Ruderfer et al. 2018; Stahl et al. 2019). At the start of my PhD there were no 
systematic reviews or meta-analyses collating information on what the non-BD 
manifestations of genetic risk for BD, using a PRS approach are, though such 
studies could help inform understanding of the aetiology of BD. Therefore, the 
next objective of this thesis is:
8. To systematically review the literature to identify and describe studies 
that have examined the phenotypic (non-BD) manifestations of 
genetic risk for BD.
Results for objective 8 can be found in Chapter 6 of the thesis.
2.3 Aim 3 
The final aim of this thesis aims to assess experimentally whether genetic risk 
for BD manifests during childhood as the psychopathology and cognitive 
phenotypes investigated in Aim 1 described above.  
2.3.1 Genetic risk for BD and psychopathology from childhood into early 
adulthood
At the start of my PhD, there were few studies investigating associations 
between genetic risk for BD, using the PRS approach, and childhood 
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psychopathology or hypomania in young adulthood. Therefore, my next set of 
objectives are:
9. To investigate whether increased genetic risk for BD is associated 
with a dimensional measure of hypomania in young adulthood.
10. To investigate whether increased genetic risk for BD is associated 
more specifically with “sunny-side” or “dark-side” features of 
hypomania, or with clinically-defined hypomania in young adulthood.
11. To examine whether genetic risk for BD is associated with childhood 
psychopathology (as examined in Aim 1).
12. To investigate the possibility of associations being due to selection 
bias.
Results for objectives 9-12 can be found in Chapter 7 of the thesis. 
2.3.2 Genetic risk for BD and cognition in childhood 
When I started my PhD, there were no studies that had used a BD-PRS to 
investigate associations with childhood cognitive functioning, although there 
were a few studies examining cognitive functioning in adults. None of these 
studies had attempted to tease out to what extent any associations were driven 
by single nucleotide polymorphisms (SNPs) shared between BD and SZ and 
those which are independent. The final set of objectives of this thesis therefore, 
are:
13. To examine whether genetic risk for BD is associated with cognitive 
domains of general intelligence indexed by intelligence quotient (IQ)
(performance, verbal and total), processing speed, working memory, 
problem solving ability, executive functioning, attention, verbal 
learning and social cognition (emotion recognition) in childhood.
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14. To determine whether any associations between genetic risk for BD 
and cognitive functioning are non-linear.
15. To examine whether the relationship between genetic risk for BD and 
cognitive functioning is explained by risk alleles which are also shared 
with schizophrenia risk.
16. To investigate the possibility of associations being due to selection 
bias.
Results for objectives 13-16 can be found in Chapter 8 of the thesis. 
Chapter 9 will conclude this thesis with an overall discussion of what I have 
found, the implications of these findings, which methodological considerations 
should be highlighted, the strengths and limitations of the work presented and 
suggestions for future research. 
The next chapter, Chapter 3, will provide details of the ALSPAC sample used to 
address Aims 1 and 3. It gives a detailed description of the methods used in 
Chapters 4, 5, 7 and 8. The methodology used for Aim 2 (the systematic review) 
will be presented in Chapter 6.
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Chapter 3: Methods
This chapter introduces causal inference, describes the Avon 
Longitudinal Study of Parents and Children (ALSPAC) sample used 
in this thesis, and provides an overview of all outcome and exposure 
measures, with some background information on the psychometric 
properties of these. In addition, the statistical analyses used in 
Chapters 4, 5, 7 and 8 are also described. 
3.1 Epidemiology and Causal Inference
Epidemiology is concerned with describing and understanding the 
aetiology and outcomes of disease(s) in different populations. 
Different study designs may be used to examine potential aetiological 
relationships between an exposure and outcome, including 
observational studies (such as longitudinal, case-control, or cross-
sectional designs) and interventional studies (such as randomised-
controlled trials (RCTs)). Where associations are identified, a number 
of explanations need to be ruled out before causality can be inferred. 
Explanations for any association include: 
i) Chance: The finding is spurious due to random variation 
ii) Confounding: The observed association between an 
exposure and outcome is explained by another variable, 
which is associated with both the exposure and outcome, 
but is not on the causal pathway between them
iii) Bias: An incorrect estimate of the association between an 
exposure and outcome occurs as a consequence of an 
error or flaw in the study, and can be due to the 
characteristics of the sample (selection bias), or of the 
measures (information bias) 
iv) Reverse causation: Presence of the exposure occurs as a 
consequence of the outcome 
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v) Causation: The outcome occurs as a consequence of the 
exposure    
The extent to which any of the explanations ii-iv above can be 
excluded as alternatives to a causal relationship depends in part on 
the study design. Whilst the strongest design for establishing 
causality is an RCT, most studies that aim to increase understanding 
of the aetiology of disease are observational rather than 
interventional. Of the observational designs, longitudinal studies are 
usually considered the strongest design as they are able to 
determine a temporal relationship between a given exposure and 
outcome, and as they are less likely to be affected by selection bias 
than case-control designs. 
In this thesis, I will be using the ALSPAC birth cohort which has a 
longitudinal or cohort study design. 
3.2 The ALSPAC cohort
3.2.1 Recruitment of participants 
The ALSPAC cohort (http://www.bris.ac.uk/alspac/) is a large 
population-based longitudinal dataset set up in April 1991, recruiting 
pregnant women whose delivery date was between April 1st 1991 
and December 31st 1992 (Boyd et al. 2013). These women were from 
the Avon area (Southmead, Bristol and Weston and Frenchay District 
Health Areas) and at the start of the study, 14,541 pregnant women 
were enrolled. Figure 1 shows a flow diagram of sample recruitment 
including final sample sizes for analyses in this thesis. 
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Figure 3 Flow diagram showing sample recruitment for the ALSPAC cohort
ALSPAC: Avon Longitudinal Study of Parents and Children; HCL: Hypomania 
Checklist
5,342 no longer 
contactable
77 with missing 
data on the HCL
Complete data on childhood 
psychopathology measures 
(ages 7-11), data on the 
HCL and all confounders
(n = 1,507 – 2,079)
Complete data on 
childhood cognition 
(age 8), data on the 
HCL and all 
confounders
(n = 1,721 – 1,848)
Complete data on the 
HCL (n = 3,371)
Invited to complete the HCL age 
22-23 years (n = 9,359)
Returned the HCL 
questionnaire (n = 3,448)
14,541 pregnancies recruited 
antenatally resulting in 14,062 children
13,988 children still alive 
at age 1 years
74 children not alive 
at age 1 years
Additional 713 eligible 
children added from 
Focus @ 7 and Focus @ 
8 clinics
14,701 children still alive 
at age 1 years
5,911 did not return 
questionnaire
Complete genetic 
data and data on 
the HCL (n = 2,654)
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The study contains extensive baseline information from the first 
trimester of pregnancy onwards. From birth, a series of assessments 
and questionnaires regarding family circumstances and the child’s 
health were sent to the parents. After the age of 7, the children were 
able to attend face-to-face interviews, from which a number of 
assessments assessing a variety of measures were conducted. In 
total, between birth and age 18 years, 68 data collection time points 
have occurred including 9 “Focus” clinical assessments, 34 child-
completed questionnaires and 25 questionnaires about the child 
completed by the mother or other main caregiver (Boyd et al. 2013). 
The study website contains details of all the data, searchable through 
the data dictionary (http://www.bris.ac.uk/alspac/researchers/data-
access/data-dictionary/). The analyses presented in this thesis were 
approved by the ALSPAC Executive Committee 
(http://www.bristol.ac.uk/alspac/researchers/research-ethics/) (project 
reference B1340). 
3.2.2 Sample representativeness 
3.2.2.1 The Cohort 
The ALSPAC research team investigated comparisons of socio-
demographic characteristics and standard school assessments (at 
age 16 years) between a nationally representative sample and the 
enrolled ALSPAC sample. When compared to participants from the 
national sample, the enrolled ALSPAC participants: i) had higher 
educational attainment, ii) are more likely to be white, iii) less likely to 
be on free school meals and iv) more likely to be female (Boyd et al. 
2013). 
3.2.2.2 The Mothers 
The ALSPAC research team also investigated differences in 
characteristics between mothers recruited to the study and the whole 
of the UK. When compared to mothers from the whole of Great 
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Britain, mothers of children living in the Avon area were: i) more likely 
to live in their own accommodation; ii) less likely to have >1 person 
per room in the household; iii) more likely to have a car available for 
the household and iv) less likely to be non-white. For the mothers 
enrolled in the study, when compared to either mothers in the whole 
of Great Britain and to mothers in the Avon area, the ALSPAC 
mothers were more likely to: i) own their own home, ii) have a car 
available to the household, iii) have more than 1 person per room in 
the household, iv) be married and more likely to be White (See Table 
4) (Fraser et al. 2013). 
Table 4 Differences in socio-economic characteristics between mothers in the 
whole of Great Britain, mothers of infants born in the Avon area (but not enrolled in 
the ALSPAC sample) and mothers who participated in the ALSPAC study
1Mothers with infants <1 year of age; 2 Assessed by questionnaire administered at 
approximately 8 months postnatally; ALSPAC: Avon Longitudinal Study of Parents 
and Children
3.3 Measures
For the continuous measures generated in the subsequent sections
(exposure and outcome measures), Z score standardization was 
used so that the rescaled variables had a mean of 0 and SD of 1 to 
aid comparison of results within this study and across other studies. 
Characteristic
Mothers in 
the whole 
of Great 
Britain1
Mothers in 
the Avon 
area1
Enrolled mothers2
Owner occupied 
accommodation 63.4% 68.7% 79.1%
> 1 person per room in 
the household 30.8% 26.0% 33.5%
Has a car available to 
the household 75.6% 83.7% 90.8%
Married couple 71.8% 71.7% 79.4%
Non-white mother 7.6% 4.1% 2.2%
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3.3.1 Hypomania 
The Hypomania Checklist-32 (HCL-32) is a self-administered 
questionnaire that was designed to screen for the presence of 
lifetime hypomania symptoms in patients with depression. It has 
been validated as a screening tool for bipolar II disorder in both 
clinical (Angst et al. 2005a; Carta et al. 2006; Forty et al. 2009; 
Rybakowski et al. 2010; Mosolov et al. 2014) and non-clinical (Meyer 
et al. 2007; Holtmann et al. 2009; Lee et al. 2016) settings. In general 
population samples, first onset of hypo(manic) episodes is rarely
diagnosed before age 25 years (Leboyer et al. 2005). Sub-threshold 
hypo(manic) symptoms may be present in childhood/adolescence, 
and the detection of these symptoms may be useful for identifying 
individuals who are more likely to go on to develop BD (Fiedorowicz 
et al. 2011), or convert from unipolar depression to BD (Tijssen et al. 
2010). The full questionnaire in its entirety can be found in Appendix 
1. The 32 questions ask about a period when an individual was “in a 
‘high’ state” and are summed to generate a total score. 
Previous factor analyses of the HCL-32 suggests there are latent 
underlying constructs, the most consistently reported being a 2-factor 
model describing ‘active/elated’ and ‘risk-taking/irritable’ factors 
(Angst et al. 2005a; Meyer et al. 2007; Holtmann et al. 2009; Fornaro 
et al. 2015). Others have additionally suggested a 
‘disinhibited/stimulation-seeking’ factor and a ‘positive social 
interaction’ factor (Haghighi et al. 2011).
3.3.1.1 Psychometric properties of the HCL-32
In a systematic review on the properties of the HCL-32, Meyer and 
colleagues reported that in 21 studies, using data from 22 
independent samples, 15 studies reported the optimal threshold to be 
classed as having clinically-defined hypomania was a score of 
≥14/32. The alternative optimum threshold score ranged between 
≥7/32 to ≥21/32 in the remaining 6 studies. In the 15 studies 
47
reporting an optimal threshold of ≥14/32, sensitivity, specificity, 
positive predictive value (PPV) and negative predictive values (NPV) 
were estimated. Sensitivity in this instance indicates the probability of 
the HCL-32 correctly identifying BD cases i.e. a true positive, whilst 
specificity indicates the probability of the HCL-32 correctly identifying 
those without BD i.e. a true negative. In the 10 samples consisting of 
people with BD (24%) and people with depressive disorder (76%), 
the pooled values were: sensitivity (80%), specificity (65%), PPV 
(47%) and NPV (50%), suggesting the HCL-32 performs well at 
identifying true BD cases in individuals with a mood disorder 
diagnosis. In the same review, the authors identified a single study 
that used an alcohol and opiate dependent sample as the 
comparison group and reported that at a threshold score of ≥14/32, 
sensitivity was high (90%), though specificity was poor (39%) (Meyer 
et al. 2014). Since that review, a single study has examined 
sensitivity and specificity using a general population sample (in which 
there were BD cases and non-clinical controls), and reported poor 
specificity (36%), but higher sensitivity (82%) (Lee et al. 2016). This 
indicates that the HCL-32 over-estimates the proportion of people 
who have BD, and particularly in general population samples 
compared to clinical samples of people with mood disorders. 
To enhance the psychometric properties of the HCL-32, a Rasch 
analysis for unidimensionality of the HCL-32 was conducted within a 
sample of 389 individuals with DSM-IV BD from the Bipolar Disorder 
Research Network (BDRN) (Court et al. 2014). Four questions were 
identified as redundant and could be excluded. These questions 
were questions 14 ‘I wear more extravagant clothes/more make-up’, 
29 ‘I drink more coffee’, 30 ‘I smoke more’ and 32 ‘I take more drugs’.
Thus, analyses in this thesis are based on the remaining 28 items, 
which were used to generate a HCL score, a binary measure of 
clinically-defined hypomania, and latent factors of the HCL. 
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3.3.1.2 Measure of hypomania in ALSPAC
Hypomania features were assessed via postal and online 
questionnaires using the HCL-32 when the ALSPAC cohort were 
aged 22-23 years. In total, 9,359 participants were invited to 
complete the HCL-32, though only 3,448 (36.8%) returned the 
questionnaire. The analyses used in this thesis are based on the 
3,371 individuals with no missing data on the HCL. 
To generate the HCL score, responses (0 = no and 1 = yes) on the 
28 questions were summed (scores ranged from 0-28) and 
standardised to produce a continuous measure of hypomania. The 
28 questions used to generate the HCL score are shown in Table 5.
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Table 5 The 28-item HCL
HCL: Hypomania Checklist
Whilst the most often reported threshold cut-off score to define 
hypomania using the full 32-item checklist is ≥14/32 (see Meyer et al. 
(2014), there are no studies that have determined the optimal 
threshold cut off score when using only the 28 items as I am using in 
this thesis. Therefore, in line with the full 32-item HCL, I have used a 
cut-off score of ≥14/28 on the HCL. Additionally, to meet criteria for 
Item
Need less sleep
More physically active
Want to travel
Enjoy work more
Make more jokes
Want to meet/do meet more people
Have more ideas/more creative
Think faster
Engage in lots of new things
Do things more quickly/easily
Less shy/inhibited
Plan more activities
More sociable
Feel more energetic
Talk more
More self-confident
Mood is higher/ more optimistic
More interested in sex
More flirtatious
More impatient/get irritable more easily
Get into more quarrels
Drink more alcohol
Tend to drive faster/take more risks when driving
Spend more/too much money
Can be exhausting/irritating to others
More easily distracted
Thoughts jump from topic to topic
Take more risks in daily life
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clinically-defined hypomania, participants were required to have had 
symptoms that lasted 2-3 days or more (as this conforms to the ICD-
10 criteria of hypomania having lasted “at least several days on end”
(World-Health-Organisation 1993), and to endorse a ‘negative’, or 
‘negative/positive’ response to questions about the impact of their 
‘high’ on their family, social, leisure, or work life (see Appendix 1, 
Questions 4, 5 and 6). This produced a binary measure of clinically-
defined hypomania, in which, 239 individuals (7.1%) were classified 
as having clinically-defined hypomania.
HCL factors were derived by Dr Hannah Jones at the University of 
Bristol using a confirmatory factor analysis (CFA) of the HCL-28. By 
running a CFA, it was possible to assign each of the 28 questions 
from the HCL to their corresponding factors (as previously identified 
through exploratory factor analysis) (Angst et al. 2005a; Vieta and 
Phillips 2007; Fornaro et al. 2015) using the mean and variance 
adjusted weighted least squares (WLSMV) method in Mplus. The 
WLSMV method incorporates diagonal elements of the full weight 
matrix allowing for factor loadings to be positive or negative. WLSMV 
estimates thresholds and polychoric correlations obtained using 
maximum likelihood methods. Parameter estimates can then be 
obtained from estimates of the asymptomatic variances of the 
threshold and polychoric correlations obtained from the diagonal 
weight matrix. This was because this method makes no assumptions 
regarding the underlying distribution of variables in the model, and 
has also been shown to produce less biased and more accurate 
factor loadings compared to the maximum likelihood methods. 
Additionally, this method is specifically designed to deal with data 
which are categorical (binary or ordinal) in which the normality 
assumption or continuity property of the variables is plausible (Li 
2016). The two factors were derived based on 19 items representing 
an ‘active/elated’ factor and 9 items representing a ‘risk-
taking/irritable’ factor (see Table 6 for factor loadings) and were 
continuous measures.
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Table 6 Standardised factor loadings for the HCL factors  
HCL: Hypomania Checklist; Factor loadings in bold indicate an item was loaded 
onto that factor
Item ‘Active/elated’ factor loading
‘Risk-taking/irritable’ factor 
loading
Need less sleep 0.303 0.091
More energetic and more 
active 0.662 -0.219
More self-confident 0.680 -0.184
Enjoy work more 0.615 -0.184
More sociable 0.623 -0.074
Want to travel and/or do 
travel more 0.417 0.114
Drive faster or take more 
risks when driving 0.039 0.342
Spend more/too much 
money 0.061 0.401
Take more risks in daily life 0.243 0.351
More physically active 
(sport) 0.492 -0.042
Plan more activities or 
projects 0.599 -0.025
Have more ideas, am more 
creative 0.531 0.061
Less shy or inhibited 0.570 0.018
Want to meet or actually 
do meet more people 0.473 0.174
More interested in sex 0.416 0.247
More flirtatious 0.457 0.251
Take more 0.539 0.057
Think faster 0.474 0.148
Make more jokes or puns -0.079 0.251
More easily distracted 0.471 0.168
Engage in lots of new 
things 0.471 0.148
Thoughts jump from topic 
to topic 0.037 0.533
Do things more quickly 
and/or more easily 0.491 0.161
More impatient -0.228 0.571
Can be exhausting or 
irritating for others -0.054 0.494
Get into more quarrels -0.213 0.502
Mood is higher, more 
optimistic 0.672 -0.120
Drink more alcohol 0.064 0.304
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3.3.2 Childhood psychopathology 
The following section refers to measures of psychopathology
examined during childhood/adolescence. These measures were 
selected to be at the youngest age available from the data available 
to me, to minimize the likelihood of reverse causality.
3.3.2.1 Borderline personality disorder (BPD) traits
At age 11 years, the cohort was invited to face-to-face interviews to 
assess their experience of BPD traits over the preceding two years. 
In total, data was available on 6,413 children.
To assess for BPD traits, an interview was conducted by a trained 
psychologist using the Childhood Interview for DSM-IV Borderline 
Personality Disorder (CI-BPD). This is a semi-structured interview 
designed to assess BPD traits in children (ages 6-12 years) (Zanarini 
et al. 2004). Though originally developed by Mary Zanarini, the CI-
BPD was adapted by Jeremy Horwood and Dieter Wolke to be used 
at the Focus 11+ clinic. The CI-BPD is based on the borderline 
module of the Diagnostic Interview for DSM-IV Personality Disorders 
(Zanarini et al. 1996). The convergent validity of the CI-BPD has 
been shown to be significantly associated with clinician diagnosis 
and other measures of BPD reported by patients and parents (Sharp 
et al. 2012a). Importantly, the purpose of the CI-BPD is not to 
diagnose a child as having BPD, rather it is to identify prevalence of 
the individual BPD traits in children and adolescence. 
A total of nine BPD traits (anger symptoms, affective instability, 
emptiness, identity disturbance, paranoid ideation, fear of 
abandonment, suicidal behaviour, impulsivity and intense 
interpersonal relationships) were assessed. Judgements were made 
by a trained assessor in the ALSPAC research team and rated as 
absent, probably present or definitely present (coded as 0, 1 and 2 
respectively). To meet criteria for being definitely present, the trait 
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had to be present at least 25% of the time (or daily). A ‘probably’
rating required the trait to be present regularly but not as often as
definitely present.
Using the scores from the 9 individual BPD traits generated by 
ALSPAC researchers, I derived a BPD traits score, which is the sum 
of the 9 BPD traits (range 0-18), and I then standardised this 
continuous measure. I also used a ‘high-risk’ for BPD binary variable 
ALSPAC researchers had derived, with individuals classified as 
‘high-risk’ if they met criteria for ‘probably present’ or ‘definitely 
present’ on 5 or more traits. There were 370 individuals (5.8%) who 
were defined as ‘high-risk’ for BPD.
3.3.2.2 Attention Deficit Hyperactivity Disorder (ADHD) 
The presence of ADHD was assessed using the parent-rated and 
teacher-rated Development and Well-Being Assessment (DAWBA), 
when the cohort were age 7.6 years (n = 8,219).
The DAWBA is a semi-structured package of interviews, 
questionnaires and rating techniques used to generate either DSM-IV 
or ICD-10 diagnoses or symptom scores of childhood 
psychopathology. This covers common emotional, behavioural and 
hyperactivity disorders. The validity of the DAWBA has been shown 
in both clinical and community based samples (Goodman et al. 
2000). 
In the ALSPAC cohort, a diagnosis of ADHD was available based on 
the DSM-IV diagnostic criteria for ADHD, and was only given where 
data were available from both teacher and parent reports. There 
were 175 children (2.2%) who were classified as having any ADHD. 
3.3.2.3 The Strengths and Difficulties Questionnaire (SDQ)
The SDQ is part of the DAWBA set of mental health measures and is 
a brief behavioural questionnaire designed to assess general 
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childhood psychopathology, particularly well adapted for use in 
general population studies. The SDQ has a five-factor structure 
where items load onto the measures of: hyperactivity-inattention, 
prosocial behaviour, emotional difficulties, conduct problems and 
peer relationship difficulties (Goodman 2001).
When the children were aged 115 months (9 years), the parents of 
the children completed the SDQ which asked about these behaviours 
during the previous 6 months. Data were available on 8,074 
individuals (Goodman 1997). 
Each SDQ subscale score was generated by ALSPAC researchers 
as the weighted sum of the score from the 5 questions within the 
questionnaire which corresponded to the psychopathology measure 
being assessed (range of subscale scores 0-10). The individual 
questions each parent was asked about their child related to the 
previous 6 months. I generated a total difficulties score which was 
the sum total of the hyperactivity, emotional difficulties, conduct 
problems and peer relationship difficulties scores to give a total 
difficulties score (range 0-40) (the prosocial behaviour subscale 
score does not contribute to the total difficulties score) (Goodman 
1997). All scores were then standardized.
3.3.2.4 The Moods and Feelings Questionnaire (MFQ) 
The MFQ is designed to detect the presence of a broad range of 
depressive symptoms in children and adolescents (Costello and 
Angold 1988). It is possible for both children (age 6–17 years) and 
the parents to complete the questionnaire which comprises of 32 
questions in total. A review of its psychometric properties suggest 
that the MFQ is both a reliable and valid measure of assessing for 
presence of depression in childhood and adolescence (Wood et al. 
1995; Daviss et al. 2006). 
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At age 9 years, the parents completed the short version of the MFQ 
(n = 8,066) which asked about how their child felt or acted in the 
previous 2 weeks (Angold et al. 1995).
The MFQ score was generated by the ALSPAC research team as the 
weighted sum of the score from each of the 13 questions (range 0-
24), which I standardised.
3.3.3 Cognitive measures 
An often used tool for assessing cognitive functioning in patients with 
schizophrenia (SZ) is the Measurement and Treatment Research in 
Cognition in Schizophrenia (MATRICS) consensus cognitive battery 
(MCCB) (Green and Nuechterlein 2004; Marder and Fenton 2004). It 
has been recommended by the Food and Drug Administration (FDA) 
in the USA to assess cognitive impairment in registry trials of SZ 
(Nuechterlein et al. 2008), and assesses the following 7 cognitive 
domains: i) Processing Speed, ii) Working Memory, iii) 
Attention/Vigilance, iv) Visual Learning i.e. immediate visual memory, 
v) Verbal Learning i.e. immediate verbal memory, vi) Problem 
Solving and Reasoning ability, and vii) Social Cognition (Nuechterlein 
et al. 2008).
However, for BD, the most appropriate tool for assessing cognitive 
functioning is not clear. In 2010, the International Society for Bipolar 
Disorder convened and suggested that based on the clinical and 
cognitive overlap between SZ and BD, the MCCB might be deemed 
an appropriate tool to examine cognitive functioning in BD patients 
(Yatham et al. 2010). Furthermore, this battery has been used more 
recently when assessing cognitive functioning in BD patients (Sperry 
et al. 2015; Bo et al. 2017). 
In ALSPAC, cognitive functioning was assessed at age 8 years and 
measured the domains of: general intelligence as indexed by 
intelligence quotient (IQ) (performance, verbal and total), processing 
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speed, working memory, problem solving ability, executive 
functioning, attention, verbal learning and social cognition. These 
cognitive domains are loosely based on the domains identified in the 
MCCB, though there was no comparable measure of visual learning 
in the ALSPAC cohort, and therefore this cognitive domain was not 
assessed. 
The cognitive domains in ALSPAC were assessed using a number of 
tools: i) the Wechsler’s Intelligence Scale for Children – IIII (WISC-III) 
assessed cognitive domains of: general intelligence (IQ), processing 
speed, working memory and problem-solving ability (Wechsler et al. 
1992), ii) the Test of Everyday Attention for Children (TEACh) 
assessed domains of: executive functioning and attention (Robertson 
et al. 1996), iii) the Children’s Test of Non-Word Repetition (CTNWR) 
assessed verbal learning (Gathercole and Adams 1994), and iv) the 
Diagnostic Analysis of Non-Verbal Accuracy (DANVA) assessed 
social cognition (emotion recognition) (Nowicki and Duke 1994).
All cognitive domain scores, irrespective of which tool was used to 
assess them, were standardised to produce continuous measures. 
Any cognitive domain scores that were >3 SD from the mean were 
removed from the analysis, as these scores can have strong effects 
on estimates (either underestimating or overestimating effect sizes). 
3.3.3.1 WISC-III
The children were administered the short form of the WISC-III at age 
8 (n = 7,405). Alternate items were used for all subtests, except the 
coding subtest which was administered in its full form. In addition to 
the 10 subtests (information, similarities, arithmetic, vocabulary, 
comprehension, picture completion, coding, picture arrangement, 
object assembly and block design), the children were also assessed 
on the forwards and backwards digit span task. Each subtest was 
administered by a trained psychologist in the ALSPAC team. 
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IQ: A measure of performance IQ (PIQ) was derived from the spatial, 
sequencing and problem-solving abilities sub-tests (n= 7,371). Verbal 
IQ (VIQ) was derived from the general knowledge, language, 
reasoning and memory skills sub-tests (n = 7,379). Total IQ (TIQ) 
(n = 7,384) was derived from the summed total of both PIQ and VIQ 
using the WISC-III. 
Processing speed: One of the subtests within the WISC-III, the 
coding subtest, was used to assess processing speed in 7,403
children. The children were shown a code in which numbers were 
assigned a symbol. The sheet contained various numbers (1-5) and 
required the children to correctly draw the symbol that corresponded 
to each number in the box as quickly as possible within a specified 
time limit.
Working memory: Working memory was assessed using the 
Freedom From Distractibility Index, originally derived by Wechsler in 
7,174 children. This index score is the combination of the arithmetic 
and digit span (forwards and backwards) tasks. The arithmetic 
subtest was split into 3 parts: i) Questions 1-5 required the children to 
respond to questions asked by the assessor, related to pictures in a 
stimulus book, ii) Questions 6-18 required the children to solve 
problems read aloud by the assessor, and iii) Questions 19-24 
required the children to read problems aloud that were printed in a 
stimulus book and then solve those problems.
The forward digit span task required the children to listen to an 
assessor who read aloud digits of increasing length and were 
required to repeat them back. Initially, the assessor started with one 
digit, and the number of digits within a sequence increased in length 
until the child could not correctly state the digits in the order they 
were spoken. 
The backward digit span immediately followed the exact forward digit 
span sequence the child was unable to correctly state in the order it 
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was spoken. Again, the initial sequence was one digit long and 
increased in length. The children were required to repeat the 
sequence in reverse order.  
Problem solving: Problem solving ability was assessed using the 
block design subtest in 7,362 children. The children were given two 
trials where they observed the assessor and constructed the same 
design as the assessor using blocks. The cubes had two sides that 
were coloured red, two sides that were coloured white, and two sides 
that were coloured both red and white. Following the demonstrations, 
the children were then shown pictures in a stimulus book and 
required to assemble the blocks to match the picture shown.
3.3.3.2 The TEACh
The TEACh was originally designed as a comprehensive assessment 
of attention performance in persons with specific attentional deficits 
(Robertson et al. 1996). Attention itself can be split into distinct 
systems: selective, divided and maintenance. Unlike other tests of 
attention, the focus of these assessments is on everyday life tasks as 
opposed to a forced laboratory setting (Posner and Petersen 1990). 
Executive functioning: The cohort were invited to complete the 
opposite worlds task (n = 7,202). ALSPAC researchers administered 
the opposite worlds task where 24 numbers were shown to the 
children. The task is akin to a basic kind of Stroop task where the 
child was required to verbalise a response that contradicted the 
visual information seen as quickly as possible. If the child saw either 
a number 1 or 2, they would say number 2 or 1 respectively.
There were two trials for the opposite worlds task. To generate an 
executive functioning score, I standardised the mean time taken to 
complete the opposite worlds task. 
Attention: The sky search task was used to measure attention in 
7,184 children. This task required the children to identify identical (20 
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in total) from non-identical spaceships and draw a circle around all 
identical pairs they could see. This task was also repeated but the 
child only had the 20 identical spaceships and was required to circle 
all spaceships. The latter task was completed to identify the speed 
with which the child was able to draw the circles. 
The score I used was the sky search task adjusted for motor speed, 
calculated by the ALSPAC research team. This was calculated as the 
time taken in the initial task of identifying identical from non-identical 
spaceships minus the time taken to complete the motor task for each 
child. 
The initial coding by ALSPAC researchers was such that higher 
scores reflected poorer performance for executive functioning and 
attention cognitive domains. I therefore recoded these variables so 
that higher scores always reflect better performance on the task.
3.3.3.3 The CTNWR
The CTNWR is designed to assess the adequacy of temporary 
phonological representations of perceived speech in short-term 
memory. Poor scores on this task are closely linked to deficits in 
vocabulary, reading and comprehensive skills in early childhood 
compared to normally developing children of the same and younger 
age (Gathercole and Adams 1994). 
Verbal learning: The children (n = 7,361) were required to listen to 
and repeat 12 nonsense words back to the assessor. Each word was 
played through an audio cassette, and after each word, the child 
repeated the word back to the assessor. Four of these words were 3 
syllables long, four were 4 syllables long and four were 5 syllables 
long.
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3.3.3.4 The DANVA  
The DANVA is a research instrument designed to detect differences 
in a child’s ability to accurately send and receive emotional 
information non-verbally by 4 means: facial expressions, gestures, 
tone of voice and posture. Differences in non-verbal processing 
ability might be attributed to various indicators of personal and social 
adjustment. Children with lower scores on the DANVA may have 
some form of dyssemia and should therefore be observed to 
determine the source of their non-verbal difficulties (Nowicki and 
Duke 1994).
Social cognition: In ALSPAC, 6,815 children completed the DANVA 
facial expressions task. Children were presented with 24 faces 
representing emotions of happiness, sadness, fearfulness or anger. 
The task required the children to make judgements and verbalise 
their interpretation of the emotion being shown on the screen. The 
emotion intensity was either low or high (making the task more 
difficult or easier respectively). Each image was shown on the screen 
for 2s. 
Each emotion score (happy, sad, fearful and angry) was scored on a 
scale of 0 to 6 and I derived a total emotion errors score which was 
the sum total of the emotion face scores and standardised this.
These were recoded so that higher scores always reflect better 
performance.
3.4 Confounding
In Chapters 4 and 5, I adjusted for a number of potential 
confounders, determined a priori based on evidence from the 
literature. They are known to be associated with both the exposure 
and outcome but not on the causal pathway. The following 
confounders were adjusted for in my analyses: 
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Gender was a binary variable coded as 0 = female and 1 = male
(Rowland and Marwaha 2018).
Maternal age at birth was assessed by the ALSPAC research team in 
response to the mother providing her date of birth. A continuous 
variable was created by the research team, with ages ranging from 
14-45 years (Menezes et al. 2010; Chang et al. 2014; Mikkelsen et 
al. 2017).
Maternal social class was assessed from returned reports at 32 
weeks’ gestation. The ALSPAC research team categorised 
responses into 6 levels (I-V, with I being the highest social class) and 
is in line with the 1991 Office of Population Censuses and Surveys 
classifications (Cohen et al. 2008; Russell et al. 2014; Arroyo-Borrell 
et al. 2017; Rowland and Marwaha 2018).
Maternal highest education level was created by the ALSPAC 
research team. Levels were based on the UK education system and 
in line with previous work (Smith et al. 2015) I categorised this into a 
dichotomous variable (0 = less than degree and 1 = degree or 
above). Mothers who were categorised in the less than degree group 
had completed either O’ levels, secondary education, A levels or 
vocational training (Sagiv et al. 2013; Etherington et al. 2016; Lin et 
al. 2017).
History of maternal depression was assessed by the ALSPAC 
research team at 12 weeks of gestation. The ALSPAC research team 
generated a dichotomous variable, which I recoded so that 0 = no 
history of depression and 1 = positive history of depression) (Lieb et 
al. 2002; Cullen et al. 2014; Wolford et al. 2017; D'Souza et al. 
2019).
Ethnicity was derived by the ALSPAC research team from responses 
received from self-reports at 32 weeks of gestation. This was a 
dichotomous variable which I recoded so that 0 = non-white and 1 = 
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white (Zilanawala et al. 2015; Coker et al. 2016; Akinhanmi et al. 
2018).
Being a victim of bullying at school at age 8 assessed using the
modified version of the Bullying and Friendships Interview Schedule
(Wolke et al. 2001). If the child scored a response of “yes” on any of 
the 5 questions asked about the type of bullying they received, they 
were classified as a victim of being bullied and produced a 
dichotomous variable coded 0 = not bullied and 1 = bullied 
(Holmberg and Hjern 2008; Undheim and Sund 2010; Wolke et al. 
2012; Palmier-Claus et al. 2016).
Being emotionally and/or physically abused by either parent since the 
child was 6 was assessed via questionnaire. The research team 
generated a categorical variable, in which several options for yes 
were included (“yes since 6th birthday”, “yes since the child’s 8th
birthday” and “yes both since the child’s 6th birthday and from 8+”)
and “no did not happen in the last 3 years”. However, in line with 
others who have examined childhood emotional and/or physical 
abuse (Lereya et al. 2015), I collapsed this into a dichotomous 
variable coded 0 = not abused and 1 = abused) (Dvir et al. 2014; 
Newnham and Janca 2014; Palmier-Claus et al. 2016; D'Souza et al. 
2019). 
Assessments of handedness were conducted by a trained 
Psychologist when the children were age 10 years. Though the 
purpose of the computer task was primarily to examined executive 
cognitive function, working memory and inhibition, a determination of 
the child’s dominant hand was recorded. This produced a 
dichotomous variable, which I coded as 0 = right-handed and 1 = left-
handed. 
In Chapters 4 and 5, a number of these confounders were adjusted 
for, with comparisons being made between unadjusted and adjusted 
models using multivariable regression. Where adjustment for 
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confounders made a substantial impact on effect size and/or strength 
of evidence of association, both unadjusted and adjusted results are 
reported in the main text. For the individual confounders adjusted for 
in each analysis, please see Chapters 4 and 5. 
3.4.1 Addressing potential sources of confounding in genetic 
analyses 
In polygenic risk score (PRS) analyses, the biggest source of 
confounding after performing quality control is population 
stratification. Population stratification is where differences in allele 
frequency between cases and controls are likely a result of ancestry 
as opposed to association of genes with the disease of interest. It is 
most commonly due to non-random mating between groups of 
individuals, often based on physical geographical distance, followed 
by genetic drift of allele frequencies in each of the groups. Not 
adjusting for population stratification in ethnically diverse populations 
can lead to detecting spurious loci which have nothing to do with the 
disease of interest (Liu et al. 2013; Choi et al. 2018). In my analyses
(Chapters 7 and 8), I did not adjust for population stratification as the 
ALSPAC sample has been shown to be homogenous, and genome-
wide analyses of phenotypes indicate low lambda, producing a
genomic inflation factor (≈1) (Zammit et al. 2014; Martin et al. 2015).
The other potential source of confounding in PRS analyses is linkage 
disequilibrium (LD) between SNPs i.e. the non-random occurrence of 
alleles at different loci. To account for LD between SNPs, clumping 
can be performed to retain SNPs that are largely independent of 
each other, and their effects summed. Therefore, as is common 
practice in PRS analyses, I clumped SNPs to preferentially retain 
SNPs most strongly associated with BD. Through clumping, it is also 
possible to retain multiple independent effects in the same genomic 
region and not simply the most strongly associated SNP in that 
region (Choi et al. 2018).
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3.5 Genetic Data
In this thesis, I will be deriving PRSs using primary genotype data 
from the ALSPAC sample and summary statistics from the 
Psychiatric Genomics Consortium (PGC) samples. I will first 
describe, in detail, the quality control measures used by the research 
teams (ALSPAC and the PGC) before describing how I derived the 
PRS.
3.5.1 ALSPAC quality control measures
The quality control measures described in this section were 
conducted by the ALSPAC research team. 
In the ALSPAC cohort, a total of 9,912 ALSPAC children were 
genotyped using the Illumina HumanHap550 quad genome wide 
single-nucleotide polymorphism (SNP) by 23andMe subcontracting 
the Wellcome Trust Sanger Institute, Cambridge, UK and the 
Laboratory Corporation of America, Burlington, NC, USA. Individuals 
were excluded from analyses if: i) their gender assignment was 
incorrect, ii) they had minimal or excessive herterozygosity (<0.320 
and >0.345 for the Sanger Data and <0.210 and >0.330 for the 
LabCorp data), iii) there were disproportionate levels of missingness 
(>3%), iv) they were not of European-ancestry and v) showed 
evidence of cryptic relatedness (>10% identity by descent). Further, 
any SNPs with a minor allele frequency (MAF) <1%, a SNP call rate 
<95% or imputation quality (INFO score) <0.8 were excluded from 
the analyses. Finally, only SNPs which passed the exact test for 
Hardy-Weinberg Equilibrium (p>5x10-7) were considered for further 
use. After the ALSPAC research team conducted quality control, 
imputation, and restriction to 1 young person per family, genetic data 
was available on 8,230 individuals. The two sites where genotyping 
was conducted had differing heterozygosity filters applied, though 
this is unlikely to confound results as genotyping site would also 
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need to be associated with the outcome of interest (as well as the 
exposure) for confounding to occur.
3.5.2 Psychiatric Genetics Consortium (PGC) quality control 
measures 
All quality control measures described in this section were conducted 
by the PGC research team. 
To genotype individuals in the second PGC GWAS for: BD 
(n = 20,352 cases and 31,358 controls) (Stahl et al. 2019), SZ (n = 
36,989 SZ cases 113,075 controls) (Ripke et al. 2014) and SZvsBD 
(n = 33,426 SZ cases and 20,129 BD “controls”) (Ruderfer et al. 
2018), four genotyping platforms were used: Affymetrix 500K, 5.0, 
6.0 and Illumina HumanHap500. SNPs were retained if their missing 
genotype rate per SNP was <0.02, Hardy-Weinberg in controls was 
p>1x10-6 and the frequency difference to Hapmap-reference was 
<0.15. 
3.5.3 Further quality control measures prior to constructing the PRS
In addition to the quality control measures run by the PGC and 
ALSPAC research teams, using R statistical software, I further 
removed SNPs in the PGC dataset if their INFO score was <0.8, if 
the SNPs had a MAF of <0.01. In addition, in line with recent 
guidelines on generating PRS (Choi et al. 2018), when discovery and 
target datasets have been genotyped on different chips, and the 
chromosome strand (positive or negative) is unknown, SNPs cannot 
be matched e.g. if A/T or C/G across datasets as it is not possible to 
determine whether the discovery or target datasets are referring to 
the same allele or not.
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3.5.4 Constructing the PRS
To generate the PRS, I followed the methods first described by the 
International Schizophrenia Consortium (Purcell et al. 2009). 
Having removed any further SNPs from either discovery or target 
datasets which did not meet criteria for inclusion in the PRS, using R, 
I generated the log odds ratio (OR) for the corresponding effect sizes 
from the PGC GWAS for BD, SZ and SZvsBD. I then merged the 
PGC summary statistics GWAS and ALSPAC datasets (PGC 2 BD 
GWAS with ALSPAC; PGC 2 SZ GWAS with ALSPAC, and PGC 2 
SZvsBD GWAS with ALSPAC) which contained information on the 
SNP ID, risk allele (A1), non-risk allele (A2), log ORs and p-values. 
From this, a file that contained information on the SNP ID, allele A1 
and corresponding log OR was generated, and a separate file, which 
contained a list of SNP IDs only were then used to construct the PRS 
in PLINK v1.9. Duplicate SNPs were identified and removed prior to 
clumping firstly by generating a file which contained duplicate SNPs 
in them and then using the grep command to remove duplicate SNPs 
from the merged file. 
Using PLINK v1.9, SNPs were linkage disequilibrium (LD) clumped, 
with r2 <0.2 within 1MB windows, as this is the typical size of an LD 
block using the –clump command. I flipped any alleles where there 
was mismatch between the target and discovery dataset i.e. A/C in 
one dataset and G/T in the other using the --flip-scan command and 
the clumped SNPs were then extracted using the –extract command.
Using R statistical software, I then generated training scores which 
contained SNPs with a p-value threshold (PT) cut-off of 0.01 (Stahl 
et al. 2019) and 0.5 (Sklar et al. 2011) for BD, PT0.05 for SZ 
(Ripke et al. 2014) and PT0.5 for SZvsBD (Ruderfer et al. 2018). 
These PT’s were selected as they have been reported to maximally 
capture liability for the disorders in their respective GWAS. For the 
SZvsBD training score, a PT0.5 was chosen as this is the PT that 
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maximally captures variance for most other phenotypes (Ware et al. 
2017). The training scores contained the SNP ID, allele A1 and 
corresponding effect size. The PT approach performs no shrinkage of 
effect size estimates of the included SNPs, but does effectively 
shrink effect sizes of non-included SNPs to zero. I then used the 
training scores produced from R to generate profile scores (i.e. 
PRSs) for each individual in ALSPAC using the –score command in 
PLINK. Each PRS is the sum total of the number of risk alleles for 
each SNP (0, 1, 2) weighted by the log of its OR. Each PRS file 
contained information on the family ID (FID), individual ID (IID), 
phenotype (PHENO), number of non-missing SNPs used for scoring 
(CNT), number of named alleles (CNT2) and the PRS itself. The PRS 
files (BD-PRS at PT0.01 and 0.05; SZ-PRS at PT0.05 and SZvsBD-
PRS at PT0.5) were then merged with the ALSPAC dataset by FID 
to create a master dataset which contained the PRSs and all 
phenotypic data. 
3.6 Statistics  
3.6.1 Measures of association 
Measures of association between an exposure and outcome can be 
relative (e.g. ratio measures) or absolute (e.g. difference measures). 
3.6.1.1 Absolute measures 
Absolute measures such as difference measures are used to 
examine the absolute change in risk of the disease according to 
different levels of exposure. One method of examining the 
differences in absolute risk of the disease when using continuous 
outcomes is linear regression. 
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3.6.1.1.1 Linear regression 
Linear regression analyses rely on a number of assumptions: i) the 
relationship between exposure and outcome is linear, ii) there is no 
or little multicollinearity i.e. the exposure measures are not highly 
correlated with each other, iii) the residuals are normally distributed, 
iv) there is no heteroscedacity i.e. the errors should not vary 
systematically across values of the exposure, and v) the residuals 
are uncorrelated. If these assumptions are violated, the regression 
coefficient may be biased, or the variance of the estimate may be 
increased. Linear regression is reasonably robust in the presence of 
mild deviation from these assumptions, particularly those of linearity 
and normality of residuals. However, in instances where there is 
large deviation from these assumptions, non-parametric methods 
e.g. the Kruskal-Wallis test may provide a more valid and less biased
measure of the association between exposure and outcome. 
To determine whether linear regression was an appropriate statistical 
method to use in analyses using continuous outcomes, I tested the 
assumptions of linear regression described above. To examine the 
possibility of a non-linear relationship, I generated quadratic terms of 
the exposure measures, and where applicable, if a non-linear 
relationship was detected, both linear and quadratic term results are 
reported. Kernel density plots of continuous outcomes were used to 
determine whether the residuals were normally distributed, and tests 
for heteroscedacity were conducted post-analysis. 
I report effect sizes (beta coefficients) and 95% confidence intervals 
(CI) to aid interpretation of the strength of evidence of association. 
These results reflect the standard deviation (SD) change in outcome 
per SD increase in exposure (if the exposure is continuous) or the 
SD change in outcome if the exposure is present compared to absent 
(if binary). 
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3.6.1.1.2 Aiding interpretation of non-linear relationships 
Whilst the addition of a quadratic term provides information on 
whether a non-linear relationship is present, to facilitate the 
interpretation of this, I derived tertiles of the exposure and compared 
the outcome when being in the lowest or highest tertiles compared to 
the middle exposure tertile. Though deriving tertiles to help facilitate 
interpretation of a non-linear effect is useful, this method of 
investigating these relationships is not without flaw. The limitations of 
deriving the tertiles are i) the increase in parameters estimated 
increases the problems of multiple testing, ii) it requires an unrealistic 
step-function of risk that assumes homogeneity of risk within groups, 
leading to both a loss of power and inaccuracy in the estimation of 
effect, and iii) it leads to difficulty comparing results across studies 
due to the data-driven cut points used to define categories (Bennette 
and Vickers 2012). 
3.6.1.2 Relative measures 
Relative measures are used when examining associations with 
binary or categorical outcomes. Relative risk is a generic term which 
includes measures such as rate ratios and risk ratios which can only 
be derived from cohort studies. Though rate ratios and risk ratios can 
be used when using longitudinal data, in this thesis, I will be using 
odds ratios (ORs) since it provides a reasonable approximation of the 
relative risk when the outcome of interest is uncommon (<10%).
3.6.1.2.1 Odds Ratio (OR)
An OR can be derived to describe the change in odds of an outcome 
across increasing levels of an exposure. ORs can be used in a 
variety of study designs including case-control, cross-sectional and 
cohort studies. 
70
It is possible to calculate the odds of disease which is the probability 
of a subject developing a disease divided by the probability that the 
subject does not develop the disease, and is calculated as follows: 
From this equation, it is then possible (for a binary exposure) to 
calculate separate odds of outcome in those who are exposed 
compared to those who are not exposed:
Logistic regression, unlike linear regression has fewer assumptions 
that are required to determine its suitability in statistical analysis: i) 
the outcome variable is binary, ii) observations should be 
independent of each other i.e. not come from matched data or 
repeated measures (unless specific methods are used to deal with 
this e.g. conditional logistic regression for matched data), iii) there 
should be no/little multicollinearity as this can lead to imprecise 
estimates, iv) the association between the independent variables and 
the log odds of the outcome is linear, and v) the sample size should 
have a minimum of 10 cases with the least frequent outcome for 
each independent variable. 
I investigated these assumptions and having done so, found that 
logistic regression was an appropriate statistical method to use for 
binary outcomes. Therefore, in this thesis, I provide ORs and 95% 
confidence intervals that represent the change in odds of the 
outcome per SD increase in exposure (if continuous and 
standardised) or presence compared to absence of the exposure (if 
binary).  
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3.6.1.3 Correlations between measures 
When investigating the extent of co-linearity between 2 continuous 
variables that are normally distributed, I used a Pearson correlation 
test, or when not normally distributed I used Spearman’s rho. If 
variables were ordinal, I used polychoric correlation. Where 
applicable, a Point-Biserial test was used to examine the correlation 
between a continuous and binary variable, and for two binary 
variables, tetrachoric correlation was used. 
3.6.1.4 Multiple imputation
To address the potential for selection bias due to missing data in my 
analyses, I used multiple imputation. There are three ways that data 
can be missing: i) data are missing completely at random (MCAR), ii) 
data are missing at random (MAR), and iii) data are missing not at 
random (MNAR). The pattern of missingness will likely guide the 
approach to deal with the missingness. 
If data are MCAR, this means that there is no relationship between 
the missingness of that data and any value, whether observed or 
missing i.e. the causes of missing data are unrelated to the data. 
Therefore, analyses on data that are MCAR are likely unbiased. 
However, in practice, this is rarely the case. If data are MAR, this 
means that there are systematic differences between missing and 
observed values, but these differences can be accounted for i.e. are 
conditional on variables in which complete information is available. 
Finally, if data are MNAR, this means the values of the missing data 
are related to the reason it is missing e.g. if data are missing on IQ 
and only those who have low IQ have missing data (Pedersen et al. 
2017). 
In the ALSPAC cohort, there is a large degree of attrition, where 
almost half the cohort have dropped out by age 7 years (Boyd et al. 
72
2013). One method of dealing with missing data is to impute values 
for missing data using values from other variables in the dataset.  
Using a single imputation often leads to over-precision of estimates 
as standard errors are too small, and does not account for the lack of 
uncertainty about the missing values. I therefore used the multiple 
imputation by chained equation model approach using the “ice” 
command in Stata 14. This works by firstly creating multiple copies of 
the dataset, and then replacing missing values with imputed values 
based on values from variables with complete data. Stage two of the 
process then uses statistical methods to fit whichever model is of 
interest to each of the imputed datasets. The estimates are then 
averaged across all the imputed datasets using Rubin’s rules, which 
will account for the uncertainty in results between imputed datasets. 
Although using 5 imputations has been reported to be sufficient on 
theoretical grounds, to reduce sampling variability as a consequence 
of the imputation process, a minimum of 20 imputations may help 
deal with the sampling variability (Sterne et al. 2009). 
To make the assumption of data being missing at random more 
plausible, I ran 100 imputations and imputed all outcome, exposure 
and potential confounders, as well as adding auxiliary variables. 
These auxiliary variables were selected based on them being 
associated with either exposure/confounder measures and 
missingness.
3.6.2 A note on interpreting statistical output
In the scientific community, it has been common practice to 
determine whether findings are meaningful (rather than due to 
chance) based upon a significance threshold for the p value. The 
arbitrary threshold commonly used is p0.05; thus, anything less 
than this value would be deemed as significant and perhaps 
meaningful, and anything greater than this as not meaningful.
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For reasons that are widely accepted in Epidemiology however, and 
in line with ALSPAC guidelines, in this thesis I take care not to rely 
on any arbitrarily-defined threshold to determine whether something 
is meaningful or not. A p-value is defined as the probability of finding 
an effect, at least as extreme as the observed, if the null hypothesis 
is true. Thus, all p-values provide some evidence against the null 
hypothesis, and it is more useful to therefore refer to the strength of 
evidence (for example extremely weak evidence, extremely strong 
evidence, or somewhere in between) based on the p-value and study 
characteristics such as the number of tests performed than to refer to 
a specific but arbitrary threshold (see (Amrhein et al. 2019), (Sterne 
and Smith 2001) and a statement along with the accompanying 
publications from the American Statistical Association (Wasserstein 
and Lazar 2016)). 
 
Even where effect sizes are small and confidence intervals include 
the null, it may still be appropriate to interpret findings as weak 
evidence of association at best. Stronger confidence in support of a 
meaningful association can be seen when confidence intervals are 
highly asymmetric around the null, rather than when the intervals are
symmetric around the null, in which case it is equally possible the 
effect is protective as well as associated with risk. Therefore, 
confidence intervals can convey useful information without ever 
relying on whether they include the null or not and can provide 
information on the strength of evidence of association.
The next chapter is the beginning of the results chapters, which firstly 
begins with the assessment of childhood psychopathology 
associated with subsequent hypomania.
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Chapter 4: Childhood psychopathology and hypomania 
The work presented in this chapter has been published and can be found 
online at: 
http://www.sciencedirect.com/science/article/pii/S0165032716323874?via%3
Dihub
Mistry, S., Zammit, S., Escott-Price, V., Jones, H., Smith, D.J. (2017). 
Borderline Personality and Attention-Deficit Hyperactivity traits in childhood 
are associated with hypomanic features in early adulthood. Journal of 
Affective Disorders, 221, 246-253
https://doi.org/10.1016/j.jad.2017.06.039
The published article has been adapted for use in this chapter to include 
additional results (available as supplementary materials online).
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4.1 Chapter summary
Patients with bipolar disorder (BD) often have delayed diagnosis by up to as 
long as 10 years. However, most report experiencing symptoms of 
psychopathology earlier on from childhood/adolescence.
In this chapter I investigated objectives 1-3 of this thesis as outlined in Chapter 
2. Using a longitudinal birth cohort, the Avon Longitudinal Study of Parents and 
Children (ALSPAC), I assessed whether a broad range of childhood 
psychopathology was associated with hypomania outcomes assessed in young 
adulthood.  
I found strong evidence of association between measures of borderline 
personality disorder (BPD) traits and hypomania, as well as depressive 
symptoms with hypomania. For the former, associations were stronger for the
‘active/elated’ factor, whilst for the latter were stronger with the ‘risk-
taking/irritable’ factor of hypomania. Associations between BPD traits and 
hypomania were not explained by confounding or selection bias. I also found 
evidence of association between attention deficit hyperactivity disorder (ADHD) 
and Strengths and Difficulties Questionnaire (SDQ) scores with the ‘risk-
taking/irritable’ factor, but much less consistent evidence of association with the 
‘active/elated’ factor. Confounding and selection bias appear, at least in part, to 
be possible explanations for associations between ADHD, SDQ and depression 
score with measures with hypomania.
These findings suggest that specific trait related psychopathology measures 
may represent early markers of risk or be potential risk factors for hypomania. 
Further studies are required to understand the mechanisms underlying these 
associations, and to inform earlier detection of BD.   
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4.2 Introduction
The lifetime risk of BD is estimated to be between 1-2% (Merikangas et al. 
2007; Merikangas et al. 2011). Whilst a diagnosis of BD depends on a history of 
(hypo)mania (Anderson et al. 2013), the accurate detection of a history of 
(hypo)mania can be difficult because individuals are more likely to present for 
help with depression, and often have poor recollection of (hypo)manic 
symptoms (Ghaemi et al. 1995; Regeer et al. 2015). This can often lead to an 
under-diagnosis of BD in depressed patients (Angst et al. 2005a; Gamma et al. 
2013). 
There are a number of commonly used semi-structured interviews to assess for 
presence of BD. However, the time required to complete these interviews can 
be lengthy and therefore, a more time-efficient way of detecting presence of 
symptoms of (hypo)mania may be the use of self-report measures (Miller et al. 
2009). One of the most studied self-report screening instruments to detect signs 
of (hypo)mania is the Hypomania Checklist-32 (HCL-32). Originally designed to 
detect less severe forms of bipolar disorders (specifically bipolar II disorder) in 
depressed patients (Angst et al. 2005a), it has since been used in community 
general population samples (Holtmann et al. 2009; Lee et al. 2016). 
Several studies have used exploratory factor analysis to determine the 
underlying factor structure of the HCL in both clinical (Angst et al. 2005a; Wu et 
al. 2008) and general population samples (Holtmann et al. 2009; Brand et al. 
2011). Irrespective of how many items are used in the questionnaire (e.g. the 
32-item HCL or the 16-item HCL), at least two factors are consistently reported, 
in which items load onto an ‘active-elated’ or ‘risk-taking/irritable’ factor (Angst 
et al. 2005a; Forty et al. 2010; Hosang et al. 2017; Glaus et al. 2018). These 
two factors reflect the underlying factor structure of hypomania previously 
described as “sunny-side” and “dark-side” features respectively (Hantouche et 
al. 2003). 
Typical age of onset (likely age at which the individual accessed clinical 
services) for BD ranges between 18-22 years (Merikangas et al. 2011), though 
a substantial proportion of those with BD (up to 60%) report the presence of 
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psychopathology during childhood/adolescence (Perlis et al. 2009). Therefore, 
the identification of early psychopathology preceding onset of BD may help with 
improving prediction and earlier diagnosis, though at present, there is 
uncertainty about the extent to which features of childhood psychopathology 
might be considered as reliable predictors for the later development of BD 
(Faedda et al. 2014; Faedda et al. 2015).
The objectives of this study were: i) to investigate whether childhood 
psychopathology (borderline personality disorder (BPD) traits, attention deficit 
hyperactivity disorder (ADHD), emotional/behavioural problems and depression 
score) in childhood are associated with a dimensional measure of hypomania, 
with latent traits underlying hypomania, or with clinically-defined hypomania in 
early adulthood, and ii) to examine whether any associations are likely to be 
due to confounding or selection bias (Objectives 1-3 in Chapter 2).
4.3 Method
4.3.1 Study participants
This study used data from individuals between ages 7 to 23 years. Recruitment 
procedures and inclusion criteria for the study can be found in Chapter 3 under 
section 3.2. Final sample numbers for outcome and exposure measures are 
shown in Figure 3 in Chapter 3. 
4.3.2 Main outcome: Hypomania
The HCL-32 is a self-rating questionnaire designed to assess for a lifetime 
history of (hypo)manic symptoms (Angst et al. 2005a). A detailed overview of 
the HCL-32, its psychometric properties and how all hypomania outcomes (HCL 
score, clinically-defined hypomania and HCL factors) were derived can be found 
in Chapter 3 under section 3.3.1. The cohort completed the HCL-32 
questionnaire when they were age 22-23 years and from the 32-item checklist, 
the 28-items used in this thesis are shown in Chapter 3, Table 5. 
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4.3.3 Childhood predictors: BPD traits, ADHD status, SDQ sub-scales
and MFQ score
4.3.3.1 Assessment of BPD traits 
At age 11 years, the cohort were interviewed to assess their experience of BPD 
traits over the preceding two years. Detailed information on the Childhood 
Interview for DSM-IV Borderline Personality Disorder (CI-BPD) can be found in 
Chapter 3 under section 3.3.2.1. 
In the present study, children were classified as being high-risk for BPD if they 
were rated ‘probably’ or ‘definitely’ on five or more of the nine traits, as used 
previously (Wolke et al. 2012). Further details on the criteria required to receive 
a rating of definitely present or probably present can be found in a study by 
Zanarini and colleagues (Zanarini et al. 2004), and further details on how I 
generated the BPD traits score are found in Chapter 3, under section 3.3.2.1. 
4.3.3.2 Assessment of childhood ADHD status
The presence of ADHD at age 7.6 years was assessed using the Development 
and Wellbeing Assessment (DAWBA) (Goodman et al. 2000). Details of the 
DAWBA package can be found in Chapter 3 under section 3.3.2.2.  
4.3.3.3 SDQ subscales
At age 9 years, the cohort were invited to complete the SDQ. In total, there are 
five SDQ subscales (hyperactivity problems, prosocial behaviour, emotional 
difficulties, conduct problems and peer relationship difficulties), though prosocial 
behaviour does not contribute towards the total difficulties score (Goodman 
1997,2001). More detailed information on recruitment, factor structure of the 
SDQ and how I generated the SDQ subscale scores can be found in Chapter 3 
in section 3.3.2.3.
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4.3.3.4 Moods and Feelings Questionnaire (MFQ)
At age 9 years, the cohort were invited to complete the short version of the 
MFQ (Angold et al. 1995). Further details on the MFQ can be found in Chapter 
3 in section 3.3.2.4. 
4.3.4 Statistical analyses
All analyses conducted in this chapter were performed using Stata statistical 
software (version 14.1 SE. College Station, TX: Statacorp LP). To determine 
whether there were differences in sociodemographic characteristics between 
the study sample (those with data on the HCL) and those without data on the 
HCL, I used a chi squared test for trend for maternal social class, and a t-test to 
examine differences between the study sample and those with no data on the 
HCL for all other sociodemographic characteristics. Further details including 
how these were coded can be found in Chapter 3, section 3.4. 
I used linear regression to compare associations between exposures (BPD 
traits, high-risk for BPD, ADHD, SDQ sub-scale scores and depression score) 
and continuous hypomania outcomes (HCL score and HCL factors). Results 
from these analyses are presented as the standard deviation (SD) change in 
hypomania outcome per 1 unit increase in exposure. A Kernel density plot of 
the residuals showed they were normally distributed and tests for 
heteroskedasticity showed homogeneity within the sample. 
For analyses examining associations between exposure measures and the 
binary clinically-defined hypomania outcome, I used logistic regression. Results 
from these analyses are presented as the change in odds of clinically-defined 
hypomania per 1 unit increase in exposure. 
4.3.5 HCL-28 Confirmatory Factor Analysis (CFA)
Previous studies have used exploratory factor analysis to determine the 
underlying structure of the HCL in both general population (Holtmann et al. 
2009; Brand et al. 2011) and clinical samples (Angst et al. 2005; Wu et al. 
2008). The 28-items were loaded onto their corresponding factors, the 
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‘active/elated’ and ‘risk-taking/irritable’ HCL factors by Dr Hannah using the 
mean and variance adjusted weighted least squares method in Mplus (see 
Chapter 3, section 3.3.1.2 for further details and Table 6 for factor loadings). 
4.3.6 Confounding 
I investigated the possibility of relationships between exposures and outcomes 
being explained by confounding. To do this, I adjusted my main analyses (as
described above) for a number of sociodemographic characteristics and 
markers of adversity: gender, ethnicity, maternal age at birth, maternal social 
class, highest maternal education level, confirmed history of maternal 
depression, being bullied at school and being emotionally and/or physically 
abused (see Chapter 3, section 3.4 for further details). Genetic risk for BD was 
initially adjusted for, however, this made little difference to the associations 
between exposure(s) and outcome measures. Therefore, to maximise sample 
size, results are presented without adjusting for genetic risk for BD. 
4.3.7 Multiple imputation 
To address the possibility of estimates being affected by selection bias, I used 
multiple imputation. I imputed all exposure and confounder measures, and 
included auxiliary variables which were predetermined on the basis of them 
being associated with either exposure/confounder measures and missingness. 
Further details on the multiple imputation approach can be found in Chapter 3, 
under section 3.6.1.4.
4.4 Results
4.4.1 Sample demographics
Table 7 shows the differences between the study sample (those with data on 
the HCL; n = 3,371) compared to those with no data on the HCL (n = 12,073). 
When compared to those with no data on the HCL, the study sample had a 
higher proportion of mothers who had a degree (21.5% vs 10.0%; p <0.001), a 
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smaller proportion of males (35.3% vs 56.2%; p <0.001), greater maternal age
at birth (29.7 years vs 27.9 years; p <0.001), higher maternal social class (p 
<0.001) and a smaller proportion of mothers who had depression (18.4% vs 
20.7%; p = 0.006). There was little evidence that ethnicity differed between the 
study sample and those with no data on the HCL. 
Table 7 Characteristics of the ALSPAC cohort who completed the HCL and those who did not
a Missing data for some variables means sample sizes vary. b P value tested by chi-squared test 
for trend; ALSPAC: Avon Longitudinal Study of Parents and Children; HCL: Hypomania 
Checklist; SD: Standard Deviation 
Characteristic
Rest of ALSPAC 
cohort (N = 
12,073)a
n (%)
Completed HCL
(N = 3,371)
n (%)
P
Gender
Male 6,449 (56.15%) 1,189 (35.26%) <0.001
Maternal social 
class
I 354 (3.76%) 243 (7.71%)
<0.001b
II 2,168 (23.01%) 1,017 (32.28%)
III (non-manual) 3,178 (33.72%) 1,150 (36.50%)
III (manual) 632 (79.90%) 159 (20.10%)
IV 821 (9.71%) 176 (5.59%)
V 191 (2.03%) 31 (0.98%)
Ethnicity
White 9,018 (97.26%) 3,060 (98.16%) 0.183
Maternal education
Degree or above 934 (9.99) 676 (21.5%) <0.001
Maternal 
Depression
Yes
1,955 (20.65%) 577 (18.38%) 0.006
Mean (SD) Mean (SD)
Maternal age at 
birth
27.9 (4.87) 29.7 (4.43) <0.001
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4.4.2 BPD traits and hypomania in young adulthood
Results from the regression analyses are presented in Table 8. I found strong 
evidence of an association between the BPD traits score (β = 0.10, 95%CI 0.06, 
0.14; p <0.001) and higher HCL score, which was unchanged after adjusting for 
potential confounders. There was very weak evidence to suggest an association 
between being in the high-risk for BPD group compared to non-high-risk group 
and HCL score (β = 0.21, 95%CI -0.04, 0.46; p = 0.095), which weakened 
further (reduction in effect size of 14%) after adjusting for potential confounders.
Associations with clinically-defined hypomania at a threshold score of 14/28 on 
the HCL were also strong for both the BPD traits score (OR = 1.39, 95%CI 1.16, 
1.66; p <0.001) and high-risk for BPD (OR = 2.84, 95%CI 1.43, 5.64; 
p = 0.003). These associations were partly attenuated (reduction in effect size 
of 13% and 38% respectively) when adjusting for confounding (Table 8).
When examining the 2 factors that best summarised the 28-items of the HCL, I 
found that associations between the BPD traits score and HCL factors were 
stronger with the ‘risk-taking/irritable’ factor than with the ‘active/elated’ factor, 
though there was little evidence of association with either factor in those who 
were high-risk for BPD compared to those who were not high-risk (Table 8). 
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Table 8 Association between the BPD traits score/high-risk for BPD and hypomania
BPD: Borderline Personality Disorder; HCL: Hypomania Checklist; CI: Confidence Intervals; OR: Odds Ratio
a adjusted for: history of maternal depression, maternal age at birth, maternal education level, maternal social class, being a victim of bullying in school at age 8 
years, gender, ethnicity, total difficulties score at ages 9 and 11, diagnosis of ADHD and experience of physical and emotional abuse when the child was 6 or 7 
years old
Exposure Outcome N  unadjusted 95%CI P value  adjusteda 95%CI Adjusted p value
BPD traits 
score HCL score 1,319
0.12 0.06, 0.18 <0.001 0.12 0.05, 0.18 <0.001
High-risk for 
BPD 0.21 -0.04, 0.46 0.095 0.18 -0.07, 0.43 0.162
BPD traits 
score
Active-elated 
factor
1,297
0.08 0.03, 0.14 0.004 0.09 0.03, 0.15 0.002
Risk-
taking/irritable 
factor
0.11 0.06, 0.16 <0.001 0.08 0.03, 0.14 0.003
High-risk for 
BPD
Active-elated 
factor 0.15 -0.09, 0.39 0.224 0.16 -0.09, 0.40 0.214
Risk-
taking/irritable 
factor
0.14 -0.08, 0.38 0.206 0.07 -0.17, 0.30 0.581
Exposure Outcome N OR unadjusted 95%CI P value OR adjusted
a 95%CI P value
BPD traits 
score Clinically-defined 
hypomania 1,319
1.39 1.16, 1.66 <0.001 1.33 1.09, 1.64 0.006
High-risk for 
BPD 2.84 1.43, 5.64 0.003 2.51 1.21, 5.21 0.013
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I next investigated whether findings of association between the BPD traits score 
and clinically-defined hypomania were robust across different cut-off thresholds 
on the HCL. I conducted sensitivity analyses using increasing threshold 
symptom number count being required to be classified as having clinically-
defined hypomania. The results at higher symptom threshold counts were, on 
the whole, consistent with those reported at a threshold of 14/28 (see 
Appendix 2).
I then wanted to determine whether the association between the BPD traits 
score and hypomania was driven by any particular BPD trait(s). The 9 BPD 
traits were correlated, with correlations ranging from 0.33 to 0.67. Most BPD 
traits were strongly associated with the HCL score, with the exception of fear of 
abandonment. Results were generally consistent when examining associations 
with clinically-defined hypomania, though there was much weaker evidence of 
association with BPD traits of anger (p = 0.178) and impulsivity 
(p = 0.160), and stronger evidence of association with fear of abandonment 
(p = 0.003) (Appendix 3). 
As anger symptoms contribute to the derivation of both the BPD traits score and 
the HCL score, I conducted a sensitivity analysis where I removed the question 
which asked about “getting into more quarrels” from the HCL score to address 
the possibility that the association between BPD traits and hypomania is simply 
a persistence of anger traits into adulthood. Having done so, there was no 
change in effect size or the strength of evidence of association between the 
BPD traits score or high-risk for BPD and the HCL score.
When examining the relationship between the individual BPD traits and HCL 
factors, most traits showed stronger evidence of association with the ‘risk-
taking/irritable’ factor than with the ‘active/elated’ factor, though fear of 
abandonment was the only trait not associated with either factor.
4.4.3 ADHD in childhood and hypomania in young adulthood
The association between a diagnosis of any ADHD disorder and hypomania 
outcomes are shown in Table 9. There was strong evidence of association 
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between childhood ADHD and the ‘risk-taking/irritable’ factor (β = 0.84, 95%CI
0.41, 1.27; p<0.001), but not with the other hypomania outcomes examined. 
Adjusting for potential confounders generally led to some attenuation of 
associations both in terms of effect size and strength of evidence of association, 
though the association with the ‘risk-taking/irritable’ factor remained strong
despite a 7% reduction in effect size.  
When examining ADHD subtypes, associations were observed between 
inattentive (p<0.001) and combined (p = 0.020) subtypes and the ‘risk-
taking/irritable’ factor, but not with the hyperactive-impulsive subtype (p = 
0.897). There was little evidence of association between ADHD subtypes and 
HCL score (all p>0.424), ‘active/elated’ factor (all p>0.181) or clinically-defined 
hypomania (all p>0.238).
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Table 9 Association between a diagnosis of any ADHD and hypomania outcomes
a adjusted for: history of maternal depression, maternal age at birth, maternal education level, being a victim of bullying in school at age 8 years, gender and ethnicity
ADHD: Attention Deficit Hyperactivity Disorder; HCL: Hypomania Checklist; CI: Confidence Interval; OR: Odds Ratio
Exposure Outcome N unadjusted 95%CI P value

adjusteda 95%CI P value
Any ADHD 
diagnosis
HCL score 2,079 0.12 -0.33, 0.56 0.612 0.06 -0.39, 0.50 0.796
Active/elated 
factor 1,839 -0.21 -0.67, 0.25 0.368 -0.28 -0.73, 0.18 0.238
Risk-
taking/irritability 
factor
1,839 0.84 0.41, 1.27 <0.001 0.78 0.35, 1.21 <0.001
Exposure Outcome N OR unadjusted 95%CI P value
OR 
adjusteda 95%CI P value
Any ADHD 
diagnosis
Clinically-
defined 
hypomania
2,079 2.53 0.73, 8.79 0.143 2.06 0.57, 7.49 0.273
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To address the problem of potentially overlapping questions in the HCL and the 
DAWBA that was used to generate a DSM-IV diagnosis of ADHD, I removed 
the following questions from the HCL: “feel more energetic”, “am more easily 
distracted”, “thoughts jump from topic to topic”, “am more impatient” and “can be 
exhausting to others”. There was little evidence of association between the 
diagnosis of any ADHD and the HCL factors re-derived after excluding the items 
listed above. 
4.4.4 SDQ in childhood and hypomania in young adulthood
I found little evidence of association between the total difficulties score and both 
the HCL score (p = 0.786) and the ‘active/elated’ factor (p = 0.436). However, 
there was stronger evidence of association with both the ‘risk-taking/irritable’ 
factor (β = 0.08, 95%CI 0.03, 0.13; p = 0.001) and with clinically-defined 
hypomania (OR = 1.37, 95%CI 1.14, 1.64; p = 0.001), though in both instances, 
adjustment for confounders reduced effect sizes by 25% and 40% respectively, 
as well as the strength of evidence of association (see Table 10).
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Table 10 Association between the total difficulties score and hypomania
a adjusted for: history of maternal depression, maternal age at birth, maternal education level, being a victim of bullying in school at age 8 years, gender and 
ethnicity; ^rounded to 2 decimal places; HCL: Hypomania Checklist; CI: Confidence Intervals; OR: Odds Ratio 
Exposure Outcome N unadjusted 95%CI P value  adjusteda 95%CI P value
Total 
difficulties 
score
HCL score 2,010 0.00^ -0.05, 0.06 0.886 0.00^ -0.05, 0.06 0.786
Active/elated 
factor 1,779 -0.04 -0.09, 0.02 0.181 -0.02 -0.07, 0.03 0.436
Risk-
taking/irritability 
factor 
1,779 0.08 0.03, 0.13 0.001 0.06 0.01, 0.11 0.020
Exposure Outcome N OR unadjusted 95%CI P value
OR 
adjusteda 95%CI P value
Total 
difficulties 
score
Clinically-
defined 
hypomania 
2,010 1.37 1.14, 1.64 0.001 1.21 1.00, 1.47 0.048
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I then investigated the association between the subscales within the SDQ to 
determine whether specific emotional or behavioural difficulties might be 
associated with hypomania. The individual SDQ subscale scores were 
correlated, with correlations ranging from -0.36 to 0.47. Negative correlations
were observed between the prosocial subscale and other SDQ subscales, 
whereas the other SDQ subscale scores were all positively correlated with each 
other. Associations between individual SDQ subscale scores and hypomania 
are presented in Appendix 4. There was generally little or inconsistent evidence 
of association between the SDQ subscales and either the HCL score or 
clinically-defined hypomania. However, there was strong evidence of 
association between all subscales (except emotional difficulties) and the ‘risk-
taking/irritable’ factor, whereas only greater prosocial behaviour and 
hyperactivity problems were associated with the ‘active/elated’ factor. 
As some of the questions asked in the hyperactivity subscale of the SDQ are 
similar to those asked in the HCL, I re-ran the analysis excluding from the HCL 
score the ADHD-related questions as described above. Having excluded these 
questions, I found weak evidence of association between higher hyperactivity 
problems and a reduction in the ‘active/elated’ factor, but not with the ‘risk-
taking/irritable’ factor. 
4.4.5 Depression score (MFQ) and hypomania
I found weak evidence of association between the depression score and HCL 
score (β = 0.05, 95%CI 0.00, 0.11; p = 0.049), which weakened further after 
adjusting for potential confounders (p = 0.095), though no reduction in effect 
size was observed. Associations between the depression score and both the 
‘risk-taking/irritable’ factor (β = 0.08, 95%CI 0.03, 0.13; p = 0.003) and clinically-
defined hypomania (OR = 1.33, 95%CI 1.11, 1.58; p = 0.001) were stronger, 
though in both instances, adjusting for confounders reduced effect sizes by 13% 
and 22% respectively and a decrease in the strength of evidence of association
was observed (see Table 11).
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Table 11 Association between the MFQ and hypomania outcomes
a adjusted for: history of maternal depression, maternal age at birth, maternal education level, being a victim of bullying in school at age 8 years, gender and 
ethnicity; ^rounded to 2 decimal places; MFQ: Moods and Feelings Questionnaire; HCL: Hypomania Checklist; CI: Confidence Intervals; OR: Odds Ratio
Exposure Outcome N unadjusted 95%CI P value  adjusteda 95%CI P value
MFQ
HCL score 1,824 0.05 0.00^, 0.11 0.049 0.05 -0.01, 0.10 0.095
Active/elated 
factor 1,614 0.02 -0.03, 0.08 0.373 0.02 -0.03, 0.08 0.427
Risk-
taking/irritable 
factor
1,547 0.08 0.03, 0.13 0.003 0.07 0.01, 0.11 0.015
Exposure Outcome N OR unadjusted 95%CI P value
OR
adjusteda 95%CI P value
MFQ
Clinically-
defined 
hypomania
1,824 1.33 1.11, 1.58 0.001 1.25 1.05, 1.50 0.012
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4.4.6 Associations between childhood psychopathology and hypomania 
using imputed data
Associations between childhood psychopathology measures and hypomania 
outcomes after multiple imputation are shown in Table 12. When compared to 
associations with non-imputed data, effect sizes and strength of evidence of 
association between the BPD traits score and hypomania outcomes were very 
similar, whereas those for a diagnosis of any ADHD were weaker. For the total 
difficulties score, effect size differences between non-imputed and imputed data
were more variable depending on which hypomania outcome was being 
examined. The effect size was larger and evidence of association stronger for 
associations with the ‘risk-taking/irritable factor in the imputed data, whereas the 
effect size was smaller and evidence of association weaker for clinically-defined
hypomania. Nevertheless, these differences did not alter the conclusions of the 
study. For the depression score, effect sizes were similar when comparing 
complete case data with imputed data for both the HCL score and HCL factors, 
though the strength of evidence for these association was in the most part 
stronger in the imputed data. For associations between the depression score 
and clinically-defined hypomania, there was a 22% reduction in effect size in the 
imputed data, though again this made no alteration to the conclusions of this 
study. 
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Table 12 Associations between childhood psychopathology and hypomania outcomes comparing imputed with non-imputed data
HCL: Hypomania Checklist; ADHD: Attention Deficit Hyperactivity Disorder; BPD: Borderline Personality Disorder; CI: Confidence Intervals
NB: imputed sample sizes for HCL factors differ from the HCL score as the HCL score contains data on individuals with information on any of the 28 items, whereas 
the HCL factors contain data on individuals with information for all 28 items
a adjusted for: history of maternal depression, maternal age at birth, maternal education level, being a victim of bullying in school at age 8 years, gender, ethnicity, 
total difficulties score at ages 9 and 11, diagnosis of ADHD and experience of physical and emotional abuse when the child was 6 or 7 years old
b adjusted for: history of maternal depression, maternal age at birth, maternal education level, being a victim of bullying in school at age 8 years, gender, ethnicity, 
and experience of physical and emotional abuse when the child was 6 or 7 years old
Exposure Outcome N  non-imputed 95%CI P value N  imputed 95%CI P value
BPD traits 
score
HCL score
1,702 0.09a 0.04, 0.14 0.001
3,124
0.09a 0.05, 0.14 <0.001
Any ADHD 
diagnosis 2,079 0.06
b -0.39, 0.50 0.796 0.04b -0.30, 0.39 0.802
Total 
difficulties 
score
2,010 0.00^b -0.05, 0.06 0.786 0.01b -0.04, 0.05 0.775
Depression 
score 2,091 0.06
b 0.01, 0.11 0.018 0.06b 0.02, 0.10 0.004
BPD traits 
score
‘Active/elated’ 
factor’
1,507 0.07a 0.02, 0.12 0.007
2,770
0.07a 0.03, 0.12 0.002
Any ADHD 
diagnosis 1,839 -0.28
b -0.73, 0.18 0.238 -0.13b -0.47, 0.21 0.450
Total 
difficulties 
score
1,779 -0.02b -0.07, 0.03 0.436 -0.02b -0.06, 0.02 0.359
Depression 
score 1,852 0.03
b -0.02, 0.08 0.243 0.03b -0.00^, 0.08 0.065
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Table 12 continued 
HCL: Hypomania Checklist; ADHD: Attention Deficit Hyperactivity Disorder; BPD: Borderline Personality Disorder; CI: Confidence Intervals; OR: Odds Ratio
NB: imputed sample sizes for HCL factors differ from the HCL score as the HCL score contains data on individuals with information on any of the 28 items, whereas 
the HCL factors contain data on individuals with information for all 28 items
a adjusted for: history of maternal depression, maternal age at birth, maternal education level, being a victim of bullying in school at age 8 years, gender, ethnicity, 
total difficulties score at ages 9 and 11, diagnosis of ADHD and experience of physical and emotional abuse when the child was 6 or 7 years old
b adjusted for: history of maternal depression, maternal age at birth, maternal education level, being a victim of bullying in school at age 8 years, gender, ethnicity, 
and experience of physical and emotional abuse when the child was 6 or 7 years old
Exposure Outcome N  non-imputed 95%CI P value N  imputed 95%CI P value
BPD traits 
score
Risk-
taking/irritability 
factor 
1,507 0.07a 0.02, 0.12 0.004
2,770
0.08a 0.04, 0.12 <0.001
Any ADHD 
diagnosis 1,839 0.78
b 0.35, 1.21 <0.001 0.53b 0.14, 0.91 0.007
Total 
difficulties 
score
1,779 0.06b 0.01, 0.11 0.020 0.08b 0.04, 0.12 <0.001
Depression 
Score 1,852 0.08
b 0.04, 0.13 0.001 0.07b 0.03, 0.11 <0.001
Exposure Outcome N OR non-imputed 95%CI P value N OR imputed 95%CI P value
BPD traits 
score
clinically-defined
hypomania
1,702 1.22a 1.02, 1.46 0.032
3,124
1.22a 1.06, 1.41 0.006
Any ADHD 
diagnosis 2,079 2.06
b 0.57, 7.49 0.273 1.22b 0.38, 4.01 0.732
Total 
difficulties 
score
2,010 1.21b 1.00, 1.47 0.048 1.13b 0.96, 1.33 0.129
Depression 
Score 2,091 1.26
b 1.07, 1.49 0.007 1.18b 1.02, 1.37 0.023
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4.5 Discussion
4.5.1 Summary of findings 
The first objective of this study was to assess whether a BPD traits score, being 
at high-risk for BPD, having a diagnosis of ADHD, scoring highly on subscales 
of the SDQ (including hyperactivity, prosocial behaviour, emotionality, conduct 
problems and peer relationship difficulties) and scoring highly on the MFQ 
assessed during childhood might be early markers of risk for hypomania in 
young adulthood. 
I found that a higher BPD traits score and being high-risk for BPD at age 11 
years was associated with hypomania outcomes. When I further investigated 
whether the relationship between the BPD traits score and hypomania was 
driven by any individual BPD traits, I found features of anger, affective 
instability, identity disturbance, paranoid ideation and intense interpersonal 
relationships were most strongly associated with the HCL score, but there was 
little evidence of association for fear of abandonment. On the whole, 
associations were similar for clinically-defined hypomania though, most notably, 
fear of abandonment was strongly associated with this ‘clinical’ outcome. There 
was little evidence to suggest confounding or selection bias was affecting the 
association between the BPD traits score and hypomania outcomes.
I found that emotional and behavioural problems (SDQ total difficulties) and 
depression (MFQ score) were associated with the ‘risk-taking/irritable’ factor 
and with clinically-defined hypomania, and a diagnosis of ADHD was also 
associated with the ‘risk-taking/irritable’ factor. All SDQ subscales (with the 
exception of emotional difficulties) were associated with the ‘risk-taking/irritable’ 
factor, whilst hyperactivity and prosocial behaviour were also associated with 
the ‘active/elated’ factor. 
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4.5.2 Findings in the context of previous work
4.5.2.1 Borderline personality traits and hypomania
My findings from this study suggest that associations between BPD traits and 
hypomania are more strongly related to “sunny-side” symptoms of hypomania
as evidenced with stronger associations with the ‘active-elated factor (see Table 
8 adjusted analyses).
There are several possible explanations which may explain why I found 
associations between BPD and hypomania outcomes. Firstly, BPD traits such 
as affective instability assessed in the CI-BPD may be capturing early 
manifestations of BD. For example, mood lability which may occur as a 
precursor to hypomania (Faedda et al. 2015) or may index mixed state 
depression (Sani et al. 2014). To address this, I removed questions from the 
HCL that overlapped closely with the anger trait captured by the CI-BPD. 
Associations between the BPD traits score and this revised measure of 
hypomania were almost identical to those when using the full HCL score. This 
suggests it is unlikely that the association observed between BPD traits score 
and HCL score is simply a persistence of anger into adulthood. 
Secondly, it is possible that BPD and BD share common aetiological 
mechanisms e.g. childhood trauma (McDermid et al. 2015) or pleiotropic 
genetic effects (Witt et al. 2014; Song et al. 2015) which could lead to a non-
causal explanation for an association between them. When I adjusted for a 
number of potential confounders, these had little impact on both effect size and 
strength of evidence of association between the BPD traits score and HCL 
score. Nevertheless, it is still possible there is residual confounding as a result 
of not adjusting for other important confounders, or if there is substantial 
measurement error in the measures of the confounders I did adjust for.
Thirdly, there may be causal effects of BPD on BD, for example secondary to 
substance use (Hidalgo-Mazzei et al. 2015) that may occur due to greater levels 
of impulsivity (Faedda et al. 2014) or as a means of coping with distressing 
emotional states (Van den Bosch et al. 2003) that are both characteristic 
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features of BPD. The minimal impact of adjusting for potential confounders 
would be consistent with a potential causal effect. Furthermore, when I 
examined associations between the BPD traits score and HCL score using 
imputed data, effect size and strength of evidence were identical to those using 
non-imputed data. This suggests that the associations observed are unlikely 
due to selection bias, consistent with either a causal explanation or BPD traits 
indexing early manifestation of BD onset. 
4.5.2.2 ADHD and hypomania
To the best of my knowledge, this is the first study to investigate associations 
between childhood ADHD and hypomania as an outcome in early adulthood. 
My findings of little evidence of association between ADHD (irrespective of 
subtype) and clinically-defined hypomania are generally consistent with findings 
from a previous review on the association between childhood ADHD and BD in 
prospective high-risk studies, which reported that a diagnosis of ADHD was not 
a reliable predictor of future BD (Duffy 2012). In the ALSPAC cohort, there are 
no data on whether individuals have a BD diagnosis, and using the criteria for 
defining clinically-defined hypomania was as similar as I could get to the BD 
outcomes studied in high-risk populations. 
Associations between a diagnosis of ADHD, and in particular, the inattentive 
and combined subtypes were stronger with the ‘risk-taking/irritable’ factor. It has 
been proposed that the core symptoms of ADHD, particularly those around 
inattention may occur as a precursor to hypomania (Youngstrom et al. 2010; 
Duffy 2012). It is possible there is a causal relationship between childhood 
ADHD and the ‘risk-taking/irritable’ aspect of hypomania, which might occur 
secondary to the psychotogenic effects of substance abuse in adolescents with 
ADHD (Erskine et al. 2016), which in itself is associated with earlier onset of BD 
symptoms (Strakowski and DelBello 2000). 
However, after removing potentially overlapping questions, there was little 
evidence of association between ADHD and hypomania, suggesting the 
association with the ‘risk-taking/irritable’ factor might just be a persistence of 
ADHD traits into adulthood. 
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I also found substantial attenuation in effect size and/or the strength of evidence 
of association between ADHD and hypomania outcomes when adjusting for 
confounding, and when comparing imputed data to complete-case data. Other 
research investigating associations between ADHD and BD have shown 
confounding can reduce effect sizes by as much as 50% (Youngstrom et al. 
2010). Polygenic risk score analyses show that common variants associated 
with risk of BD are able to predict childhood ADHD (Hamshere et al. 2013), and 
that to some extent there are common variants that are implicated in the 
aetiology of both disorders (Cross-Disorder Group of the Psychiatric Genomics 
Consortium 2013; O'Connell et al. 2019). It seems more plausible that 
confounding and selection bias more likely explain my findings for ADHD in this 
study. 
4.5.2.3 SDQ and hypomania 
Associations between the total difficulties score and hypomania were strongest 
with the ‘risk-taking/irritable’ factor, whilst all SDQ subscales with the exception 
of emotional difficulties were also associated with the ‘risk-taking/irritable’ factor. 
On an individual SDQ subscale level, findings between studies examining this 
relationship are inconsistent in terms of which subscales are associated with the 
‘risk-taking/irritable’ HCL factor (Holtmann et al. 2009; Hosang et al. 2017). It is 
possible that the inconsistencies might be attributed to the person completing 
the SDQ. In the current study, the SDQ was completed by the parents of the 
children whereas those from other studies were completed by adolescents. 
Adolescents may have better recognition of the types of behaviours they exhibit, 
and may be more likely report minor disturbances which the parents of the 
children in the current study may not detect (Arman et al. 2013; Liu et al. 2017). 
I found inconsistent evidence of associations between the total difficulties score 
and hypomania when adjusting for potential confounders, and when comparing 
imputed to non-imputed data estimates. Whilst adjusting for confounding led to 
some attenuation of association, suggesting estimates may have been over-
estimated, results from imputed data suggest that selection bias might have led 
to underestimating causal effects in the observed (non-imputed) data. 
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Therefore, it is unclear to what extent my findings might be over-estimates (due 
to residual confounding) or under-estimates (due to uncorrected selection bias) 
of a causal effect of childhood emotional and behavioural problems on adult 
hypomania. 
Epidemiological evidence suggests that having depression is strongly 
associated with increased risk of developing BD (Weissman et al. 1996). 
However, when I examined the association between emotional difficulties 
assessed using the SDQ and hypomania outcomes, (irrespective of how they 
were defined), I found little evidence of association. The most likely explanation 
for this is that emotionality assessed using the SDQ is not an adequate 
measure of depression. Closer examination of the individual questions that are 
asked in the SDQ emotional difficulties subscale highlights that these questions 
are more closely aligned with anxiety symptoms than with depressive 
symptoms.
4.5.2.4 MFQ and hypomania 
To the best of my knowledge, at the time of the original publication (Mistry et al. 
2017), I was not aware of any studies that have examined associations between 
measures of childhood depression and either BD or hypomania using a general 
population sample. Since that time, one study reported strong evidence of a 
correlation between those who scored highly on the MFQ at age 17 years and 
the HCL-16. When examining associations with the HCL factors, stronger 
evidence of correlation between the MFQ and the ‘risk-taking/irritable’ factor 
was found (Hosang et al. 2017), a finding which is consistent with the findings in 
the current study. Findings from high-risk offspring of BD parents suggest that 
compared to non-high-risk offspring, high-risk offspring often have presence of 
minor mood disorders including depression prior to developing BD (Duffy et al. 
2017b; Duffy et al. 2019).
One possible explanation for finding evidence of association between the MFQ 
and both the ‘risk-taking/irritable’ factor and clinically-defined hypomania is 
overlap in common variants implicated in both depression and BD (Cross-
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Disorder Group of the Psychiatric Genomics Consortium 2013; Amare et al. 
2019). 
Alternatively, the association between childhood depression symptoms and 
hypomania could be a result of childhood neglect/abuse which in itself 
increases risk of experiencing symptoms of both depression (Nanni et al. 2012)
and BD (Aas et al. 2016). One meta-analysis reported that adults with BD were 
2.63 times more likely than controls to have experienced any kind of childhood 
maltreatment, and if broken down into subtypes of abuse, fourfold more likely 
(OR = 4.04) to have experienced emotional abuse (Palmier-Claus et al. 2016). 
It is therefore possible that traumatic experience in childhood is a non-specific 
risk factor which leads to increased levels of psychopathology which may
further increase the risk of developing BD amongst other psychiatric conditions 
(van Nierop et al. 2015).
4.5.3 Strengths and Limitations 
There are a number of strengths and limitations of this study. Firstly, at the 
beginning of the study, ALSPAC was considered representative of the UK
general population in terms of socio-demographic characteristics, and this 
cohort has extensive information from the first trimester of pregnancy onwards 
(Boyd et al. 2013; Fraser et al. 2013). However, I found a number of differences 
in socio-demographic and background characteristics between the study 
sample (those with data on the HCL), and the rest of the cohort (those with no 
data on the HCL). This could introduce selection bias due to missing data. To 
examine whether this was the case, I used multiple imputation to impute values 
for exposures and confounders. Whilst I used a range of auxiliary variables in 
the imputation models to make the missing at random assumption more 
plausible, it is nevertheless possible that some selection bias remains, even in 
the imputed analyses. However, a previous study using simulation of missing 
data in the ALSPAC cohort reported that missingness has little impact on the 
association between early life exposures and psychopathology measures 
(including disruptive disorders such as ADHD) (Wolke et al. 2009). 
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To the best of my knowledge, this is also the largest study to date that has 
investigated associations between childhood psychopathology and hypomania 
as an outcome, though others have investigated associations with BD (Henin et 
al. 2007; Rubino et al. 2009).
Thirdly, the assessments of BPD, ADHD, emotional/behavioural difficulties and 
depression were conducted well before the assessment of hypomanic features. 
The associations I observe are therefore not due to bias in the recall of 
presence of childhood psychopathology by adult hypomania severity level. 
It also seems unlikely that the association between these childhood 
psychopathology measures and hypomania are due to reverse causation, 
whereby child psychopathology arises due to the presence of hypomanic 
symptoms in childhood, although as there wasn’t a screen for hypomania 
symptoms in childhood, I cannot rule this out definitively. 
I have used valid and reliable measures wherever possible. DAWBA-generated 
DSM-IV diagnoses of psychiatric disorders have been shown to reliably 
discriminate those with psychiatric disorders from those who do not in both 
clinical and community samples (Goodman et al. 2000). Similarly, the CI-BPD 
has been validated in an adolescent inpatient psychiatric sample reliably 
discriminating those with a BPD diagnosis compared to those without a BPD 
diagnosis (Sharp et al. 2012b), and the SDQ is a widely used screening tool for 
assessing presence of emotional/behavioural difficulties in children (Mieloo et 
al. 2012). The shortened version of MFQ has been validated in both child and 
adolescent samples and reliably discriminates those with a depression 
diagnosis defined by ICD/DSM criteria from those who do not have depression 
(Thapar and McGuffin 1998; Thabrew et al. 2018). However, both ADHD 
diagnoses and the SDQ were based on parent and/or teacher reports which 
might increase measurement error when compared to the CI-BPD. 
Though there are several strengths, there are also a number of limitations 
important to acknowledge. Firstly, the hypomania outcomes I examined (HCL 
score and HCL factors) are not the same as a DSM-IV or ICD-10 diagnosis of 
BD. However, the clinically-defined hypomania outcome I derived was based 
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loosely on ICD-10 criteria for a hypomanic episode and took into consideration 
both a symptom number count required as well as the impact on function. My 
findings cannot be interpreted as association with BD per se, but rather a 
propensity to BD. Data were not available on the number of participants who 
have gone on to receive a diagnosis of BD, which means it is unclear as to how 
valid the HCL is as a proxy measure for BD. Nevertheless, previous studies 
have used the HCL to distinguish those with BD from controls drawn from the
general population (Holtmann et al. 2009; Lee et al. 2016). In one such study, 
Lee and colleagues recruited super healthy controls as a comparison group to 
those with BD, and reported in a sample of 220 BD patients and 313 controls, 
that the HCL-32 had the following values: sensitivity (0.36), specificity (0.82), 
positive predictive value (58%) and negative predictive value (65%) indicating 
that the HCL-32 does not adequately distinguish BD cases from these super 
healthy controls (Lee et al. 2016). Unlike categorical diagnoses of BD, adopting 
a dimensional approach can be particularly useful, as a first episode of clinical-
level (hypo)mania is unlikely to have been diagnosed by a clinician at the time 
(hypo)mania symptoms were assessed at age 22-23 years in the ALSPAC 
sample (Leboyer et al. 2005). In addition, when investigating the aetiology of 
psychiatric disorders more generally, as exemplified using the Research 
Domain Criteria, dimensional approaches allow the characterisation of 
psychopathology as a distribution of departure from the norm, which allows for 
the heterogeneous presentation of complex psychiatric phenotypes (Cuthbert 
and Insel 2013; Cuthbert 2015).
The HCL questionnaire is a self-report measure and therefore reporting bias, 
often termed “social desirability bias” may be introduced. This is particularly 
evident when asking questions about sexual activity, risk-taking and alcohol 
use, in which participants are more likely to deliberately report the more 
favourable option (Latkin et al. 2017). This could lead to non-differential 
misclassification bias (i.e. irrespective of childhood psychopathology status, the 
response would bias the hypomania measure in the same way). This would 
likely lead to an underestimate of the effect size and true strength of evidence of 
association reported. Alternatively, there may be differential misclassification 
bias if social desirability bias is affected by childhood psychopathology, and this 
could lead to either under-estimates or over-estimates. 
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Another potential limitation is the use of the binary exposure high-risk for BPD 
at age 11 years. At this age, a diagnosis of any personality disorder is not 
possible, and the symptom presentation may transition to one of several 
disorders (e.g. depression disorders, anxiety disorders, substance abuse 
disorders and eating disorders) or none as the child develops. However, it is 
important to recognise that in the current study high-risk for BPD does not mean 
the child has a clinical DSM-IV or ICD-10 diagnosis of BPD. Rather, it is 
indexing the child having any 5 or more BPD traits occurring at least 25% of the 
time and daily. Although the assessment of a child being classified as high-risk 
for BPD has been assessed using a reliable measure, and the criteria required 
to be classified as high-risk are comparable to criteria required for an adult 
diagnosis of BPD, there are no data available in the ALSPAC cohort to 
determine the proportion of children who have subsequently gone on to meet 
criteria for BPD in adulthood. However, presence of BPD traits in adolescence 
has been shown to be associated with later adult BPD diagnosis (Winograd et 
al. 2008), and therefore suggests this may be an accurate reflection of the BPD 
phenotype.   
Finally, I examined many exposure-outcome relationships which could lead to 
stronger evidence for some associations simply as a result of chance (random 
error). To minimise the impact of this, exposure and outcome measures were 
determined a priori, and results are discussed based on the strength of 
evidence from statistical testing (rather than based on an arbitrary cut-off) within 
the context of this (and other) study limitations.
4.5.4 Conclusions
In this study, I found BPD trait measures were consistently associated with 
hypomania outcomes, irrespective of how these were defined, and do not 
appear to be explained by a range of confounders or selection bias. 
Associations between other psychopathology measures and the risk-taking 
factor of hypomania were also observed, but were less consistent and more 
likely to be explained by confounding and selection bias.
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Further studies are needed to determine what explains the associations I 
observed between psychopathology measures and hypomania. For example, 
whether there may be causal effects of psychopathology on hypomania,
whether these psychopathology measures are early expressions of 
BD/hypomania, or early expressions of genetic risk for BD. I will examine the 
latter in Chapter 7 by using a polygenic risk score (PRS) approach to 
investigate whether higher genetic risk for BD is associated with the childhood 
psychopathology and hypomania outcome measures assessed in this chapter. 
The next chapter, Chapter 5 will explore the associations between cognitive 
functioning in childhood and hypomania outcomes (HCL score, latent HCL 
factors and clinically-defined hypomania) in early adulthood.
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Chapter 5: Cognitive functioning in childhood and 
hypomania 
5.1 Summary
The relationship between cognitive functioning in childhood and subsequent 
development of mania or hypomania in adulthood is unclear. Studies of adults 
with BD have found mixed results on premorbid cognitive function. 
In this chapter, I investigated objectives 4-7 of this thesis as outlined in Chapter 
2. I examined whether cognitive functioning in childhood was associated with 
hypomania outcomes in the Avon Longitudinal Study of Parents and Children 
(ALSPAC) cohort. 
Overall, there was little evidence of association between cognitive functioning in 
childhood and clinically-defined hypomania in adulthood, but better functioning 
in the domains of working memory, problem solving, verbal learning and
emotion recognition was associated with Hypomania Checklist (HCL) score and 
the ‘active-elated’ factor in adulthood, and for some domains this relationship
was non-linear.
Tentatively, my findings suggest that better performance on specific cognitive 
domains in childhood may represent early markers of risk for hypomanic 
symptoms. These findings may aid earlier detection of BD and could guide 
clinical treatment. 
5.2 Introduction 
The relationship between enhanced intelligence, creativity and sociability with 
bipolar disorder (BD) has been of interest for centuries (Murray and Johnson 
2010; Johnson et al. 2012). A substantial body of research now exists 
examining the relationship between cognitive functioning and BD across all 
phases of the illness (premorbid, acute or euthymic). 
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Cognitive deficits are present in approximately 40-60% of those with BD (Sole 
et al. 2017), and evidence from meta-analyses suggests these deficits persist 
independent of mood state (Torres et al. 2007; Arts et al. 2008; Bora et al. 
2009). A number of cognitive domains have been identified as impaired in 
adults with BD: i) general intelligence as indexed by intelligence quotient (IQ), ii) 
processing speed, iii) working memory, iv) problem solving, v) verbal learning, 
vi) visual learning, vii) executive functioning, and viii) social cognition (Bora et 
al. 2009; Hidiroglu et al. 2015; Bora et al. 2016; Bora and Ozerdem 2017b; Bora 
2018). However, assessing cognitive functioning after someone has developed 
BD does not allow one to examine the temporal relationship between early 
cognitive functioning and BD as an outcome, i.e. to establish whether cognitive 
deficits are present in the premorbid phase, or only present after illness onset.
To study cognitive functioning in the premorbid phase, a longitudinal/cohort 
study design can be employed, and one of two groups of individuals can be 
studied. Offspring of BD parents (sometimes termed high-risk offspring) and 
offspring of control parents (non-high-risk offspring) can be followed up over 
time and cognitive ability during development compared between those who 
develop BD and those who do not. Alternatively, general population samples 
can be used, and cognitive functioning at baseline can be related to incidence 
of BD during follow up. 
There have been a number of studies investigating premorbid cognitive 
functioning using birth cohorts and military conscription data, with these studies 
reporting: i) no differences in premorbid IQ (Reichenberg et al. 2002; Zammit et 
al. 2004; Mortensen et al. 2005) or scholastic achievement (Kendler et al. 
2016b), ii) higher IQ (Koenen et al. 2009; MacCabe et al. 2010; Gale et al. 
2013; Smith et al. 2015), better arithmetic ability (Tiihonen et al. 2005) and 
social functioning (Reichenberg et al. 2002), and higher levels of academic 
achievement in those who develop BD (Vreeker et al. 2016), and iii) poorer IQ 
(Gale et al. 2010; MacCabe et al. 2010; Gale et al. 2013; Hiyoshi et al. 2017)
and visuospatial reasoning (Tiihonen et al. 2005) in those subsequently 
hospitalised with BD. On face value, these studies appear contradictory in their 
findings. One possible explanation for this is that the relationship between 
cognitive functioning in childhood and BD is non-linear, whereby those with 
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lower and those with higher than average cognitive ability are at increased risk 
of developing BD (Parellada et al. 2017). A recent review on cognitive 
functioning across all phases of BD illness reported that overall, findings are 
generally inconsistent, and based on much fewer studies than those examining 
premorbid IQ and schizophrenia (SZ). Furthermore, studies do not necessarily 
separate psychotic from non-psychotic BD individuals, which may be important 
given that those with psychotic BD often show cognitive impairments which are 
quantitatively more similar to those with SZ than those with non-psychotic BD
(Van Rheenen et al. 2019).
The high-risk offspring study design provides researchers with a distinct 
population of participants deemed at high genetic risk whose clinical trajectory 
can be meticulously detailed (some will develop psychopathology whereas 
others will remain well). Evidence from one recent meta-analysis of high-risk 
offspring of BD parents compared to controls suggests strong evidence of 
impairments in the domains of global cognition (lower IQ) and visual memory, 
with weaker evidence of impairments in domains of verbal memory, processing 
speed, sustained attention, executive functioning, and social cognition, and little 
evidence of impairments in working memory (Bora and Ozerdem 2017a).
Therefore, presence of deficits is detectable irrespective of clinical disease 
state. Importantly, the findings of this meta-analysis are reporting studies using 
genetic risk for BD as the exposure and cognition as the outcome, as opposed 
to cognition as the exposure and association with BD as the outcome. 
Whilst the high-risk-offspring design has clear advantages of a distinct 
population of individuals who are at much higher than average risk of 
developing the disorder, an often-reported limitation of such studies is small 
sample size, and therefore limited power to detect small-medium effects. The
other limitation of such a study design is that it is not possible to distinguish 
whether associations are due to familial risk or family environment since high-
risk offspring will likely have both. Studies using general population samples 
tend to be better powered, but just as with the high-risk study design, can be 
subject to attrition which may introduce selection bias.
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In contrast to consistent evidence reporting premorbid deficits in domains of 
general intelligence (IQ) from population-based studies (Khandaker et al. 2011), 
or evidence from youth at high-risk for developing schizophrenia in which 
deficits are reported in domains of general intelligence (IQ), visual memory, 
executive functioning, sustained attention, fluency, visual and verbal learning
(Bora et al. 2014), it is unclear whether premorbid cognitive deficits are present 
in those who eventually go on to develop BD. Most longitudinal study designs 
using general population samples have typically focussed on examining IQ only, 
and it is possible that deficits may be present in some domains but not others. 
Furthermore, whilst a large body of research exists examining associations 
between cognitive functioning and a diagnosis of BD, there are few studies 
examining associations with dimensional measures of hypomanic symptoms. 
Using a dimensional approach (with hypomania as a continuous measure) has 
the potential advantage of being statistically more powerful if the effect of 
cognition operates across the whole hypomania dimension rather than relying 
on a somewhat arbitrary threshold for classifying clinically-relevant hypomania. 
The objectives of this study were to: i) determine whether childhood cognitive 
functioning (processing speed, working memory, problem solving ability, 
executive functioning, attention, verbal learning and emotion recognition) is 
associated with dimensional measures of hypomania (including “sunny-side” 
and “dark-side” hypomania) and clinically-defined hypomania, ii) determine 
whether both higher and lower cognitive functioning is associated with 
hypomania (i.e. whether associations are non-linear), and iii) examine whether 
any associations are due to confounding or selection bias (Objectives 4-7).
5.3 Methods
5.3.1 Participants 
This study used data from individuals between ages 8 to 23 years from the 
ALSPAC cohort. Full details of recruitment procedures and inclusion criteria for 
the study can be found in Chapter 3 under section 3.2. 
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5.3.2 Outcome measures: Hypomania features
The Hypomania Checklist 32 (HCL-32) is a self-report questionnaire designed 
to assess lifetime hypomanic symptoms (Angst et al. 2005a). Further detailed 
information on the HCL-32, including how all hypomania outcomes (HCL score, 
HCL factors and clinically-defined hypomania) were derived, can be found in 
Chapter 3 under section 3.3.1. The 28 items used to derive the HCL score can 
be found in Chapter 3, Table 5. 
5.3.3 Exposure measures: Cognitive domains
At age 8 years, the children were invited to complete a series of tasks 
assessing cognitive functioning. The cognitive domains available in ALSPAC 
are loosely based on the domains assessed using the Measurement and 
Treatment Research to Improve Cognition in Schizophrenia Consensus Battery 
(MCCB), which the International Society for Bipolar Disorder deemed 
appropriate to use for assessing cognitive functioning in BD (Yatham et al. 
2010): processing speed, working memory, problem solving, executive 
functioning, attention, verbal learning and social cognition. I standardised all 
cognitive domains examined in this chapter.
Detailed information on how cognitive domains assessed using the Wechsler 
Intelligence Scale – III (WISC-III) (Wechsler et al. 1992) were derived by 
ALSPAC researchers can be found in Chapter 3, in section 3.3.3.1. I used the 
following tasks to investigate domains of: 
Processing Speed: I used the coding subtest where the children were required 
to correctly place a symbol above each number as quickly as possible. 
Working Memory: I used the previously derived Freedom From Distractibility 
index score which was a combination of the arithmetic and digit span tasks. 
Problem Solving: I used the block design task where the children needed to 
copy specific patterns of blocks on a picture and replicate using real blocks. 
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Details of how ALSPAC researchers calculated scores for cognitive domains 
assessed using the TEACh (Robertson et al. 1996) can be found in Chapter 3, 
section 3.3.3.2. I assessed the following cognitive domains: 
Executive Functioning: I used the opposite world’s task where the child saw a 
number 1 or 2 and was required to verbalise an answer which contradicted what 
they saw. 
Attention: I used the sky search task adjusted for motor speed. Here, the child 
had to distinguish identical from non-identical spaceships and circle all pairs as 
quickly as possible. 
Other cognitive domains investigated included: 
Verbal Learning: I used the nonword repetition task taken from the Children’s 
Test of Nonword Repetition (CTNWR) (Gathercole and Adams 1994). The child 
listened to 12 nonsense words and repeated each word back to the assessor 
(see Chapter 3, section 3.3.3.3 for further details). 
Social cognition: I used the emotion recognition task assessed using the 
Diagnostic Analysis of Nonverbal Accuracy (DANVA) (Nowicki and Carton 
1993) to assess social cognition. The child saw a facial expression and was 
required to identify whether the image they saw was that of a happy, sad, fearful 
or angry face. My primary outcome of interest was an emotion errors score 
which was the sum total of each of the individual face scores. Further details 
can be found in Chapter 3, in section 3.3.3.4. 
5.3.4 Confounding variables  
I adjusted my analyses for a number of potential confounders. These were 
determined a priori based on evidence from the literature and included gender, 
maternal education level, maternal age at birth, maternal social class, childhood 
emotional abuse, childhood physical abuse, childhood victimization, and being 
left-handed (Rich et al. 2008; MacCabe et al. 2010; Higier et al. 2014; Smith et 
al. 2015; Vierck et al. 2015; Dunn et al. 2018). 
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5.3.5 Multiple imputation
As with Chapter 4, I investigated the possibility of estimates being affected by 
selection bias by using multiple imputation. All exposure and confounder 
measures were imputed, along with a number of auxiliary variables 
predetermined on the basis of being associated with either the 
exposure/confounder and missingness. Details on the multiple imputation 
approach can be found in Chapter 3, section 3.6.1.4.
5.3.6 Statistical analyses
All analyses in this chapter were performed using Stata statistical software 
(version 14.1 SE. College Station, TX: Statacorp LP).
I used a Pearson correlation test to determine the extent of co-linearity between 
the cognitive domains, with these results presented in Table 13. Cognitive 
domains assessed using the same tool i.e. WISC-III and TEACh were most 
strongly correlated with each other.
Table 13 Correlations between cognitive domains
PS: Processing Speed; WM: Working Memory; PrS: Problem Solving; EF: Executive 
Functioning; ATT: Attention; VL: Verbal Learning; ER: Emotion Recognition
PS WM PrS EF ATT VL ER
PS 1.00
WM 0.31 1.00
PrS 0.25 0.36 1.00
EF 0.33 0.24 0.19 1.00
ATT 0.34 0.16 0.21 0.25 1.00
VL 0.12 0.41 0.21 0.13 0.08 1.00
ER 0.14 0.14 0.10 0.14 0.11 0.17 1.00
111
Where necessary, cognitive domain scores were recoded so that higher scores 
on all cognitive tasks always reflect better performance (see Chapter 3, section 
3.3.3). Furthermore, any cognitive domain scores >3 SD from the mean were 
removed from the analysis because they can have strong effects on estimates. 
I used linear regression to examine associations between cognitive domain 
scores and dimensional hypomania (HCL score/HCL factors), with results 
presented as the standard deviation (SD) change in HCL score per SD increase 
in cognitive domain score. 
To examine for a non-linear relationship between cognitive functioning and 
hypomania, I included a quadratic term in the regression model. P values 
reported are from likelihood ratio tests comparing models with linear and 
quadratic terms with models with the linear term only. To further clarify this 
relationship, any domains for which a non-linear relationship was found, I 
derived tertiles of cognitive domain scores and compared associations with 
hypomania outcomes in the lowest and the highest tertiles with the middle 
cognitive tertile. 
Logistic regression analyses were used to examine associations between 
cognitive domain scores and clinically-defined hypomania. These results are 
presented as the change in odds of clinically-defined hypomania per SD 
increase in cognitive domain score.  
5.4 Results
Both unadjusted and adjusted results for analyses comparing associations 
between cognitive domain scores and the HCL score are found in Table 14. 
5.4.1 Associations with the HCL score
Adjusting for confounding when examining the associations between cognitive 
domains and HCL score made little difference. Therefore, adjusted results are 
presented in the main text and the reader is directed to Table 14 for full results. 
For domains of working memory (adjusted ß = 0.09, 95%CI 0.04, 0.14; p 
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<0.001), problem solving (adjusted ß = 0.10, 95%CI 0.05, 0.14; p <0.001), 
verbal learning (adjusted ß = 0.08, 95%CI 0.03, 0.13; p = 0.001) and emotion 
recognition (adjusted ß = 0.07, 95%CI 0.02, 0.12; p = 0.005), I found strong 
evidence that better cognitive performance was associated with higher HCL 
scores. There was weaker evidence of association between better performance 
in domains of processing speed (adjusted ß = 0.04, 95%CI -0.00, 0.09; p = 
0.078) and executive functioning (adjusted ß = 0.06, 95%CI 0.01, 0.10; p = 
0.026) and higher HCL score, but little evidence of association with attention 
(adjusted ß = 0.02, 95%CI -0.04, 0.08; p = 0.480).
Table 14 Association between cognitive domains in childhood and HCL score in early adulthood
^rounded to 2 decimal places; HCL: Hypomania Checklist; CI: Confidence Intervals
*Adjusted for: gender, maternal education level, maternal age at birth, maternal social class, 
child being emotionally abused, child being physically abused, child being a victim of bullying 
and being left-handed
5.4.2 Test for quadratic effects of cognitive functioning and HCL score 
I next investigated whether the association between cognitive functioning and 
the HCL score is non-linear and consistent with hypomania being more 
common both in those with higher than average cognition, and in those with 
lower than average cognitive function. Full results are presented in Table 15. 
Exposure N ß unadjusted 95%CI P
ß 
adjusted* 95%CI P
Processing 
speed 1,848 0.03 -0.01, 0.08 0.178 0.04 -0.00^, 0.09 0.078
Working 
memory 1,802 0.11 0.06, 0.15 <0.001 0.09 0.04, 0.14 <0.001
Problem 
Solving 1,836 0.12 0.07, 0.17 <0.001 0.10 0.05, 0.14 <0.001
Executive 
functioning 1,796 0.05 0.00^, 0.10 0.031 0.06 0.01, 0.10 0.021
Attention 1,782 0.01 -0.04, 0.06 0.777 0.02 -0.04, 0.08 0.480
Verbal 
learning 1,845 0.10 0.05, 0.14 <0.001 0.08 0.03, 0.13 0.001
Emotion 
recognition 1,721 0.06 0.01, 0.11 0.014 0.07 0.02, 0.12 0.005
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I found strong evidence of a quadratic effect for processing speed (p quadratic 
= 0.001), weaker evidence for working memory (p quadratic = 0.01), for verbal 
learning (p quadratic = 0.03) and for attention (p quadratic = 0.063), and little 
evidence to suggest quadratic effects of the other cognitive domains (all 
p>0.487). 
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Table 15 Association between linear and quadratic terms for cognitive domains and HCL score
^rounded to 2 decimal places; HCL: Hypomania Checklist; CI: Confidence Intervals
*Adjusted for: gender, maternal education level, maternal age at birth, maternal social class, child being emotionally abused, child being physically abused, child 
being a victim of bullying and being left-handed
Exposure N  unadjusted 95%CI P  adjusted* 95%CI P
Processing 
speed 1,967
Linear 0.05 0.00^, 0.10 0.048 0.06 0.01, 0.11 0.016
Quadratic -0.06 -0.09, -0.02 0.002 -0.06 -0.09, -0.02 0.001
Working 
memory 1,917
Linear 0.13 0.08, 0.17 <0.001 0.11 0.06, 0.16 <0.001
Quadratic -0.04 -0.07, -0.00^ 0.079 -0.05 -0.08, -0.01 0.010
Problem 
solving 1,954
Linear 0.14 -0.06, 0.35 0.177 0.17 -0.04, 0.37 0.112
Quadratic -0.00^ -0.00^, 0.00^ 0.839 -0.00^ -0.00^, 0.00^ 0.487
Executive 
functioning 1,915
Linear 0.06 -0.01, 0.13 0.118 0.05 -0.02, 0.13 0.136
Quadratic 0.00^ -0.00^, 0.00^ 0.877 -0.00^ -0.00^, 0.00^ 0.943
Attention 1,903
Linear -0.03 -0.10, 0.04 0.349 -0.02 -0.09, 0.05 0.583
Quadratic -0.02 -0.05, -0.00^ 0.048 -0.02 -0.05, 0.00^ 0.063
Verbal 
learning 1,965
Linear 0.09 0.05, 0.14 <0.001 0.08 0.03, 0.12 0.002
Quadratic -0.04 -0.08, -0.00^ 0.028 -0.04 -0.08, -0.00^ 0.030
Emotion 
recognition 2,357
Linear 0.06 0.00^, 0.11 0.047 0.06 0.01, 0.12 0.023
Quadratic -0.01 -0.04, 0.02 0.677 -0.01 -0.04, 0.02 0.638
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As shown in Table 15, positive linear and negative quadratic terms
were present for domains of processing speed, working memory and 
verbal learning. This suggests that the biggest difference in HCL 
score appears to be at the lower end of the cognitive distribution.
However, for attention, there was some very weak evidence of a
quadratic effect, in which both linear and quadratic terms were 
negative. This suggests that the largest differences in HCL score is in 
those at both the lower and higher end of the cognitive distribution
i.e. an inverted U-shape.
To further clarify the patterns of non-linearity, I derived tertiles of 
cognitive functioning for domains of processing speed, working 
memory, verbal learning and attention. For domains of processing 
speed, working memory and verbal learning, the relationship 
suggested that those in the lowest compared to middle cognitive 
tertile had the lowest HCL scores, with little difference in HCL score 
in those in the highest tertile compared to those in the middle tertile. 
For attention, there was very weak evidence to suggest that those in 
both the lowest and highest compared to middle cognitive tertile had 
lower HCL scores (Figure 4 and Appendix 5).   
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Figure 4 Association between low and high cognitive performance and HCL score after adjusting for potential confounders
Horizontal line is  = 0; PS: Processing Speed; WM: Working Memory; ATT: Attention; VL: Verbal Learning; Error bars represent 95% confidence intervals; _L: 
Lowest tertile; _H: Highest tertile; Adjusted for: gender, maternal education level, maternal age at birth, maternal social class, child being emotionally abused, child 
being physically abused, child being a victim of bullying and being left-handed
-0.4
-0.3
-0.2
-0.1
0
0.1
0.2
PS_L PS_H WM_L WM_H ATT_L ATT_H VL_L VL_H
117
5.4.3 Associations with HCL factors 
Having investigated associations with the HCL score, I also investigated 
whether cognitive functioning might be associated with the different aspects of 
hypomania. Overall, the same cognitive domains associated with the HCL score 
as described above were associated with the ‘active-elated’ but not with ‘risk-
taking/irritable’ factor (Appendix 6). Similarly, the same cognitive domains for 
which a non-linear effect was detected in section 5.4.2, were also present with 
the ‘active-elated’ but not ‘risk-taking/irritable’ factor.  
5.4.4 Associations with clinically-defined hypomania 
Associations between cognitive functioning and odds of being classified as 
having clinically-defined hypomania are shown in Table 16. On the whole, there 
was little evidence to suggest an association between most cognitive measures 
and clinically-defined hypomania, though there was some weak evidence of 
association between better processing speed and reduced odds of hypomania 
(adjusted OR = 0.83, 95%CI 0.70, 1.03; p = 0.089). 
Table 16 Association between cognitive functioning and clinically-defined hypomania
CI: Confidence Interval; OR: Odds Ratio 
*Adjusted for: gender, maternal education level, maternal age at birth, maternal social class, 
child being emotionally abused, child being physically abused, child being a victim of bullying 
and being left-handed
Exposure N OR unadjusted 95%CI P
OR 
adjusted* 95%CI P
Processing 
speed 1,848 0.81 0.68, 0.98 0.028 0.83 0.70, 1.03 0.089
Working 
memory 1,802 0.85 0.71, 1.02 0.089 0.89 0.74, 1.08 0.236
Problem 
solving 1,836 0.92 0.76, 1.11 0.373 0.94 0.77, 1.14 0.532
Executive 
functioning 1,796 0.96 0.83, 1.12 0.633 0.98 0.84, 1.15 0.827
Attention 1,782 0.91 0.75, 1.12 0.389 0.92 0.74, 1.13 0.405
Verbal 
learning 1,845 0.90 0.75, 1.09 0.290 0.91 0.75, 1.09 0.305
Emotion 
recognition 1,721 1.04 0.85, 1.28 0.678 1.08 0.88, 1.33 0.459
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With the possible exception of attention (p quadratic = 0.063) and the emotion 
errors score (p quadratic = 0.035), there was little evidence of non-linear 
relationships between most cognitive domains and clinically-defined hypomania 
(all p>0.376) (Appendix 7). 
5.4.5 Associations using imputed data
I investigated whether selection bias might be affecting my results by using 
multiple imputation. Overall, there was little evidence to suggest selection bias 
had an impact on associations between most cognitive domains with 
hypomania outcomes. However, for the domains of processing speed and 
executive functioning, a reduction in effect size of 50-60% and 30-50%
respectively was observed in the imputed data (see Appendices 8, 9 and 10 for 
full results). Despite the reductions in effect size and strength of evidence of 
association in the imputed data, this does not alter the conclusions of this study. 
5.5 Discussion 
5.5.1 Summary of findings
5.5.1.1 Associations with hypomania
The first objective of this study was to determine whether cognitive functioning 
in childhood was associated with hypomania. When examining associations 
between cognitive domains and dimensional hypomania (HCL score and HCL 
factors), the strongest associations were with working memory, problem solving 
ability, verbal learning, and emotion recognition. The association was such that 
better performance on these measures was associated with an increase in HCL 
score, and from the analyses with the HCL factors, these associations were 
primarily with the ‘active-elated’ rather than ‘risk-taking/irritable’ factor. There 
was little evidence to support associations between cognitive domains and 
clinically-defined hypomania. 
5.5.1.2 Testing for non-linear effects 
The second objective of this study was to examine whether there was a non-
linear relationship between cognitive functioning and hypomania. For the 
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domains of processing speed, working memory, verbal learning and attention, a 
non-linear effect was detected. I found that for the former three domains, poorer 
compared to average performance on these cognitive measures was 
associated with lower HCL score, with little difference in HCL score in those 
with high compared to average cognitive performance in these domains. This 
can be seen more clearly when looking at the results using the tertiles of 
cognitive performance. For problem solving ability and emotion recognition, a 
linear pattern was detected i.e. increasing HCL score across the whole range of 
cognitive performance, and for attention, both higher and lower compared to 
average attention performance was associated with a reduction in HCL score.
5.5.1.3 Examining the impact of confounding and selection bias 
The third objective of this study was to determine the extent to which any 
associations observed are likely due to confounding or selection bias. For most 
cognitive domains, there was little evidence to suggest that either confounding 
or selection bias were impacting the associations observed, irrespective of how 
hypomania was defined. Nevertheless, there will likely be some residual 
confounding which could not be accounted for which may bias my findings. 
One reason why average, and better than average cognition might be 
associated with reporting more hypomania symptoms is that increased 
energy/activity levels in childhood, if not at an extreme, might allow children to 
maintain their concentration for longer periods of time, enabling them to perform 
better on cognitive tasks. If these energy/activity levels persist, they may also 
lead to higher scores on hypomania assessments in adulthood. Similarly, other 
precursors of hypomania, if present in childhood and affecting cognitive ability, 
could confound the association between cognition and hypomania/BD.
However, I found that for processing speed and executive functioning, the 
adjusted results suggest that confounding (and perhaps residual confounding) 
might lead to an underestimate in the effect size in the unadjusted model, and 
therefore the likely impact of residual confounding on the association between 
cognition and hypomania is unclear.
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When examining the impact of selection bias on my findings, a 33% and 50% 
reduction in effect size was observed in the imputed data for associations 
between executive functioning and processing speed with dimensional 
hypomania respectively, suggesting that selection bias in the complete-case 
analysis was over-estimating the true association for these domains. The main 
findings however, of associations between working memory, problem solving 
ability, verbal learning, and emotion recognition and hypomania were 
unchanged.
5.5.2 Findings in the context of previous work 
Placing these findings in the context of previous work is difficult for a number of 
reasons: i) longitudinal general population studies examine associations 
between cognitive functioning and BD as an outcome rather than hypomania as 
an outcome, ii) in these studies examining cognition and BD, the focus is 
typically on examining associations with general intelligence (IQ) and not with 
specific cognitive domains, and iii) the time-point at which cognition has been 
assessed is often in late adolescence/early adulthood, rather than childhood as 
I examine here. 
To the best of my knowledge, this is the first and largest study of its kind 
examining associations between a broad range of tests of cognitive function in 
childhood and hypomania as an outcome in early adulthood within the general 
population. One study, using the ALSPAC sample, examined associations 
between IQ categories and the HCL. The authors reported that children who 
scored in the superior and very superior IQ category reported higher lifetime 
hypomania features compared to the mid-IQ group, but that those who scored 
in the borderline or extremely low category did not report higher lifetime 
hypomania features (Smith et al. 2015). Higher, but not lower childhood IQ has 
also been reported in those who eventually go on to develop BD in the Dunedin 
(Koenen et al. 2009) and Swedish (Gale et al. 2013) cohorts. In the Swedish 
general population, both poorer, and particularly better compared to average 
scholastic achievement assessed at age 16 years was associated with 
increased risk of BD (MacCabe et al. 2010). Whilst one possible explanation for 
inconsistencies in the literature on premorbid IQ and BD might be a result of 
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both better and poorer IQ being associated with increased risk of BD, the 
findings from the current study do not support this explanation for the specific 
cognitive domains investigated. Whilst a larger body of literature seems to show 
that BD/hypomania is more common in those with the highest cognitive ability 
than in those with the lowest, it is less clear as to whether this pattern is linear
or not. Further, if this pattern is non-linear, it remains to be determined whether 
the biggest difference in BD/hypomania risk is between those with the lowest 
compared to average cognitive ability, or between those with the highest 
compared to average cognitive ability. 
Evidence from several meta-analyses examining cognitive functioning in adults 
with BD report deficits in multiple domains across all phases of the illness, with 
severity of deficits typically greater in those with BD type I compared to BD type 
II, and in those with psychotic compared to non-psychotic BD (Arts et al. 2008; 
Bora et al. 2009; Bora et al. 2011; Bo et al. 2017; Bora 2018). My findings of 
associations between better cognition and higher HCL score do not appear 
consistent with the findings from these meta-analyses. However, the studies 
examined in these meta-analyses have examined cognition after the individual 
has developed BD, rather than before, or at an older age than was assessed in 
my study. It is therefore possible that cognition in childhood is relatively 
preserved, and that deficits in those who develop BD occur as a consequence 
of the disorder or treatment. Some studies have suggested that deficits are 
related to increasing number of mood episodes (Latalova et al. 2011), or only 
become evident once mood symptoms reach syndromal levels (Duffy et al. 
2017a). To determine the extent to which any of these situations may occur, 
cohort studies with repeat measures of cognition from childhood through to 
adulthood would be needed. 
5.5.3 Strengths and limitations 
This study has a number of strengths and limitations. Firstly, at the time of 
enrolment, ALSPAC was considered as representative of the UK general 
population in terms of maternal social class, ethnicity and educational level 
attained. It is also one of the most detailed birth cohort studies worldwide, with 
extensive data on both environmental and genetic factors that can affect a 
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person’s health and development (Boyd et al. 2013). This meant that it was 
possible to adjust my analyses for a number of potential confounders which 
might affect the association between cognitive performance and hypomania, 
though there may still be residual confounding present. However, over time 
attrition has occurred which might introduce selection bias due to missing data. 
As mentioned in Chapter 4 section 4.5.2, by imputing values for exposures, 
confounders and auxiliary variables, it was possible to build an imputation 
model to make the missing at random assumption of the multiple imputation 
approach more plausible. Though every effort was made to minimise selection 
bias, it is still possible that some bias remains, even in the imputed analyses.  
Whilst a broad range of cognitive domains in childhood and their associations 
with hypomania as an outcome were examined, based on the cognitive 
domains identified as impaired in those with BD using the MCCB (Yatham et al. 
2010), I was unable to examine visual learning as no comparable measure was 
available in the ALSPAC cohort. Nevertheless, most studies examining 
premorbid cognitive functioning using a longitudinal study design in individuals 
from the general population and subsequent development of BD typically focus 
on examining one or two domains (Zammit et al. 2004; Smith et al. 2015; Koike 
et al. 2018), whereas the current study was able to examine 6 cognitive 
domains. 
The assessment of cognitive domains at age 8 years, approximately 14 years 
before the assessment of hypomania features means that the observed effects
are more likely to represent change in risk of hypomania in relation to cognitive 
performance as opposed to reverse causation by the presence of hypomanic 
symptoms. However, with no assessment of hypomanic symptoms in childhood 
to confirm this, it is not possible to rule this out definitively.
Although I used well validated measures for assessing cognitive functioning in 
childhood (Wechsler et al. 1992; Nowicki and Carton 1993; Gathercole and 
Adams 1994; Robertson et al. 1996), the measures used may less than 
perfectly capture the domains I examined which could introduce measurement 
error and bias the results. This is further complicated by the knowledge that 
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neuropsychological tests rarely examine a single cognitive domain in isolation 
(Howieson 2019).
When examining associations with hypomania, I have done so dimensionally 
(HCL score and HCL factors) and categorically (clinically-defined hypomania). 
To avoid repetition, the reader is directed to Chapter 4, section 4.5.2 for a 
discussion surrounding the HCL and the relative advantages of using the 
dimensional approach when investigating the aetiology of psychiatric disorders 
as exemplified using the RDoC (Cuthbert and Insel 2013; Cuthbert 2015). 
However, it is unclear as to the extent to which my findings using the HCL 
directly translate onto (hypo)mania/BD in clinical samples.  
Finally, as mentioned in Chapter 4, I have examined many exposure-outcome 
relationships which could lead to stronger evidence for some associations due 
to chance (random error). To minimise the impact of this, exposure and 
outcome measures were determined a priori, and results are discussed based 
on the strength of evidence from statistical testing (rather than based on an 
arbitrary cut-off) within the context of this (and other) study limitations.
5.5.4 Conclusions
Within this prospective study, I found better performance on specific cognitive 
domains was associated with a dimensional measure of hypomanic symptoms, 
although for some domains this was non-linear. Associations were primarily with 
the ‘active-elated’ rather than ‘risk-taking/irritable’ factor of hypomania, with little 
to no evidence of association between cognitive domains and clinically-defined 
hypomania.
Further work in large population samples is required to determine the 
replicability of these findings in other general population samples at a similar 
age. Further work could also investigate whether associations with these 
cognitive measures changes with age, and to determine whether genetic risk for 
BD is associated with these cognitive domains. In Chapter 8 I will examine the 
latter by using a polygenic risk score approach (PRS) to determine whether 
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increased genetic risk for BD is associated with the cognitive domains 
examined in this chapter. 
The next chapter, Chapter 6 will systematically review the literature 
investigating associations between a BD-PRS and non-BD phenotypes.
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Chapter 6: Systematic review
The work presented in this chapter has been published and can be found online 
at 
https://www.sciencedirect.com/science/article/pii/S016503271732373X?via%3D
ihub
Mistry, S., Harrison, J.R., Smith, D.J., Escott-Price, V., Zammit, S. (2018). The 
use of polygenic risk scores to identify phenotypes associated with genetic risk 
of bipolar disorder and depression: A systematic Review. Journal of Affective 
Disorders, 234, 148-155 https://doi.org/10.1016/j.jad.2018.02.005
The published article has been adapted for use in this chapter to include 
additional results (that were available as supplementary materials in the 
published article). The focus of this Chapter will be reporting the results of 
phenotypes associated with genetic risk for bipolar disorder only. 
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6.1 Chapter summary
One way to enhance understanding of the aetiology of bipolar disorder (BD) is 
to identify the phenotypic manifestations of increased genetic liability for BD. 
One method to investigate increased genetic liability for BD is the polygenic risk 
score (PRS) approach. This approach allows the exploration of how genetic risk 
is manifest in different populations. 
In this chapter, I investigated objective 8 of this thesis as outlined in Chapter 2. 
To do this, I conducted a systematic review of the literature to identify studies 
examining associations between a BD-PRS and a broad range of phenotypic 
outcomes. I followed the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines, and searched three databases: Medline, 
EMBASE and PsycINFO (from 6th August 2009 – 14th March 2016) in addition 
to the references of included studies. 
For the purpose of this Chapter, 18 studies were included. Overall, the BD-PRS 
was more strongly associated with other (non-discovery sample phenotypes i.e. 
not BD) psychiatric disorders such as depression and schizophrenia, and with 
greater symptom severity of depression, although it explained only a small 
proportion of the variance in most phenotypes (<2%). I also developed and 
published a reporting framework for future studies to use, that can help interpret 
findings across studies and allow meta-analyses to be conducted.
By using larger discovery and adequately powered target samples to determine 
which phenotypes are associated with increased genetic for BD, the PRS 
approach could be used in the future to develop stratified medicine approaches. 
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6.2 Introduction
Evidence from twin, family and adoption studies suggest mood disorders such 
as depression and BD are common, highly heritable psychiatric conditions 
(Sullivan et al. 2000; Oswald et al. 2003; Shih et al. 2004; Bienvenu et al. 
2011). Given the negative impact on the lives of those with BD, the early 
identification of individuals who are at high genetic risk of BD, may help to 
inform risk prediction. One method to examine phenotypes associated with 
genetic risk is to prospectively follow high-risk offspring of BD parents. Recent 
reviews on the clinical trajectory of BD (Duffy et al. 2017b; Pfennig et al. 2017; 
Duffy et al. 2019), using offspring of BD parents compared to offspring of 
parents without BD, have highlighted several phenotypes being present at 
higher rates in high-risk offspring compared to non-high-risk offspring and 
include: i) having anxiety and sleep disorders in childhood (Duffy et al. 2010; 
Nurnberger et al. 2011; Ritter et al. 2012; Duffy et al. 2014), ii) increased risk of 
any psychopathology, but particularly substance use disorders if having a 
parent with diagnosed BD prior to birth and being exposed to the parent 
showing BD symptoms from birth to 10 years (no comparison group was 
reported) (Goodday et al. 2018) iii) exposure to early life events (family 
disruption, parental somatic illness, parental psychopathology, parental labour 
market exclusion, parental criminality, placement in out-of-home care, parental 
natural death and parental unnatural death) compared to exposure to no life 
events (Bergink et al. 2016), v) increased maternal but not paternal perceived 
neglect (Doucette et al. 2016), vi) presence of ADHD and other behavioural 
disorders (Nurnberger et al. 2011; Duffy 2012; Egeland et al. 2012; Axelson et 
al. 2015) and vii) having a parent who was diagnosed with BD before age 22 
years (Preisig et al. 2016). 
From the available evidence using prospective longitudinal studies of offspring 
of BD parents, the manifestations of being at increased genetic risk for BD in 
childhood/adolescence varies, extending beyond increased risk of having the 
same disorder as the parent (i.e. a BD diagnosis) (Rasic et al. 2014). These 
high-risk studies can at times report conflicting results, particularly when 
comparing results to population-based registries. These discrepant findings may 
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be attributed to i) small sample sizes when assessing rates of psychopathology 
in the offspring, which may lead to lack of statistical power to detect small effect 
sizes (Cohen’s d ≤0.2), and ii) methodological differences between studies, 
particularly in the validity of diagnostic instruments used. 
Newer molecular genetic approaches such as genome-wide association studies 
(GWAS), alongside collaborative consortia, mean that is it now possible to 
overcome the limitations of using the high-risk offspring of BD parents study 
design. GWAS are able to examine many genetic variants in the genome 
simultaneously, without an a priori hypothesis. 
Since the first GWAS of BD using the Wellcome Trust Case Control Consortium 
(Wellcome Trust Case Consortium et al. 2007), a number of GWAS have been 
conducted and have reported, albeit inconsistently, a number of risk variants 
occurring more frequently in BD cases compared to controls (Baum et al. 
2008a; Ferreira et al. 2008; Sklar et al. 2008; Cichon et al. 2009; Schulze et al. 
2009; Scott et al. 2009; Smith et al. 2009; Djurovic et al. 2010; Sklar et al. 
2011). Though the number of risk variants is lower than for schizophrenia 
(Purcell et al. 2009; Ripke et al. 2014), this is most likely attributed to the 
smaller sample numbers used in the GWAS for BD.
On an individual level, single nucleotide polymorphisms (SNPs) have very small 
effect on disease risk, but summing the weighted allelic dosage across all SNPs 
and collapsing into a single polygenic risk score (PRS), allows the exploration of 
how genetic risk is manifest in individuals from different populations (Wray et al. 
2014). 
Initially, the first paper to use a PRS approach found that a schizophrenia PRS 
(SZ-PRS), derived from summary statistics of a GWAS of schizophrenia, was 
associated with schizophrenia case status compared to controls, and to a lesser 
extent BD case status compared to controls (Purcell et al. 2009). Since that 
time, there have been many studies published examining associations between 
other psychiatric and non-psychiatric polygenic risk scores and a range of 
phenotypic outcomes. 
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The PRS was initially used to predict case status and determine the extent to 
which common genetic variants can explain variation in a particular disorder. 
However, the investigation of associations between a PRS and other 
phenotypes, (different from those in the GWAS used to derive the PRS), may 
help understanding of the aetiology of the disorder, as well as its manifestations 
which may be useful markers of risk. I previously conducted a systematic review 
and identified a number of non-schizophrenia diagnosis phenotypes associated 
with increased genetic risk for schizophrenia using a PRS approach. The 
strongest associations were with other psychiatric disorders, particularly 
depression and BD, though explained little of the variance in these phenotypes 
(<2%) (Mistry et al. 2018b).
Over the last 10 years, there has been an accumulation of studies that have 
used a PRS approach to determine possible non-BD diagnosis phenotypes 
associated with increased genetic risk for BD. Identifying these phenotypic 
manifestations may help understand the aetiology of BD, the PRS’s usefulness 
in risk prediction, and potentially facilitate earlier intervention prior to the onset 
of clinically relevant symptoms. Therefore, the purpose of this study was to 
explore the phenotypic (non-BD diagnosis) manifestations of increased genetic 
liability for BD by conducting a systematic review of the literature (Objective 8). 
6.3 Methods
I followed Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines for conducting systematic reviews and meta-
analyses (Moher et al. 2009). A completed version of the table recommended 
for use by Moher and colleagues can be found in the original publication (Mistry 
et al. 2018a). 
Initially, I had planned to conduct a single systematic review examining 
phenotypes associated with increased genetic risk for schizophrenia, BD and 
depression. However, upon conducting the search, a collective decision was 
made between my supervisors and I to split the findings into two separate 
systematic reviews; one examining literature of phenotypes associated with a 
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SZ-PRS (Mistry et al. 2018b), and the other examining associations with either 
a BD-PRS or a depression PRS (Mistry et al. 2018a).
6.3.1 Search strategy
6.3.1.1 Data sources
I searched three databases (EMBASE, Medline via Ovid and PsychINFO) from 
06/08/2009 to 14/03/2016. In addition, I hand searched the references of 
articles included in this chapter. The start date was chosen as this was the first 
paper to use the PRS approach, and the end date was selected based on when 
I began the original search. 
6.3.1.2 Search terms and delimiters
I searched for articles using the terms “bipolar (or variations of)” AND “polygenic 
(or variations of)”. Full search strategy terms from the original systematic review 
are listed in Appendix 11. 
6.3.1.3 Inclusion/Exclusion criteria
I included articles that examined associations between a BD-PRS (derived from 
a GWAS of participants with a diagnosis of BD and a measurable phenotype
but excluding neuro-imaging outcomes). Neuroimaging outcomes were not 
included because this represents a more specialised area of work beyond the 
focus of this review. As the purpose of this study was to identify non-BD 
diagnosis phenotypes, articles reporting associations only between the BD-PRS 
and a diagnosis of BD were not included. Articles were required to be in peer 
reviewed journals and published in English (see Appendix 12 for 
inclusion/exclusion criteria specific to this chapter).
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6.3.2 Data collection and analysis
6.3.2.1 Selection of studies
Once I had identified all potential studies, after de-duplication, I screened the 
title and abstract of each study (see Figure 5 for flow diagram). If it was unclear 
whether the paper contained relevant data, or the abstract was not available, I 
retrieved the full-text article. Full-text articles were reviewed and checked 
against inclusion/exclusion criteria by Dr Judith Harrison and I independently. 
Any disagreements were resolved by a third author (Professor Stanley Zammit). 
I extracted relevant data using a data extraction form see (Mistry et al. 2018a)
for a blank version of this. From this, I summarised the results using a narrative 
approach as most studies did not report standardised effect sizes, (or provide 
data that would allow me to calculate this) as is required to conduct a meta-
analysis.
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Figure 5 Study selection flow diagram
SZ; Schizophrenia, PRS; Polygenic Risk Score, BD; Bipolar Disorder, MDD; Major Depressive 
Disorder
6.4 Results
In total, 18 studies assessed associations between the BD-PRS and a 
measurable phenotype. The majority of these studies used the first GWAS from 
the Psychiatric Genomics Consortium (PGC) (Sklar et al. 2011) as a discovery 
set from which the derive the PRS, with individual studies using different p-
value threshold cut-off scores (PTs) to assess the relationship between genetic 
risk for BD and phenotype(s) (Tables 18-22). Most studies were of 
White/Caucasian adults of European ancestry. Table 17 provides a summary of 
these 18 studies. 
Databases searched: Embase, Medline via Ovid, PsychINFO. Total 
papers retrieved: 1443
400 duplicate 
papers removed
Abstracts read: 1043
Irrelevant 
title/abstract (981 
papers removed)
Full texts retrieved: 62
Studies that did not 
meet inclusion criteria 
(31 papers removed)
Mood 
(BD/MDD) PRS 
only (11)
BD/MDD PRS 
(25)
SZ PRS (30)
SZ PRS only (25) Multiple PRS (14)
BD-PRS only 
(18)
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Table 17 Summary of studies examining associations between genetic risk of BD and 
phenotypes
BD; Bipolar Disorder, MDD; Major Depressive Disorder, SZ; Schizophrenia
a A ‘study’ is defined as an examination between the BD-PRS and a phenotype. As many 
publications examine multiple phenotypes, the number of studies in this table exceeds the 
number of publications included in this chapter 
6.4.1 Associations with adult psychiatric disorders 
The data extracted from studies examining associations between the BD-PRS 
and adult psychiatric disorders can be found in Table 16. 
 
Using data from the PGC, the BD-PRS was strongly associated with SZ 
(strongest PT<0.3, p = 1x10-50) and Major Depressive Disorder (MDD)
(strongest PT<0.5, p = 1x10-16 (Cross-Disorder Group of the Psychiatric 
Genomics Consortium 2013). 
Support of these findings of associations between the BD-PRS and both 
depression and SZ came from a study that used the GAIN-MDD and GAIN-SZ 
samples. The authors reported the BD-PRS was higher in SZ cases compared 
to controls (no PT reported, p = 2.9x10-9; AUC = 0.56) and depression cases 
compared to controls (no PT reported, p = 7.32x10-7; AUC = 0.55) (Schulze et 
al. 2014).
Phenotype group
Number of studies 
examined
Number of studies with 
evidence of association at 
p<0.05
BD related phenotypes 10 6
MDD related phenotypes 17 13
SZ related phenotypes 18 8
Other psychiatric 
phenotypes
9 5
Other phenotypes 8 4
134
There was strong evidence of associations between the BD-PRS and Seasonal 
Affective Disorder (SAD) (strongest PT<0.1, p = 0.004) using data from the 
Australian Twin Registry (ATR) and Midwest Alcohol Research Centre (Byrne et 
al. 2015), and weaker evidence of association with post-traumatic stress 
disorder (PTSD) (strongest PT<0.3, p = 0.028) in the Marine Resilience Studies 
(Nievergelt et al. 2015).
Associations between the BD-PRS and post-partum depression (PPD) varied 
according to which dataset(s) the authors used. When data were combined 
from the Netherlands Study of Depression and Anxiety (NESDA)/Netherlands 
Twin Registry (NTR) samples, the Queensland Institute of Medical Research 
(QIMR) sample, the ALSPAC sample and the Swedish Twin Registry (STR) 
sample, there was strong evidence of association with PPD (strongest PT<0.1, p 
= 0.005), and similarly when examining data from the QIMR study alone 
(strongest PT<0.1, p = 3.04x10-5) and NESDA/NTR samples (strongest 
PT<0.001, p = 0.001) alone. There was no evidence to support association
between the BD-PRS and PPD in either the ALSPAC or STR samples (Byrne et 
al. 2014).
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Table 18 Associations between the BD-PRS and adult psychiatric disorders
BD: Bipolar Disorder; PRS: Polygenic Risk Score; PT: P-value threshold; OR: Odds Ratio; CI: Confidence Interval; PGC: Psychiatric Genomicsso Consortium; SZ: 
Schizophrenia; MDD: Major Depressive Disorder; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders-IV; ICD-10: International Classification of 
Diseases-10; MRS: Marine Resilience Studies: PTSD: Post-Traumatic Stress Disorder; CAPS: Clinician Administered PTSD Scale; ATR: Australian Twin Registry; 
SPAQ: Seasonal Pattern Assessment Questionnaire; NEDSA: Netherlands Study of Depression and Anxiety; QIMR: Queensland Institute of Medical Research;  
NTR: Netherlands Twin Registry; STR: Swedish Twin Registry; ALSPAC: Avon Longitudinal Study of Parents and Children; PPD: Post-Partum Depression; EPDS: 
Edinburgh Postnatal Depression Scale; GAIN: Genetic Association Information Network; RDC: Research Domain Criteria; PT reported is either the only one 
examined or one with strongest evidence if more than one PT was examined
Author and 
Year
Discovery 
sample
Target 
sample 
Outcome (measure 
used) N PT ß/OR/correlation 95%CI P R
2 (%)
Cross 
Disorders 
2013
PGC-1-BD 
PGC 1 SZ SZ (Clinical interview - DSM-IV or ICD-10)
9397 cases 
and 7736 
controls
0.3
Not reported Not reported
1x10-50 2.2
PGC MDD
MDD (Clinical 
interview - DSM-IV or 
ICD-10)
9227 cases 
and 7383 
controls 
0.5 1x10-12 0.48
Schulze et 
al., 2014 WTCCC BD 
GAIN SZ 
SZ (Clinical interview 
– RDC or DSM-IV)
1343 SZ 
cases and 
1378 
controls 
Not 
reported Not reported Not reported
2.9x10-9 
Not 
reportedGAIN MDD 7.32x10-7 
Byrne et al., 
2015 PGC-1-BD 
ATR and the 
Midwest 
Alcohol 
Research 
Centre study
Global seasonality 
score (SPAQ)
4156 general 
population 
adults
0.01 Not reported Not reported 0.250 0
0.1 Not reported Not reported 0.004 0.4
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Table 18 continued
BD: Bipolar Disorder; PRS: Polygenic Risk Score; PT: P-value threshold; OR: Odds Ratio; CI: Confidence Interval; PGC: Psychiatric Genomicsso Consortium; SZ: 
Schizophrenia; MDD: Major Depressive Disorder; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders-IV; ICD-10: International Classification of 
Diseases-10; MRS: Marine Resilience Studies: PTSD: Post-Traumatic Stress Disorder; CAPS: Clinician Administered PTSD Scale; ATR: Australian Twin Registry; 
SPAQ: Seasonal Pattern Assessment Questionnaire; NEDSA: Netherlands Study of Depression and Anxiety; QIMR: Queensland Institute of Medical Research;  
NTR: Netherlands Twin Registry; STR: Swedish Twin Registry; ALSPAC: Avon Longitudinal Study of Parents and Children; PPD: Post-Partum Depression; EPDS: 
Edinburgh Postnatal Depression Scale; GAIN: Genetic Association Information Network; RDC: Research Domain Criteria; PT reported is either the only one 
examined or one with strongest evidence if more than one PT was examined
Author and 
Year
Discovery 
sample
Target 
sample 
Outcome (measure 
used) N PT ß/OR/correlation 95%CI P R
2 (%)
Bryne et al., 
2014 PGC-1-BD
QIMR +  
NESDA/NTR 
+  STR + 
ALSPAC
PPD (EPDS)
1420 cases 
of and 9473 
controls 
0.1
Not reported Not reported
0.005 0.13
NESDA/NTR
208 cases 
and 761 
controls
0.01 0.001 0.17
STR
100 cases 
and 1209 
controls
1 0.270 0.22
ALSPAC
616 cases 
and 6311 
controls
1 0.420 0.02
QIMR
484 cases 
and 1024 
controls
0.1 3.04x10-5 1.64
Nievergelt et 
al., 2015 PGC-1-BD MRS
PTSD (Clinical 
interview - CAPS)
940 cases 
and 2554 
controls
0.3 Not reported Not reported 0.028 0.025
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6.4.2 Associations with childhood psychiatric disorders 
There were two studies that reported associations between the BD-PRS and 
childhood psychiatric disorders (Table 19). The first reported weak evidence of 
association between the BD-PRS and both ADHD and autism spectrum 
disorder (ASD) (strongest PT<0.4, p<0.05; strongest PT<0.001, p<0.05 
respectively) (Cross-Disorder Group of the Psychiatric Genomics Consortium 
2013).
A second study also found weak evidence of a higher BD-PRS in ADHD cases 
compared to controls (strongest PT<0.5; p = 0.052) using combined data from 
UK community child psychiatry and paediatric clinics from Dublin, Ireland. 
(Hamshere et al. 2013). 
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Table 19 Associations between the BD-PRS and childhood psychiatric disorders
BD: Bipolar Disorder; PRS: Polygenic Risk Score; PT: P-value threshold; OR: Odds Ratio; CI: Confidence Interval; PGC: Psychiatric Genomics Consortium; ADHD: 
Attention Deficit Hyperactivity Disorder; ASD: Autism Spectrum Disorder; PT reported is either the only one examined or one with strongest evidence if more than 
one PT was examined
Author and 
Year
Discovery 
sample
Target 
sample 
Outcome (measure 
used) N PT ß/OR/correlation 95%CI P R
2 (%)
Cross 
Disorder 
Group 2013
PGC-1-BD
PGC ADHD 
ADHD (Clinical 
interview - DSM-IV or 
ICD-10)
840 cases 
and 688 
controls
0.0001
Not reported Not reported 
<0.05 0.18
PGC ASD 
ASD (Clinical 
interview - DSM-IV or 
ICD-10)
161 cases 
and 526 
controls 
0.4 <0.05 0.078
Hamshere 
et al., 2013 PGC-1-BD 
UK/Irish 
ADHD 
GWAS 
ADHD (DSM-III-R or 
DSM-IV or ICD-10)
727 cases 
with ADHD 
and 2067 
controls 
without any 
psychiatric or 
neurological 
disorders
0.5 Not reported Not reported 0.052 0.11
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6.4.3 Association with psychotic disorders and symptoms 
There were 5 studies in total that examined associations between a BD-PRS 
and psychotic disorders and symptoms (see Table 20). 
In individuals with SZ drawn from the first PGC GWAS of SZ, the BD-PRS was 
associated with a manic symptom factor (strongest PT<0.3, p = 0.003), but not 
with positive, negative or depressive symptom factors across any PT (no 
statistics reported) (Ruderfer et al. 2014). 
There was weak evidence that the BD-PRS was associated with a positive 
history of psychosis in individuals with BD (strongest PT<0.05, p = 0.079) in the 
Thematically Organised Psychosis (TOP) sample (Aminoff et al. 2015). 
A study using data from the first PGC SZ sample reported strong evidence of 
association between the BD-PRS and SZ, either when comparing those with SZ
and a negative family history of psychotic illness to controls (strongest at PT<1, 
1-sided p<1x10-300), or when comparing those with SZ and a positive family 
history of psychotic illness to controls (strongest at PT<1, 1-sided p = 7.11x10-
149). Evidence of association between the BD-PRS and SZ cases with a positive 
family history of psychotic illness compared to SZ cases with a negative family 
history of psychotic illness was substantially weaker (strongest PT <0.4, one-
sided p = 0.012) (Bigdeli et al. 2016). 
Using data from a Norwegian sample, the BD-PRS was not associated with a 
lifetime history of psychosis in BD-spectrum cases compared to BD-spectrum 
cases with no lifetime history of psychosis (no PT or p value reported), or when 
SZ spectrum cases were compared to BD spectrum cases (strongest PT<0.05; 
p = 0.13). However, the BD-PRS was higher in SZ-spectrum cases compared to 
controls without SZ, BD or MDD (strongest PT<0.05; p = 0.01) (Tesli et al. 
2014).
One study found weak evidence of association between the BD-PRS and both 
decreased paranoia (strongest PT<0.5, one-sided p = 0.064) and decreased 
anhedonia (one-sided p = 0.048), but not with parent-rated negative symptoms, 
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grandiosity, cognitive/disorganization symptoms and hallucinations in 
adolescents from the population-based Longitudinal Experiences and 
Perceptions (LEAP) study at PT<0.5 (Sieradzka et al. 2014).
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Table 20 Associations between the BD-PRS and psychotic disorders and symptoms
Author 
and Year
Discovery 
sample
Target 
sample Outcome (measure used) N PT ß/OR/correlation 95%CI P R
2 (%)
Tesli et 
al., 2014 PGC-1-BD
Norwegian 
sample
SZA (Clinical interview - DSM-
IV)
64 with SZA and 
415 controls with 
no history of 
psychiatric 
disorder
Not 
reported
Not reported Not reported Not reported
Not 
reported
PNOS (Clinical interview -
DSM-IV)
96 with PNOS 
and 415 controls 
with no history of 
psychiatric 
disorder
BDNOS (Clinical interview -
DSM-IV)
47 with BDNOS 
and 415 controls 
with no history of 
psychiatric 
disorder
SZ spectrum (Clinical 
interview - DSM-IV)
268 with SZ 
spectrum 
disorder and 415 
controls with no 
history of 
psychiatric 
disorder
Mean difference 
= 0.2 0.04, 0.35 0.01
Lifetime psychosis (Clinical 
interview - DSM-IV)
465 with lifetime 
psychosis and 
415 controls with 
no history of 
psychiatric 
disorder
Not reported Not reported 0.012
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Table 20 continued
NB: Beta values for the Sieradzka et al. 2014 study are unstandardised
Author 
and Year
Discovery 
sample
Target 
sample Outcome (measure used) N PT ß/OR/correlation 95%CI P R
2 (%)
Sieradzka 
et al. 2014
PGC -1-
BD TEDS
Cognitive/disorganised 
symptoms (SPEQ)
2157 general 
population 
adolescents
0.5
β = -1256 β = -5243, 2731 0.269 0
Grandiosity symptoms 
(SPEQ)
2160 general 
population 
adolescents
β = -243 β = -712, 226 0.156 0
Parent-rated negative 
symptoms (SPEQ)
2162 general 
population 
adolescents
β = -204 β = -720, 311 0.219 0
Paranoia symptoms (SPEQ)
2157 general 
population 
adolescents
β = -440 β = -1008, 127 0.064 0.001
Anhedonia symptoms (SPEQ)
2158 general 
population 
adolescents
β = -243 β = -19999, 1610 0.048 0.062
Hallucinations (SPEQ)
2138 general 
population 
adolescents
β = -204 β = -878, 331 0.188 0
Ruderfer 
et al. 2014
PGC-1- 
BD PGC-2-SZ
Manic symptom factor (EFA)
9369 with SZ 
and 8723 
controls with 
no history of 
neurological or 
psychiatric 
disorder
0.3
Not reported Not reported
0.003 2
Depressive symptom factor 
(EFA) 0.001 0.160 0.5
Positive symptom factor (EFA) 0.01 0.470 0.01
Negative symptom factor 
(EFA) 0.001 0.550 0
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Table 20 continued
Author 
and Year
Discovery 
sample
Target 
sample Outcome (measure used) N PT ß/OR/correlation 95%CI P R
2 (%)
Aminoff et 
al. 2015
PGC-1- 
BD TOP
Positive history of psychosis in 
BD (having one or more 
lifetime psychotic episodes)
148 with history of 
psychosis and 107 
without
0.05
Not reported Not reported 0.079
Not 
reported
BD I vs BD II (Clinical interview 
- SCID-I)
181 with BD I and 
74 with BD II
Mean for BD I = 
0.16;
Mean for BD II = 
0.15
BD I
(-0.83, 1.15)
BD II
(-0.90, 1.20)
0.913
Presenting polarity (Clinical 
interview – SCID-I)
152 with 
depressive polarity 
and 91 with elated 
polarity
Mean for 
depressive = 0.14
Mean for elated = 
0.20
Depressive
(-0.85, 1.13)
Elated
(-0.85, 1.25)
0.568
Age at onset (Clinical interview 
– SCID-I)
150 early onset, 71 
mid onset and 32 
late onset
Mean for early = 
0.10
Mean for mid = 
0.27
Mean for late = 
0.17
Early
(-0.92, 1.12)
Mid
(-0.73, 1.27)
Late
(-0.78, 1.12)
0.628
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Table 20 continued
BD: Bipolar Disorder; PRS: Polygenic Risk Score; PT: P-value threshold; OR: Odds Ratio; CI: Confidence Interval; PGC: Psychiatric Genomics Consortium, SZ: 
Schizophrenia; OPCRIT: Operational Criteria; DSM-IV: Diagnostic and Statistical Manual for Mental Disorders-IV; SZA: Schizoaffective Disorder; PNOS: Psychosis 
Not Otherwise Specified; BDNOS: Bipolar Disorder Not Otherwise Specified; TEDS: Twins Early Development Study; SPEQ: Specific Psychotic Experiences 
Questionnaire; TOP: Thematically Organised Psychosis; SCID-I: Structured Clinical Interview for DSM-IV Axis I Disorders; EFA: Exploratory Factor Analysis; PT
reported is either the only one examined or one with strongest evidence if more than one PT was examined
Author 
and Year
Discover
y sample
Target 
sample Outcome (measure used) N PT
ß/OR/
correlation 95%CI P R
2 (%)
Bigdeli et 
al., 2016
PGC-1-
BD PGC-1-SZ SZ (OPCRIT) – (DSM-IV) 
978 cases with 
SZ and a family 
history of 
psychotic illness 
and 8285 controls
1 β = 0.175
Not reported
7.11x10-149 16.9
4503 cases of SZ 
with no family 
history of 
psychotic illness 
and 8285 controls
1 β = 0.160 <10x10-300 22.3
978 cases with 
SZ and a family 
history of 
psychotic illness 
and 4503 cases 
of SZ with no 
family history of 
psychotic illness
0.3 β = 0.016 0.012 0.14
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6.4.4 Association with depression related symptoms/severity
Table 21 shows the data extracted from the five studies examined associations 
between a BD-PRS and depression related symptoms/severity.
A study used combined data from the NESDA and NTR samples and reported 
the BD-PRS was associated with MDD (strongest PT<0.5, p = 0.001) and both 
severe typical (strongest PT<0.5; p = 0.018) and severe atypical MDD (strongest 
PT<0.1, p = 0.032) (Milaneschi et al. 2016). 
Another study investigated the relationship between the BD-PRS and episode 
count of MDD in individuals with MDD. The authors reported some evidence of 
associations with greater episode count of MDD (strongest PT<0.2, p = 0.015) 
and stronger evidence in MDD cases and a positive family history of MDD 
(strongest PT<0.2, p = 0.004) using data from the RADIANT sample (Ferentinos 
et al. 2014).
There was inconsistent evidence of associations between the BD-PRS and 
characteristics of depression (including severity, age of onset, history of suicide 
attempt, recurrence, and atypicality) within a multivariate framework, or with 
subclinical mania, in the Sequenced Treatment Alternatives to Relieve 
Depression (STAR*D), Mannheim and NESDA samples (Wiste et al. 2014). 
The BD-PRS was not associated with antidepressant response in individuals 
with MDD treated with Noradrenaline Reuptake Inhibitors (NRIs) monotherapy, 
Selective Serotonin Reuptake Inhibitors (SSRIs) monotherapy, or either 
antidepressant in the New Medications in Depression and Schizophrenia
(NEWMEDS) sample. This pattern was similar when examining associations 
with response to citalopram in the STAR*D sample (Tansey et al. 2014). 
Finally, in a combined analysis using data from three different samples 
(RADIANT, GSK-Munich and the Bipolar Association Case Control Study 
(BACCS)), the BD-PRS was not associated with a greater number of suicide 
attempts (strongest PT<0.1; no p-value reported) (Mullins et al. 2014). 
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Table 21 Associations between the BD-PRS and depression related symptoms/severity
Author 
and Year
Discovery 
sample
Target 
sample Outcome (measure used) N PT ß/OR/correlation 95%CI P R
2 (%)
Ferentinos 
et al., 2014 PGC-1-BD RADIANT
Episode count of depression 
(SCAN)
1966 cases of 
MDD
0.2 Not reported Not reported
0.015 0.3
Episode count of depression 
with a positive family history of 
depression (SCAN)
1364 cases of 
MDD with a 
family history 
of MDD
0.004 1.8
Mullins et 
al., 2014 PGC-1-BD
RADIANT, 
GSK-
Munich and 
BACCs 
combined
Suicide attempt number 
(SCAN) 3270 cases of depression 0.1 Not reported
Not 
reported
Not 
reported 0.001
Tansey et 
al., 2014 PGC-1-BD
NEWMEDS
Antidepressant response 
using either SSRIs or NRIs 
(HRSD/MADRS/BDI/clinician 
rated QIDS)
1790 with 
MDD and 
treated with an 
antidepressant
0.3
Not reported Not reported
0.623 0.0001
Antidepressant response 
using SSRIs 
(HRSD/MADRS/BDI/clinician 
rated QIDS)
1222 with 
MDD and 
treated with an 
antidepressant
0.05 0.613 0.0002
Antidepressant response 
using NRIs 
(HRSD/MADRS/BDI/clinician 
rated QIDS)
568 with MDD 
and treated 
with an 
antidepressant
0.1 0.168 0.0034
STAR*D
Antidepressant response 
using citalopram 
(HRSD/MADRS/BDI/clinician 
rated QIDS)
1107 with 
MDD and 
treated with an 
antidepressant
0.3 0.826 0.0001
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Table 21 continued
Author 
and Year
Discovery 
sample
Target 
sample Outcome (measure used) N PT ß/OR/correlation 95%CI P R
2 (%)
Wiste et al. 
2014
PGC-1- 
BD
STAR*D Multi-level model of MDD 
(Clinical interview - HRSD, 
SCID, PDSQ/MDQ + 
OPCRIT/IDS)
1274 with 
MDD 0.1
Not reported Not reported
0.03
Not 
reported
NESDA 992 with MDD 0.01 0.02
Mannheim 583 with MDD 0.05 0.300
STAR*D
Severity of MDD (HRSD 
score)
1274 with 
MDD Not 
reported
OR = 0.98
Not 
reported
0.800 Not reported
Early onset of MDD (Clinical 
interview - SCID) OR = 1.21 0.002 0.02
Recurrent MDD (Clinical 
interview - SCID) OR = 1.14 0.04 0.05
History of suicide attempt 
(medical records) OR = 1.26 0.006 0.01
Manic symptom (PDSQ) OR = 1.18 0.04 0.05
Psychotic symptom (PDSQ) OR = 1.05 0.500 Not reported
Atypical depression (SCID) OR = 0.96 0.600 Not reported
NESDA
History of suicide attempt 
(medical records) 992 with MDD OR = 0.69 0.002 0.023
Subclinical mania (PDSQ)
0.05 OR = 1.3 0.048
Not 
reportedSTAR*D
1274 with 
MDD 0.01 OR = 1.18 0.006
Mannheim 583 with MDD 0.2 OR = 1.21 0.300
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Table 21 continued
BD: Bipolar Disorder; PRS: Polygenic Risk Score; PT: P-value threshold; OR: Odds Ratio; CI: Confidence Interval; PGC: Psychiatric Genomics Consortium; SCAN: 
Schedules for Clinical Assessment in Neuropsychiatry; MDD: Major Depressive Disorder; OPCRIT: Operational Criteria; DSM-IV: Diagnostic and Statistical Manual 
for Mental Disorders-IV; SCID: Structured Clinical Interview for DSM-IV; STAR*D: Sequenced Treatment Alternatives to Relieve*Depression; NEDSA: Netherlands 
Study of Depression and Anxiety; HRSD: Hamilton Rating Scale for Depression; PDSQ: Psychiatric Diagnostic Screening Questionnaire; MDS: Mood Disorders 
Questionnaire; IDS: Inventory of Depressive Symptomology; NEWMEDS: Novel Methods leading to New Medications in Depression and Schizophrenia; SSRIs: 
Author 
and Year
Discovery 
sample
Target 
sample Outcome (measure used) N PT ß/OR/correlation 95%CI P R
2 (%)
Milaneschi 
et al., 2016 PGC-1-BD
NESDA and 
NTR
MDD (CIDI)
1530 with 
MDD and 
1700 controls 
with no history 
of a 
psychiatric 
disorder
0.5 OR = 1.13 1.05, 1.21 0.001 0.3
MDD (CIDI)
228 with 
severe typical 
MDD and 
1700 controls 
with no history 
of a 
psychiatric 
disorder
0.5 OR = 1.19 1.03, 1.37 0.018 0.3
MDD (CIDI)
251 with 
severe 
atypical MDD 
and 1700 
controls with 
no history of a 
psychiatric 
disorder
0.1 OR = 1.16 1.01, 1.33 0.032 0.3
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Selective Serotonin Reuptake Inhibitors; NRIs: Noradrenaline Reuptake Inhibitors; MADRS: Montgomery-Asberg Depression Rating Scale; BDI: Beck Depression 
Inventory; QIDS: Quick Inventory for Depression Symptomology; CIDI: Composite International Diagnostic Interview; NTR: Netherlands Twin Registry; PT reported is 
either the only one examined or one with strongest evidence if more than one PT was examined
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6.4.5 Other phenotypes 
The BD-PRS was also associated with other phenotypes which do not link with the 
subsections of the results section in this chapter (see Table 22). 
One study used data from the National Institute of Neurological Disorders and stroke 
(NINDS) sample and reported no evidence of association between the BD-PRS and 
Parkinson’s disease (no PT or p-value reported; AUC = 0.5) (Schulze et al. 2014). 
The BD-PRS was not associated with measures of latent inhibition (Auditory Steady 
State Response (ASSR), P3 latency or P50 ratio), but there was strong evidence of 
an association between the BD-PRS and P3 amplitude (strongest PT<1x10-5; p = 
0.005) in a sample of individuals with psychotic illness and controls (Hall et al. 2015).
Lastly, in an Icelandic general population study, the BD-PRS was associated with 
greater scholastic achievement defined as greater number of years in school (p = 
4.8x10-9) and having a university degree (p = 5.2x10-7), and with creativity (strongest 
at PT<0.2; p = 5.2x10-6), defined as belonging to a creative profession (actors, 
dancers, musicians, visual artists and writers) (Power et al. 2015).
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Table 22 Associations between the BD-PRS and other phenotypes
Author and 
Year
Discovery 
sample
Target 
sample
Outcome 
(measure 
used)
N PT ß/OR/correlation 95%CI P R2 (%)
Power et al. 
2015 PGC-1-BD
Icelandic 
general 
population
Creativity 
(CAQ)
1024 general 
population 
adults
0.2
OR = 1.17
Not reported
3.8x10-6 0.26
Number of 
years in 
school 
(national 
register)
ß = 0.15 4.8x10-9 Not reported
Having a 
university 
degree 
(national 
register)
OR = 1.09 5.2x10-7 0.13
Schulze et al., 
2014 PGC-1-BD NINDS PD
PD (Clinical 
diagnosis)
984 PD 
cases and 
908 controls
Not reported Not reported Not reported Not reported Not reported
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Table 22 continued
BD: Bipolar Disorder; PRS: Polygenic Risk Score; PT: P-value threshold; OR: Odds Ratio; CI: Confidence Interval; PGC: Psychiatric Genomics Consortium; CAQ: 
Creative Achievement Questionnaire; NINDS: National Institute of Neurological Disorders and Stroke; PD: Parkinson’s Disease; AOB: Auditory Odd Ball; ASSR: 
Auditory Steady State Response; EEG: Electroencephalogram; PT reported is either the only one examined or one with strongest evidence if more than one PT was 
examined
Author 
and Year
Discovery 
sample
Target 
sample Outcome (measure used) N PT ß/OR/correlation 95%CI P R
2 (%)
Hall et al., 
2015 PGC-1-BD Not reported
P3 amplitude (AOB)
127 cases of 
BD and 148 
controls
1x10-4 
Not reported Not reported
0.005 3
P3 latency (AOB) 1x10-5 
Not 
reported
0.7
ASSR (Gamma oscillation 
(auditory steady state 40-Hz 
click stimulation paradigm)
1x10-3 1
P50 ratio (EEG) 1x10-4 0.3
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6.5 Discussion
This study investigated objective 8 of this thesis which was to determine what 
the phenotypic (non-BD) manifestations of increased genetic risk for BD might 
be. To do this, I conducted a systematic review of the literature. This work is the 
first systematic review collating information from studies investigating non 
discovery sample phenotypes for BD.   
Overall, I found a higher BD-PRS was associated with increased risk of different 
psychopathologies and that, on the whole, R2 values for other psychiatric
disorders (0.5-2%) was greater than for other phenotypes examined (most 
<1%). A possible anomaly is the study by Bigdeli and colleagues that reported 
the BD-PRS explained either 17% or 22% of the variance for SZ (based on 
presence or absence of family history of psychotic illness respectively). These 
values seem likely to be over-estimates given that in their study, Bigdeli and 
colleagues reported the SZ-PRS explained 12%-13% of the variance for SZ
(Bigdeli et al. 2016). I contacted the authors of this study to see if they could 
provide a potential explanation of this finding, or for them to check this finding, 
though they did not respond. 
6.5.1 Associations with psychiatric disorders
Associations between genetic risk for BD and psychiatric disorders was 
stronger for disorders typically presenting in adulthood rather than in childhood, 
most notably SZ and MDD. The variance explained in SZ by the BD-PRS was 
larger (R2 = 2.2%) than that for MDD (R2 = 0.48%), ADHD (R2 = 0.18%) and 
ASD (R2 = 0.08%), in line with higher genetic correlation between BD/SZ (r = 
0.68) compared to between BD/MDD (r = 0.47), BD/ADHD (r = 0.05) and 
BD/ASD (r = 0.04) (Cross-Disorder Group of the Psychiatric Genomics 
Consortium 2013). These findings may have been attributed to the limited 
sample sizes and therefore lack of power in childhood onset psychiatric 
disorders used by the Cross-Disorder Group. More recently, the Cross 
Disorders Group conducted LD score regression analyses for the 8 psychiatric 
disorders (the 5 main psychiatric disorders described above in addition to 
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Tourette’s Syndrome (TS), Obsessive Compulsive Disorder (OCD) and 
Anorexia Nervosa (AN)). Findings were consistent with the 2013 study, with the 
strongest correlations being between BD/SZ (r = 0.70) and BD/MDD (r = 0.36), 
whilst increased genetic correlation compared to the 2013 study was found for
BD/ADHD (r = 0.14) and BD/ASD (r = 0.14). It is therefore more likely that 
evidence of pleiotropy between the main psychiatric disorders found in the 2013 
study are true effects. However, further investigation is needed to determine the 
precise genetic structure underlying these conditions.
Findings for associations between the BD-PRS and MDD are consistent with a 
systematic review that reported a 2.5 fold increase in odds of MDD in a first 
degree relative (FDR) with at least one proband who has a BD diagnosis 
compared to a FDR of a healthy control proband (Wilde et al. 2014). They are 
also consistent with a recent study reporting an increased risk of MDD in those 
at high genetic risk for BD in the Danish population (Musliner et al. 2019).
Findings of association between increased genetic liability to BD and SZ are 
supported by evidence of increased recurrence risk (RR) of having offspring 
(RR = 2.4), or a sibling (RR = 3.9) with SZ when the proband has BD. This 
highlights a substantial genetic overlap between these two disorders 
(Lichtenstein et al. 2009). 
Molecular genetic research into BD and adult psychiatric disorders including SZ
and MDD supports evidence of pleiotropy across these disorders, rather than 
them being considered as aetiologically independent (Gale et al. 2016). 
Furthermore, through GWAS, a number of shared common risk loci have been 
identified between SZ and BD (Andreassen et al. 2013; Forstner et al. 2015; 
Ruderfer et al. 2018), between MDD and SZ (Wray et al. 2018; Amare et al. 
2019), and more recently between BD and MDD (Amare et al. 2019). 
6.5.2 Association with psychotic disorders and symptoms
The strength of evidence for associations between the BD-PRS and psychotic 
disorders and symptoms were, on the whole, weaker than most other 
phenotypes assessed (with the possible exception of one study) (Bigdeli et al. 
155
2016). More recently, similar to the findings of studies reported in this review, 
others have also reported little evidence of association with depressive,
negative, anhedonia, cognitive/disorganised and parent-rated negative 
symptom dimensions of schizophrenia (Jones et al. 2018; Pain et al. 2018; 
Ruderfer et al. 2018). Similarly, recent studies have also reported findings 
consistent with those in the current chapter including: i) with a manic symptom 
factor and psychotic disorder (Ruderfer et al. 2018), ii) broadly defined 
psychosis (Calafato et al. 2018) and iii) paranoia (Pain et al. 2018).
These genetic findings of associations with psychosis more generally support 
the hypothesis of shared genetic architecture across 
BD/schizophrenia/psychosis, and provide evidence of these psychotic disorders 
existing on a psychosis continuum (DeRosse and Karlsgodt 2015). They also fit 
with evidence suggesting a substantial proportion of those experiencing 
psychotic symptoms have a current diagnosis of a mood disorder (Hanssen et 
al. 2003).
6.5.2 Association with depression symptoms/severity
The BD-PRS was associated with greater episode count of MDD, particularly in 
those who also had a family history of MDD and earlier age of onset of MDD 
(Ferentinos et al. 2014; Wiste et al. 2014; Milaneschi et al. 2016). More recent 
studies published after the review end date find consistent evidence of 
association with earlier age at onset of depression (Power et al. 2017; Verduijn 
et al. 2017), but inconsistent evidence with higher BD-PRS in those with a 
positive family history of depression (Verduijn et al. 2017).
In line with earlier age of onset of MDD being a risk factor for developing BD, 
these genetic findings suggest that age of onset may be a useful way of 
indexing individuals who may be more likely to have an underlying BD than 
unipolar depression. Using information on age of onset could reduce the 
likelihood of someone transitioning to a (hypo)manic episode as a result of 
antidepressant monotherapy, particularly if their age of onset is earlier than mid-
twenties (Benazzi and Akiskal 2008; Woo et al. 2015). 
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Irrespective of which antidepressant class was investigated, genetic risk for BD 
was not associated with antidepressant response. However, this does not rule 
out the possibility that associations may be observed with response to other 
antidepressant classes, such as tricyclics or monoamine oxidases which have 
not been investigated. I am not aware of any further studies that have 
investigated the relationship between the BD-PRS and antidepressant 
response, though two recent studies have investigated whether a depression 
PRS is associated with antidepressant response. These studies also reported 
little evidence of such association when using the same antidepressant classes 
used by Tansey and colleagues (Garcia-Gonzalez et al. 2017; Ward et al. 
2018). 
This suggests that neither genetic risk for BD nor MDD is currently helpful in 
determining whether an individual will respond better to a particular class of 
antidepressant. However, preliminary findings examining associations between 
increased genetic risk for schizophrenia and lithium response in BD patients, 
suggest lower polygenic load for psychiatric disorders is associated with better 
response to lithium, and lower genetic loading for MDD is also associated with 
better response to lithium in BD patients (Amare et al. 2018). These findings 
highlight that using a PRS approach may be useful in predicting response to 
other classes of drugs, though at present, this is not the case for 
antidepressants.   
6.5.3 Associations with other phenotypes
Increased genetic risk for BD was associated with creativity and greater 
educational attainment (Power et al. 2015). These genetic findings are 
consistent with epidemiological studies suggesting that those with BD, as well 
as their family members are overrepresented in artistic professions (Kyaga et al. 
2011; Kyaga et al. 2013; MacCabe et al. 2018). One possible explanation for 
these findings is that individuals with BD have increased openness to 
experience, impulsivity and extraversion (Murray and Johnson 2010). This may 
lead those with BD to choose a creative occupation which better suits an 
unconventional lifestyle, given the difficulties of maintaining stable employment 
as a result of having BD (Marwaha et al. 2013; Tse et al. 2014). 
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The BD-PRS was strongly associated with reduced P3 amplitude, which was 
strongest at the most stringent PT, indicating that this reduction in amplitude is 
likely limited to a small subset of SNPs, which might be more causally related to 
BD than SNPs at higher PT’s (Hall et al. 2015). These genetic findings are 
consistent with epidemiological evidence from meta analyses reporting reduced 
P3 amplitude in BD patients, particularly those with the bipolar I disorder 
subtype (Johannesen et al. 2013; Morsel et al. 2018).
6.5.4 Quality of the studies included in this chapter 
There were a number of limitations with some of the studies included in this 
systematic review. Firstly, a large number of studies examined in this review 
(see Tables 18-22) did not report confidence intervals or standardised effect 
sizes which would help interpret the strength of evidence of associations 
observed (or not). In isolation, a p-value alone does not provide sufficient 
information to allow someone to understand the range of values within which 
the true population value lies, nor does it allow one to examine the magnitude of 
the effect being reported. It is possible, for example, to have a highly significant 
result (i.e. very small p-value) and yet have a very small effect size with wide 
confidence intervals that limits the clinical relevance of the findings, with the 
‘highly significant result’ largely being attributable to a very large sample size 
(Ranstam 2012; Sullivan and Feinn 2012).
A second limitation is that some studies included in this chapter failed to give a 
clear description of sample ascertainment, and at times provided insufficient 
information to determine which comparison groups had a high PRS. This is 
problematic as it does not allow you to determine whether genetic risk is 
associated with an increased or decreased risk of the outcome, and it is 
therefore difficult to interpret these findings in relation to other studies which 
asses similar phenotypes using the same study design. Following on from this, 
if it is not clear which target sample(s) are used, it is not possible to determine 
whether both discovery and target datasets are independent of each other. If 
there is any overlap, this will likely inflate risk estimates (Choi et al. 2018).  
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It is also necessary to have adequately powered discovery and target sample 
sizes to optimise association testing and risk prediction (Dudbridge 2013). The 
majority of the studies included in this chapter were adequately powered to 
detect small-to-moderate effect sizes (OR = 1.2 - 1.5 per standard deviation 
increase in PRS), based on the assumption of no measurement error in the 
PRS. The power to detect these effect sizes will likely increase as newer and 
larger GWAS of BD cases and controls becomes available. 
The use of a one-sided p-value as reported in one study (Bigdeli et al. 2016) is 
inappropriate as, whilst the literature may consistently report an effect in one 
direction only, the possibility of an effect going in the opposite direction is 
automatically ruled out when using a one-sided test, which may restrict the 
ability to make informed inferences about the underlying biology (Kim and Bang 
2016).
As a means of trying to address some of the limitations of the studies included 
in this chapter, alongside my co-authors, I developed a reporting framework 
which future studies could use to improve interpretation and comparison 
between studies. The guidelines suggested can be used in a tick box like 
fashion to ensure robust reporting of PRS analyses (see Table 23). 
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Table 23 Framework for future studies checklist
SD: Standard Deviation; QC: Quality Control; SNP: Single Nucleotide Polymorphism; MAF: 
Minor Allele Frequency used to determine which SNPs can potentially contribute to PRS; H-W: 
Hardy Weinberg; PRS: Polygenic Risk Score; OR: Odds Ratio
6.5.5 Strengths and limitations 
By investigating a broad range of phenotypic outcomes, I was able to provide a 
comprehensive and thorough overview of the phenotypic manifestations of 
increased genetic liability for BD. Another strength is that I used a 
comprehensive search strategy, and in doing so, have reduced the likelihood of 
omitting eligible studies. As I used a systematic search strategy, I will likely 
have omitted potential reviewer selection bias which would result in inaccurately 
representing information on the phenotypic manifestations of increased genetic 
risk for BD. In addition, by supplementing the results from my systematic review 
with studies published since the end date of my search strategy, I have been 
able to examine whether the findings from the systematic review are supported.
PRS criteria Yes/No
Discovery sample(s) and n number if phenotype is 
binary
Discovery sample(s) and mean (SD) if phenotype is 
continuous
Target sample(s) used and n number if phenotype 
is binary
Target sample(s) used and mean (SD) if phenotype 
is continuous
Phenotype(s) of interest and how this is defined
Pre-QC SNP number
Post-QC SNP number
Which genotyping platform(s) have been used
Has the MAF been reported?
Has the H-W equilibrium been reported for each 
sample?
Have the authors a priori identified a primary p-
value threshold to test for association along with a 
justification for using this threshold?
Has population stratification been adjusted for?
Has the PRS been standardized to allow 
comparison across studies?
Has an estimate of association been reported (e.g. 
OR/ß) and units of exposure and outcome provided 
to allow interpretation of effect size?
Have the confidence intervals been reported?
Have the authors used a 2-tailed test for 
association, or if 1-tailed, has this been adequately 
justified?
Do the results in the abstract accurately reflect the 
findings in the results?
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One of the limitations in the methodology used in this chapter is that I have 
omitted any articles not in the English language. This means there may be 
articles which may have provided additional information on further phenotypes 
associated with increased genetic liability for BD.  
A second limitation is that I excluded neuroimaging phenotypes as this was 
beyond the focus of the systematic review, and beyond the expertise of any of 
the authors. However, a recent systematic review investigated associations 
between a BD-PRS and functional magnetic resonance imaging studies and 
suggested the effects of the BD-PRS on brain functioning are not limited to 
specific neuronal pathways. However, much like the current chapter, the 
authors reported inconsistent findings in the literature, which appear to be in 
part due to small sample sizes and differences in methodology (Dezhina et al. 
2018).
A third limitation of the current chapter is that I was unable to perform a meta-
analysis of the studies included. This was not possible as there were insufficient 
studies reporting standardised effect sizes or confidence intervals to allow 
comparisons across studies. Further, as I was not able to conduct a meta-
analysis, I was also unable to assess for the presence of publication bias, or to 
explore whether any heterogeneity was present, and if so, what possible 
reasons there may be for this. It is possible that publication and citation bias 
have occurred, and this would mean information on phenotypes not associated 
with increased genetic risk for BD will not have been captured. 
6.5.6 Conclusions
In the current chapter, I investigated objective 8 of this thesis. I found the BD-
PRS was associated with a broad range of phenotypic outcomes, and the 
strongest associations were with other psychiatric disorders, typically explaining 
up to 2% of the variance. 
In addition to using adequately powered target samples, larger discovery BD 
GWAS datasets, and well-validated phenotypic measures, it would be useful for 
future studies to follow a framework for reporting results from PRS analyses, 
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such as the one I developed with my supervisors (see Table 23), to help make 
meta-analysis possible and aid comparison between studies. 
In my systematic review, with the exception of the Cross-Disorders Group study 
and the study by Hamshere and colleagues, there were no peer reviewed 
published studies that investigated associations between a BD-PRS and 
childhood/adolescent phenotypes. Chapters 7 and 8 will build on the findings 
from Chapters 4 and 5 respectively, to address a largely unexplored area of 
scientific investigation – how genetic risk for BD is manifest in childhood in 
relation to both psychopathology and cognition.
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Chapter 7: Genetic risk for bipolar disorder and 
psychopathology 
The work presented in this chapter has been published and can be found online 
at 
https://www.sciencedirect.com/science/article/pii/S0165032718321177?via%3Di
hub
Mistry, S., Escott-Price, V., D. Florio, A., Smith, D.J., Zammit, S. (2019). 
Genetic risk for bipolar disorder and psychopathology from childhood to early 
adulthood. Journal of Affective Disorders, 246, 633-639
https://doi.org/10.1016/j.jad.2018.12.091
The published article has been adapted for use in this chapter to include 
additional results (available as supplementary materials online). 
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7.1 Chapter summary
Studying the phenotypic manifestations of increased genetic liability for Bipolar 
Disorder (BD) can increase understanding of its aetiology and potentially help 
earlier identification. 
In this chapter, I investigated objectives 9-12 of this thesis as outlined in 
Chapter 2. I used the 2nd Psychiatric Genomics Consortium (PGC) BD genome 
wide association study (GWAS) as a discovery dataset, and the Avon 
Longitudinal Study of Parents and Children (ALSPAC) cohort as a target 
dataset to derive a BD polygenic risk score (BD-PRS). I investigated whether 
increased genetic risk for BD was associated with a broad range of 
psychopathology measures, assessed in Chapter 4, from childhood to early 
adulthood.  
Increased genetic risk for BD was very weakly associated with clinically-defined 
hypomania, though evidence strengthened as the hypomania symptom count 
required to be classified as having hypomania increased. I found strong 
evidence of association between the BD-PRS and a diagnosis of attention 
deficit hyperactivity disorder (ADHD), particularly inattentive ADHD, but there 
was little evidence to suggest associations between the BD-PRS and other 
childhood psychopathology or hypomania measures. 
The findings from this chapter suggest that, with the possible exception of 
ADHD, and to a lesser extent clinically-defined hypomania, genetic risk for BD 
does not appear to manifest in childhood to the same extent as schizophrenia 
genetic risk has been reported to do. 
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7.2 Introduction
Given the long delay in first diagnosis of BD, as described in Chapter 1, section 
1.3, identifying potential clinical markers of risk for BD in childhood/adolescence 
may help to predict future onset of BD. Evidence from cohort studies following 
up high-risk offspring of BD parents suggests that up to 60% of those who 
develop BD report presence of psychopathology in childhood/adolescence 
(Raouna et al. 2018; Duffy et al. 2019). These psychopathologies extend 
beyond depressive symptoms (Duffy et al. 2010; Topor et al. 2013), and include 
ADHD, conduct problems and hyperactivity in childhood (Henin et al. 2007; 
Donfrancesco et al. 2011; Singh et al. 2014). Borderline personality disorder 
(BPD) is also a frequently observed comorbidity in adults with BD (Friborg et al. 
2014; Bezerra et al. 2015; Fornaro et al. 2016; Parker et al. 2016), though onset 
of potential traits can be traced back to childhood/adolescence (Biskin 2015; 
Bozzatello et al. 2019). 
One possible explanation for the phenomenological overlap and high rates of 
comorbidity between the measures of psychopathology described above and 
BD is that this may be attributed to shared genetic heritability (Cross-Disorder 
Group of the Psychiatric Genomics Consortium 2013; Witt et al. 2017). As is 
evident from my findings in Chapter 6 of this thesis, the phenotypic 
manifestations of increased genetic risk for BD during childhood, adolescence, 
and early adulthood in the general population have not yet been thoroughly
investigated. By understanding and identifying the most robustly associated 
phenotypic manifestations of genetic risk for BD, it may be possible to minimise 
misdiagnosis and incorrect treatment such as antidepressant monotherapy 
(Ghaemi et al. 1995; Hirschfeld and Vornik 2004; Keck et al. 2008).
Narrow sense heritability estimates from twin, adoption and molecular genetic
studies of BD suggest BD has a heritability of approximately 60-85% (Craddock 
and Sklar 2013). GWAS have identified a number of single nucleotide 
polymorphism (SNP) risk alleles occurring more frequently in BD cases relative 
to controls (Sklar et al. 2011; Cross-Disorder Group of the Psychiatric 
Genomics Consortium 2013; Ruderfer et al. 2018; Stahl et al. 2019). As these 
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SNP risk alleles have small effect on disease risk, one method, the PRS 
approach, combines these alleles into a single genetic score, previously shown 
to provide biologically valid indicators of disease risk for research (Purcell et al. 
2009; Cross-Disorder Group of the Psychiatric Genomics Consortium 2013). 
Taken together, alleles on current GWAS platforms explain approximately 4% of 
the genetic variation for BD on the liability scale (Ikeda et al. 2018; Ruderfer et 
al. 2018; Stahl et al. 2019).
The purpose of the work in this chapter was to address objectives 9-12 as 
outlined in Chapter 2. These objectives were to: i) examine whether a BD-PRS 
is associated with dimensional, categorical and factor structures of hypomania, 
ii) examine whether a BD-PRS is associated with measures of childhood 
psychopathology as assessed in Chapter 4 (BPD (traits score and ‘high-risk’ 
categorisation), ADHD (any ADHD diagnosis, inattentive ADHD, hyperactive-
impulsive ADHD and combined ADHD), emotional and behavioural difficulties 
(hyperactivity problems, prosocial behaviour, emotional difficulties, conduct 
problems and peer relationship difficulties) and a depression score, and iii) to 
investigate the possibility that associations between genetic risk for BD and 
psychopathology were due to selection bias.
7.3 Methods 
7.3.1 Participants
The current study used data on individuals aged 7-23 years from the ALSPAC 
cohort. Recruitment procedures and inclusion criteria are described in Chapter 
3, section 3.2.1. Final sample numbers for all outcome measures are shown in 
Table 24. 
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Table 24 Table showing number of individuals with outcome measures
*Threshold score used to define clinically-defined hypomania was a score of ≥14/28; HCL: 
Hypomania Checklist; SDQ: Strengths and Difficulties Questionnaire; ADHD: Attention Deficit 
Hyperactivity Disorder; DAWBA: Development and Wellbeing Assessment; CI-BPD: Childhood 
Interview for DSM-IV Borderline Personality Disorder; MFQ: Moods and Feelings Questionnaire
7.3.2 Hypomania
Hypomania outcomes in ALSPAC were assessed using the Hypomania 
Checklist-32 (HCL-32). Detailed information providing an overview of the 
psychometric properties and how hypomania outcomes were derived can be 
found in Chapter 3 under section 3.3.1. For the 28 items used to generate the 
HCL score, please see Table 5 found in Chapter 3.
7.3.3 Assessment of BPD traits
When the children were 11 years old, they were interviewed to assess their 
experience of BPD traits over the preceding two years. Further information on 
Outcome Measure Instrument Age (years)
Measure 
type N (%)
HCL score
HCL-28 22-23
Standardised 
score 2,654
Clinically-defined 
hypomania*
Binary 
outcome 2,654 (7%)
Active/elated factor
Standardised 
score 2,654Risk-taking/irritable
factor
Total difficulties score SDQ 9 Standardised score 6,111
ADHD DAWBA 7.6 Binary outcome 6,105 (2%)
Borderline personality 
disorder traits score
CI-BPD 11
Standardised 
score 5,246
‘High-risk’ 
categorisation
Binary 
outcome 6,412 (6%)
Depression score MFQ 9 Standardised score 8,066
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the procedures and how outcomes were derived can be found in Chapter 3 
under section 3.3.2.1. 
7.3.4 Assessment of childhood ADHD 
At age 7.6 years, using the Development and Wellbeing Assessment (DAWBA), 
the presence of ADHD was assessed. Further information on the DAWBA 
package can be found in Chapter 3 under section 3.3.2.2. 
7.3.5 Emotional and behavioural difficulties
When the children were age 9 years, emotional and behavioural difficulties 
were assessed using the Strengths and Difficulties Questionnaire (SDQ), which 
was completed by the parents. Further information on the SDQ subscales and 
how these were derived can be found in Chapter 3 under section 3.3.2.3. 
7.3.6 Depression score
When the children were 9 years old, they were invited to complete the short 
version of the Moods and Feelings Questionnaire (MFQ) which measures 
aspects of depression. Further details can be found in Chapter 3 in section 
3.3.2.4.
7.3.7 Genetic data
7.3.7.1 Genetic data in ALSPAC
Of the 9,912 participants with genetic data, 8,230 were left with data after 
quality control, restriction to one young person per family and imputation. 
Detailed information on the genotyping platforms and the quality control 
measures ALSPAC researchers conducted can be found in Chapter 3 under 
section 3.5.1. 
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7.3.7.2 Genetic data in the PGC 
For the PGC 2 BD GWAS, a total of 4 genotyping platforms were used on 
20,385 BD cases and 31,358 controls. The details of quality control measures 
performed by the PGC team can be found in Chapter 3 under section 3.5.2.  
7.3.7.3 Further quality control measures prior to constructing the BD-PRS
In addition to the quality control measures conducted by the ALSPAC research 
team and the PGC as described in Chapter 3, section 3.5.1 and 3.5.2 
respectively, I performed additional quality control measures (see Chapter 3, 
section 3.5.3 for further details). After doing so, I generated a file using R 
statistical software that contained information on the SNP ID, risk allele (A1) 
and corresponding log odds ratio. 
7.3.7.4 Constructing the BD-PRS
To construct the BD-PRS, I used the file containing information on SNP ID, risk 
allele (A1) and log odds ratio, generated by merging the ALSPAC dataset with 
summary statistics from the PGC 2 BD GWAS to linkage disequilibrium clump 
SNPs using PLINK v 1.9. From this, I retained SNPs with a PT≤0.01 (Stahl et al. 
2019) and PT≤0.5 (Sklar et al. 2011) as these have been reported to maximally 
capture BD liability in their respective GWASs. I then generated a training score 
file in R, which was used to derive a PRS for each individual in ALSPAC. 
Further information on clumping parameters and what each of the different files 
generated contained can be found in Chapter 3 under section 3.5.4.  
7.3.8 Multiple imputation
To address the possibility of selection bias due to missing data affecting the 
results, I used multiple imputation. Details on the multiple imputation approach 
can be found in Chapter 3, section 3.6.1.4. All exposure/confounder measures 
along with auxiliary variables were predetermined on the basis of being 
associated with either the exposure/confounder and missingness. 
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7.3.9 Statistics
All association analyses in this chapter were performed using Stata statistical 
software (version 14.1 SE. College Station, TX: StataCorp LP). To examine 
associations between the BD-PRS and binary outcomes (clinically-defined 
hypomania, ADHD subtypes and ‘high-risk’ for BPD), I used logistic regression. 
Results from these analyses are reported as change in odds of outcome per 
standard deviation (SD) increase in PRS. For analyses assessing associations 
between the BD-PRS and continuous outcomes (HCL score, HCL factors, BPD 
traits score, SDQ scores and depression score), I used linear regression. For 
these results, findings are presented as the SD change in outcome per SD 
increase in PRS. As a measure of reporting variance in outcome explained by 
the BD-PRS, I used R2 values (and Naglekerke r2 for logistic). 
Previous studies have shown that the ALSPAC sample has no significant 
population stratification, and genome-wide analyses of phenotypes indicate a 
low genomic inflation factor (≈1) (Zammit et al. 2014; Martin et al. 2015). 
Therefore, I did not adjust for population stratification using principle 
components analysis. Genotyping site was not included as a covariate in the 
analysis, though it seems unlikely that this would confound the relationship 
between genetic risk and psychopathology. Whilst it seems plausible that 
genotyping site may lead to higher PRS from one site over another, it seems to 
be less likely that genotyping site would be related to psychopathology 
outcomes. Further details on sources of confounding in genetic analyses can be 
found in Chapter 3, section 3.4.1.
In the published article of this work (Mistry et al. 2019), I examined associations 
between genetic risk for BD and psychopathology using a PRS derived at a 
PT≤0.5, as this was the previously reported threshold which maximally captures 
BD liability (Sklar et al. 2011). However, for the purposes of this Chapter, I now 
use a PT≤0.01 for my primary analyses as this is the most recent threshold 
reported to maximally capture BD liability (Stahl et al. 2019). 
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7.4 Results 
7.4.1 BD-PRS and hypomania
The proportion of individuals who were deemed to meet criteria for clinically-
defined hypomania was 7%, a finding similar to that in another birth cohort 
study based in New Zealand (Richards et al. 2019), and within the 5-10% range 
reported by other longitudinal general population studies based in Germany and 
Sweden (Meyer et al. 2007; Holtmann et al. 2009). There was little evidence to 
suggest increased genetic risk for BD was associated with the HCL score (p = 
0.998), HCL factors (both p >0.546), or clinically-defined hypomania (p = 0.382). 
These results are presented in Table 25. 
 
Table 25 Associations between the BD-PRS and hypomania outcomes at PT≤0.01
Exposure Outcome N β 95%CI P R2 (%)
BD-PRS at 
PT0.01
HCL score 2654 0.00^ -0.04, 0.04 0.998 0
Active/elated
factor
2363
0.01 -0.03, 0.05 0.546 0.02
Risk-
taking/irritable
factor
-0.01 -0.04, 0.03 0.747 0
Outcome N (%) OR 95%CI P R
2 (%)
BD-PRS at 
PT0.01
Clinically-defined 
hypomania* 239 (7.1) 1.07 0.92, 1.24 0.382 0.06
*Threshold score used to defined clinically-defined hypomania was a score of ≥14/28 on the 
HCL; ^rounded to 2 decimal places; BD-PRS: Bipolar Disorder-Polygenic Risk Score; HCL: 
Hypomania Checklist; CI: Confidence intervals; PT: P-value threshold
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At my secondary PT of ≤0.5, I also found little evidence to suggest the BD-PRS 
was associated with the HCL score (p = 0.336) or HCL factors (both p >0.292). 
However, I did find very weak evidence that the BD-PRS was associated with 
increased odds of being classified as having hypomania at the threshold cut off 
score of ≥14/28 (OR = 1.13, 95%CI 0.98, 1.32; p = 0.097) (see Appendix 13).
7.4.1.1 Sensitivity analysis 
As a sensitivity analysis, I examined clinically-defined hypomania outcomes that 
required increasing symptom number counts to be classified as having 
hypomania (the same thresholds examined in Chapter 4). No corrections for 
multiple testing were made as the purpose of the sensitivity analysis was 
exploratory and to determine whether associations were consistent across the 
thresholds used to define hypomania.
Associations between genetic risk for BD and clinically-defined hypomania at 
my primary PT showed little evidence of association, with the exception of a 
HCL score of ≥20/28 (OR = 1.32, 95%CI 1.06, 1.64; p = 0.013) (Appendix 14). 
Associations between the BD-PRS and clinically-defined hypomania at my 
secondary PT were stronger than those at my primary PT, and the strongest 
evidence of association was also when the threshold to be classified as having 
clinically-defined hypomania was also at a score of ≥20/28 (OR = 1.33, 95%CI 
1.07, 1.65; p = 0.01) (Appendix 14). As a visual representation, Figure 6 shows 
the proportion of variance explained in clinically-defined hypomania by the BD-
PRS at both PT’s. 
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Figure 6 Results of sensitivity analyses when examining associations between the BD-PRS and clinically-defined hypomania 
Values in brackets on the x axis represent the number of individuals classified as having clinically-defined hypomania; HCL: Hypomania Checklist; PT: P-value 
threshold; BD-PRS: Bipolar Disorder Polygenic Risk Score; Blue bars represent values at my primary PT0.01 and red bars represent values at my secondary 
PT0.5
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7.4.2 BD-PRS and BPD outcomes
When examining associations between increased genetic risk for BD and the 
BPD outcomes, I found little evidence of association with the BPD traits score at 
either PT (both p >0.183), and similarly little evidence of an association with 
being classified as ‘high-risk’ for BPD (both p >0.107) (see Table 26).
Table 26 Association between the BD-PRS and BPD outcomes
^rounded to 2 decimal places; BD-PRS: Bipolar Disorder-Polygenic Risk Score; PT: P-value 
threshold; BPD: Borderline Personality Disorder; CI: Confidence Intervals; OR: Odds Ratio
7.4.3 BD-PRS and ADHD 
When I examined associations between the BD-PRS and ADHD subtypes, 
there was little evidence of association at my primary PT of 0.01 (all p >0.265), 
but at the less stringent PT of 0.5, I found strong evidence of association 
between the BD-PRS and increased odds of being diagnosed with any ADHD 
disorder (OR = 1.31, 95%CI 1.10, 1.57; p = 0.003). There was also stronger 
evidence of association for inattentive ADHD (OR = 1.37, 95%CI 1.06, 1.79; p = 
0.018) than hyperactive-impulsive or combined ADHD (both p >0.119); 
however, confidence intervals for all subtypes overlapped substantially at both 
PT’s (see Table 27).
Exposure Outcome N β 95%CI P R2
BD-PRS at  
PT0.01
BPD traits 
score
5,246 -0.02 -0.05, 0.01 0.183 0.03
BD-PRS at  
PT0.5 5,246 0.00^ -0.03, 0.03 0.898 0.00
Outcome N (% with outcome) OR 95%CI P r
2 (%)
BD-PRS at  
PT0.01
‘High risk’ for 
BPD
5,247 
(5.8%)
0.91 0.81, 1.02 0.107 0.11
BD-PRS at  
PT0.5 1.01 0.90, 1.13 0.860 0.00
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Table 27 Associations between the BD-PRS and diagnosis of ADHD subtypes
BD-PRS: Bipolar Disorder-Polygenic Risk Score; ADHD: Attention Deficit Hyperactivity 
Disorder; PT: P-value threshold; CI: Confidence Interval; OR: Odds Ratio
7.4.4 BD-PRS and the SDQ  
When investigating associations between the BD-PRS and the SDQ, there was 
little evidence of association with the total difficulties score, nor any of the SDQ 
subscales at both primary (all p >0.319) and secondary (all p >0.131) PT’s 
(Table 28).
Exposure Outcome N (% with outcome) OR 95%CI P r
2 (%)
BD-PRS at 
PT0.01
ADHD 6,105 (7.00) 1.11 0.93, 1.32 0.265 0.11
Inattentive 
ADHD
6,102 
(0.85) 1.12 0.86, 1.46 0.407 0.11
Hyperactive-
impulsive 
ADHD
6,102 
(0.30) 1.12 0.70, 1.77 0.644 0.09
Combined 
ADHD 
6,102 
(0.97) 1.09 0.82, 1.44 0.556 0.06
Exposure Outcome N (% with outcome) OR 95%CI P r
2 (%)
BD-PRS at 
PT0.5
ADHD 6,105 (7.00) 1.31 1.10, 1.57 0.003 0.73
Inattentive 
ADHD
6,102 
(0.85) 1.37 1.06, 1.79 0.018 0.88
Hyperactive-
impulsive 
ADHD
6,102 
(0.30) 1.44 0.91, 2.30 0.119 0.99
Combined 
ADHD 
6,102 
(0.97) 1.19 0.90, 1.57 0.230 0.25
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Table 28 Association between the BD-PRS and SDQ
^ Rounded to 2 decimal places; BD-PRS: Bipolar Disorder-Polygenic Risk Score; PT: P-
value threshold; CI: Confidence Intervals; SDQ: Strengths and Difficulties Questionnaire
Exposure Outcome N β 95%CI P R2 (%)
BD-PRS at 
PT<0.01
Hyperactivity 6,134 0.00^ -0.02, 0.03 0.736 0.00
Prosocial 6,138 -0.00^ -0.03, 0.02 0.800 0.00
Emotional 6,117 0.01 -0.01, 0.03 0.435 0.01
Conduct 6,133 0.01 -0.01, 0.04 0.319 0.02
Peer 
relationship 6,128 0.01 -0.02, 0.03 0.509 0.01
Total difficulties 6,111 0.01 -0.01, 0.04 0.357 0.01
Exposure Outcome N β 95%CI P R2
BD-PRS at 
PT0.5
Hyperactivity 6,134 -0.00^ -0.03, 0.02 0.760 0.00
Prosocial 6,138 -0.001 -0.03, 0.02 0.951 0.00
Emotional 6,117 0.02 -0.01, 0.04 0.175 0.03
Conduct 6,133 0.02 -0.01, 0.04 0.131 0.04
Peer 
relationship 6,128 0.02 -0.01, 0.04 0.231 0.02
Total difficulties 6,111 0.01 -0.01, 0.04 0.302 0.00
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7.4.5 BD-PRS and the MFQ  
I found little evidence of association between increased genetic risk 
for BD and depression score at either PT (both p >0.405) (see Table 
29).
Table 29 Association between the BD-PRS and MFQ
^ Rounded to 2 decimal places; BD-PRS: Bipolar Disorder Polygenic Risk Score; 
MFQ: Moods and Feelings Questionnaire; CI: Confidence Intervals; PT: P value 
threshold cut off score
7.4.6 Associations between the BD-PRS and psychopathology 
measures using imputed data
In an attempt to address the possibility of my results being affected 
by selection bias due to attrition, I compared the results from my 
complete-case analyses to those using imputed data. When 
examining associations with measures of hypomania as the 
outcome, the effect sizes and strength of evidence were similar for 
the HCL score, whereas those with clinically-defined hypomania 
were slightly weaker, though they did not alter the conclusions of this 
study (see Table 30). 
Exposure Outcome N β 95%CI P R2 (%)
BD-PRS at  
PT0.01
Depression 
score 6,128
0.00^ -0.02, 0.02 0.985 0.00
BD-PRS at  
PT0.5 0.01 -0.01, 0.03 0.405 0.01
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Table 30 Associations between the BD-PRS and hypomania outcomes comparing imputed with non-imputed data
^ Rounded to 2 decimal places; BD-PRS: Bipolar Disorder Polygenic Risk Score; CI: Confidence Intervals; PT: P value threshold cut off score; HCL: Hypomania 
Checklist; OR: Odds Ratio
Exposure Outcome N  non-imputed 95%CI P value N  imputed 95%CI P value
BD-PRS at  
PT0.01 HCL score 2,654 0.00^ -0.04, 0.04 0.998 3,371 -0.00^ -0.04, 0.04 0.944
Exposure Outcome N OR non-imputed 95%CI P value N OR imputed 95%CI P value
BD-PRS at  
PT0.01
Clinically-defined 
hypomania at 
threshold ≥14/28
2,654
1.07 0.92, 1.24 0.382
3,371
1.06 0.92, 1.23 0.405
Clinically-defined 
hypomania at 
threshold ≥20/28
1.32 1.06, 1.64 0.013 1.29 1.03, 1.60 0.023
Exposure Outcome N  non-imputed 95%CI P value N  imputed 95%CI P value
BD-PRS at  
PT0.5 HCL score 2,654 0.02 -0.02, 0.06 0.336 3,371 0.02 -0.03, 0.06 0.448
Exposure Outcome N OR non-imputed 95%CI P value
N OR imputed 95%CI P value
BD-PRS at  
PT0.5
Clinically-defined 
hypomania at 
threshold ≥14/28
2,654
1.13 0.98, 1.32 0.097
3,371
1.12 0.96, 1.35 0.144
Clinically-defined 
hypomania at 
threshold ≥20/28
1.33 1.07, 1.65 0.010 1.29 1.03, 1.61 0.025
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When examining associations between genetic risk for BD and 
measures of childhood psychopathology, effect sizes and strength of 
evidence of association in the imputed and complete-case data were 
similar for most outcomes, regardless of which PT was being used to 
derive the BD-PRS. However, there was much stronger evidence of 
association and a substantial increase in effect size for inattentive 
ADHD at my primary PT in the imputed data (see Table 31).
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Table 31 Associations between the BD-PRS and measures of childhood psychopathology comparing imputed and non-imputed data
^ Rounded to 2 decimal places; BD-PRS: Bipolar Disorder Polygenic Risk Score; PT: P value threshold cut off; CI: Confidence Intervals; BPD: Borderline Personality 
Disorder; MFQ: Moods and Feelings Questionnaire; OR: Odds Ratio; ADHD: Attention Deficit Hyperactivity Disorder
Exposure Outcome N  non-imputed 95%CI P value N  imputed 95%CI P value
BD-PRS at  
PT0.01
BPD traits score 5,246
-0.02 -0.05, 0.01 0.183
6,411
-0.02 -0.04, 0.01 0.228
BD-PRS at  
PT0.5 0.00^ -0.03, 0.03 0.898 0.00^ -0.02, 0.03 0.971
BD-PRS at  
PT0.01 Total difficulties 
score 6,108
0.01 -0.01, 0.04 0.357
8,034
0.01 -0.01, 0.04 0.383
BD-PRS at  
PT0.5 0.01 -0.01, 0.04 0.305 0.01 -0.01, 0.04 0.314
BD-PRS at  
PT0.01
Depression score 5,246
-0.02 -0.05, 0.01 0.183
6,411
-0.02 -0.04, 0.01 0.228
BD-PRS at  
PT0.5 0.00^ -0.03, 0.03 0.898 0.00^ -0.02, 0.03 0.971
Exposure Outcome N OR non-imputed 95%CI P value N OR imputed 95%CI P value
BD-PRS at  
PT0.01
Inattentive ADHD 6,102
1.12 0.86, 1.46 0.407
8,216
1.29 1.03, 1.60 0.023
BD-PRS at  
PT0.5 1.37 1.06, 1.79 0.018 1.34 1.03, 1.74 0.030
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7.5 Discussion
7.5.1 Summary of findings 
7.5.1.1 Associations with hypomania 
The first objective of this study was to determine whether increased genetic risk 
for BD was associated with hypomania outcomes (HCL score, HCL factors and 
clinically-defined hypomania) in young adulthood. 
I found that associations between the BD-PRS and hypomania were strongest 
for clinically-defined hypomania, particularly when a greater symptom number 
count was required to be classified as having clinically-defined hypomania. 
However, I found little evidence of association between the BD-PRS and 
dimensional measures of hypomania (HCL score/HCL factors). There was little 
to suggest that selection bias was affecting associations between genetic risk 
for BD and hypomania outcomes as evidenced by similar effect sizes/strength 
of evidence of association in the complete-case and imputed data. 
7.5.1.2 Associations with childhood psychopathology 
The second objective of this study was to assess whether the BD-PRS was 
associated with a broad range of childhood psychopathology measures as 
examined in Chapter 4 of this thesis. Overall, there was little evidence to 
suggest an association between the BD-PRS and most psychopathology 
measures, with the possible exception of inattentive ADHD. Furthermore, there 
was little evidence to suggest selection bias was affecting the association 
between the BD-PRS and these measures. However, for inattentive ADHD, the 
results following multiple imputation suggests that selection bias led to an 
underestimate in the effect size and strength of evidence of association at my 
primary PT in the complete-case analysis.  
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7.5.2 Interpretation of findings in the context of previous work
7.5.2.1 BD-PRS and hypomania 
The findings from the current study suggest that genetic risk for BD is weakly 
associated with clinically-defined hypomania (the association was stronger for 
hypomania defined using a higher threshold of symptoms). To the best of my 
knowledge there are no studies examining associations between a BD-PRS and 
hypomania as an outcome per se, although two studies have examined whether 
the BD-PRS can discriminate BD subtypes (BD-I vs BD-II), reporting 
inconsistent results (Aminoff et al. 2015; Charney et al. 2017). My findings of 
association with clinically-defined hypomania are weaker than those from a 
number of studies have examined associations with BD case status in clinical 
samples (Schulze et al. 2014; Tesli et al. 2014; Power et al. 2015; Charney et 
al. 2017). 
Given the potential for greater statistical power using dimensional (rather than 
symptom threshold) measures of hypomania, it was perhaps surprising to find 
little evidence of associations between the BD-PRS and either the total HCL 
score or HCL factors. 
Researchers investigating psychosis have described an extended phenotype 
whereby psychotic experiences and psychotic disorders are at different ends of 
a distribution (van Os and Reininghaus 2016), with genetic risk for 
schizophrenia showing stronger associations with phenotypes at the more 
severe end of this spectrum (Mistry et al. 2018b). It is possible that hypomanic 
experiences and BD also exist as an extended phenotype, and that BD genetic 
risk is more strongly associated with more severe than less severe phenotypes.
Other (non-genetic) factors might influence the presence of HCL items to a 
greater extent than they do the presence of BD, and hence the association 
between the BD-PRS and HCL score would be diluted; this might explain why I 
observe an association with clinically-defined hypomania, but not with the HCL 
score or HCL factors. 
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Alternatively, the lack of evidence of association with the HCL score might be 
related to the ability of the HCL to reliably distinguish those with BD from those
without. As is evident from a recent systematic review and meta-analysis, the 
HCL has high sensitivity (82%), but low specificity (57%) indicating that its 
ability to determine true negatives i.e. people who do not have BD is poor 
(Wang et al. 2019). There are few studies that have examined sensitivity and 
specificity in general population samples, though one study in a Chinese 
population found high sensitivity but even poorer specificity (32%) (Lee et al. 
2016). Therefore, if the HCL does not accurately capture hypomania in general 
population samples, this could explain the weak evidence of association 
between the BD-PRS and HCL-related outcomes in my study. 
It is also possible that my finding of a lack of evidence of association between 
the BD-PRS and trait measures of hypomania is due to selection bias in the BD 
discovery sample GWAS. If individuals with BD were more likely to be part of 
the GWAS because they spent more time in clinical services, for example due 
to more severe symptoms/behavioural issues or psychotic experiences, then it 
is possible that the BD-PRS indexes these characteristics rather than genetic 
risk for BD per se. Selection bias in the GWAS from which the BD-PRS was 
derived could partly explain why there is little evidence of association with 
hypomania traits in a general population sample such as ALSPAC. 
Despite the evidence of association with hypomania in my study being weaker 
than that published for BD case status, they are nevertheless consistent with a 
causal relationship between genes conferring risk for BD and developing 
clinically-defined hypomania. The minimal difference observed when comparing 
effect size and strength of evidence of association in imputed vs non-imputed 
data suggests selection bias is an unlikely explanation for this, though 
nevertheless cannot be entirely ruled out. 
On the whole though, the findings in this study suggest that genetic risk for BD 
does not strongly influence hypomania, as captured by the HCL, in the young 
adult general population. 
183
7.5.2.2 BD-PRS and BD-PRS and measures of childhood psychopathology 
I found little evidence of association between the BD-PRS and most measures 
of childhood psychopathology, with the possible exception of ADHD, and in 
particular the inattentive subtype.
Data on possible childhood phenotypic manifestations of increased genetic risk 
for BD is limited (Mistry et al. 2018a), however, the BD-PRS (derived using the 
smaller PGC-1-BD GWAS) has previously been reported as associated with 
ADHD (Cross-Disorder Group of the Psychiatric Genomics Consortium 2013; 
Hamshere et al. 2013), but not with either externalising or internalising scales 
on the Child Behavioural Checklist (Jansen et al. 2018), a measure assessing 
similar constructs to the SDQ used in the current study. Therefore, the findings 
of the current study are consistent with these previous studies, though my 
findings of association with ADHD are stronger than previously reported. 
Stronger evidence of association with ADHD could be attributed to using a more 
accurate and precise PRS (derived from the larger and more recent PGC-2-BD 
GWAS) (Dudbridge 2013,2016). 
For most childhood psychopathology measures, selection bias had little impact 
on the associations with genetic risk, with the exception of inattentive ADHD 
where stronger evidence of association (and an increase in effect size) was 
found at my primary PT in the imputed data. Post hoc analyses showed that 
children with ADHD were more likely to have missing data on the HCL 
compared to either the MFQ or being ‘high-risk’ for BPD which means that 
associations in the complete-case data are more likely to have been 
underestimated for ADHD.
As is evident from several GWAS, genetic overlap exists between BD and: i) 
ADHD (Cross-Disorder Group of the Psychiatric Genomics Consortium 2013; 
van Hulzen et al. 2017; Demontis et al. 2019), ii) depression (Power et al. 2017; 
Wray et al. 2018; Howard et al. 2019) and BPD (Witt et al. 2014; Witt et al. 
2017). Findings from high-risk offspring of BD parents suggest that compared to 
non-high-risk offspring, high-risk offspring are more likely to have experienced 
ADHD and behavioural problems in childhood/adolescence (Raouna et al. 
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2018; Duffy et al. 2019). However my findings suggest that in contrast to 
evidence of association between genetic risk for schizophrenia and childhood 
psychopathology (Nivard et al. 2017), genetic risk for BD might not be manifest 
to the same extent, or might manifest later in development. However, with so 
few studies examining associations between increased genetic risk for BD 
(using a PRS) and childhood/adolescent phenotypes, it is difficult to know the 
extent to which this statement is true or not. A recent study also using the 
ALSPAC cohort examined associations between a BD-PRS (derived using the 
smaller PGC-1-BD GWAS) and depression examined using the MFQ at age 16 
years and also reported little evidence of association (Jones et al. 2018). 
Therefore, evidence from family studies reporting presence of these 
psychopathologies in high-risk offspring suggests the environment in which the 
child is brought up may have greater importance in the expression of these
psychopathologies than the child’s own genetic risk (Duffy et al. 2019).
Alternatively, given the low number of individuals with an ADHD diagnosis in the 
current study, it is possible that sparse data bias is present and estimates are 
being biased away from the null (Greenland et al. 2016). 
Nevertheless, the BD-PRS is still likely to be underpowered and therefore lack 
of association between the BD-PRS and psychopathology measures might be a 
result of lack of power.
7.5.3 Strengths and limitations
This study has a number of strengths and limitations. This is the first study that 
has investigated associations between a BD-PRS (derived using summary 
statistics from the PGC-2-BD GWAS) and psychopathology from childhood into 
early adulthood. I have therefore used the largest and most recent Bipolar 
Disorder GWAS from the PGC as the discovery dataset (PGC-2-BD) (Stahl et
al. 2019) from which to derive the PRS, thus minimising measurement error and 
maximising power. Nevertheless, the variance explained in BD by the PRS is 
still only 4% and it is therefore likely that there is still substantial measurement 
error. Second, ALSPAC is one of the most phenotypically rich birth cohort 
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studies of its kind, and using this rich phenotypic data allowed me to examine a 
broad range of potential manifestations of increased genetic risk for BD in 
childhood. 
Third, with the exception of the hypomania outcomes, all phenotypes were 
assessed in childhood, and irrespective of which phenotype was examined, all 
measures are well validated which reduces information bias. Nevertheless, it is 
unlikely they perfectly capture psychopathological domains without error, which 
could bias my results. Given the number of phenotypes investigated, multiple 
testing could have led to some false positive results. I specified primary 
measures of exposure (p-thresholds) and outcomes a priori to reduce this, and 
conducted sensitivity analyses where possible (for example using different cut-
off thresholds to define clinically-defined hypomania) to determine whether 
associations were consistent across the thresholds used. I have avoided relying 
on p-value thresholds to determine ‘significance’ of results, but tried to interpret 
the strength of evidence in support of associations in the context of the number 
of associations examined and the study design limitations, as recommended for 
epidemiological studies (Sterne and Smith 2001).
I also investigated the possibility that selection bias might be affecting the 
interpretation of associations between the BD-PRS and psychopathology 
measures. By including a number of auxiliary variables that are associated with 
the measures I examined and with missingness in my imputation model, I have 
made the missing at random assumption more plausible. However, it is possible 
that the imputation model I used might not adequately deal with the missing at 
random assumption, in which case the results in the imputed data would still be 
biased. 
Importantly, my results are only applicable to effects of common variants, which 
means that they do not reflect the possible effects of rare copy number variants 
(CNVs) on risk of BD. These CNVs are usually larger (>100kb) and rarer in the 
population, though findings are inconsistent as to which CNVs are present in 
BD cases (McQuillin et al. 2011; Olsen et al. 2011; Ono et al. 2015). On the 
whole, these inconsistent findings suggest CNVs may not play as important a 
role in susceptibility to BD as compared to schizophrenia (Lowther et al. 2017; 
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Zhuo et al. 2017), though recent evidence has suggested CNVs may play a 
greater role in schizoaffective disorder (Charney et al. 2019). 
7.5.4 Conclusions
Overall, I found little evidence that genetic risk for BD (as captured by the BD-
PRS) manifests as psychopathology in childhood, or dimensional measures of 
hypomania in young adulthood. However, there was some evidence genetic risk 
for BD manifests as inattentive ADHD/clinical hypomania, though it is unclear as 
to the robustness of these findings given they are based on small numbers for 
the former, and inconsistent with other HCL measures for the latter. Therefore, 
further work using large, general population-based longitudinal study designs is 
required to determine the replicability of the findings in this study, and to explore 
whether phenotypic manifestation of increased genetic risk for BD changes with 
age. By studying and understanding the phenotypic manifestations of increased 
genetic risk for BD in childhood/adolescence, it may be possible to inform early 
recognition in those who are at greatest risk of developing the BD.
The next chapter, Chapter 8 will explore associations between increased 
genetic risk for BD and cognitive functioning in childhood.
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Chapter 8: Genetic risk for bipolar disorder and cognitive 
functioning in childhood 
The work presented in this chapter has been published and can be found online 
at 
https://www.sciencedirect.com/science/article/pii/S0165032719301296?via%3Di
hub
Mistry, S., Escott-Price, V., D. Florio, A., Smith, D.J., Zammit, S. (2019). 
Investigating associations between genetic risk for bipolar disorder and 
cognitive functioning in childhood. Journal of Affective Disorders, 259, 112-120
https://doi.org/10.1016/j.jad.2019.08.040
The published article has been adapted for use in this chapter to include 
additional results (available as supplementary materials online). 
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8.1 Chapter summary
Identifying the phenotypic manifestations of genetic risk for bipolar disorder 
(BD) in childhood could increase understanding of aetiological mechanisms 
underlying the disorder. 
In this chapter, I investigated objectives 13-16 as outlined in Chapter 2. To 
derive a BD polygenic risk score (BD-PRS), I used the 2nd Psychiatric 
Genomics Consortium (PGC) BD genome wide association study (GWAS), and 
the Avon Longitudinal Study of Parents and Children (ALSPAC) cohort as a 
target dataset. I also derived a schizophrenia PRS (SZ-PRS) and a SZvsBD 
PRS using summary statistics from the second PGC-SZ GWAS and second 
SZvsBD GWAS respectively. I investigated whether increased genetic risk for 
BD was associated with childhood cognitive functioning. I also examined 
whether associations were due to single nucleotide polymorphism (SNP) risk 
alleles that have shared risk effects on schizophrenia.
At my primary PT, PT≤0.01, I found the BD-PRS was associated with poorer 
executive functioning and, more weakly with poorer processing speed. At my 
secondary PT, PT≤0.5, associations were still with poorer executive functioning, 
and were stronger for poorer processing speed and performance IQ. In the
current study, associations with performance IQ and processing speed were 
primarily driven by genetic effects that are shared with schizophrenia risk, 
whereas those for executive functioning were more specific to BD risk. 
The findings from this chapter suggest that genetic risk for BD manifests as 
impaired cognition in childhood, and this is driven by risk SNP risk alleles that 
are also shared with SZ genetic risk (for performance IQ and processing speed) 
and potentially more specific to BD (for executive functioning). Further 
elucidation of which cognitive domains are most affected by genetic risk for BD 
could help understanding of aetiology and improve prediction of BD.
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8.2 Introduction
From the initial works of Kraepelin who first distinguished dementia praecox
(now schizophrenia) from manic-depressive insanity (now termed bipolar 
disorder (BD), cognitive deficits have long been recognised as being a core part 
of the schizophrenia phenotype. For BD, this was initially viewed as a mood 
disorder with a remitting course, not typically associated with cognitive 
deterioration (Angst 2002). However, a substantial proportion (approximately 
40-60%) of adults with BD exhibit cognitive deficits even when they are 
euthymic (Arts et al. 2008; Bora et al. 2009). Several meta-analyses in adults 
with BD have found impairments in the domains of general intelligence, as 
indexed by intelligence quotient (IQ), processing speed, working memory, 
problem solving, verbal learning, visual learning, executive functioning, and 
social cognition (Bora et al. 2009; Bortolato et al. 2015; Bora and Ozerdem 
2017b). 
Findings from both familial high-risk and cohort study designs have suggested 
cognitive deficits in childhood being a potential precursor to BD (Bora and 
Ozerdem 2017a,b). When compared to studies examining cognitive deficits in 
the premorbid phase in those who eventually develop schizophrenia 
(Khandaker et al. 2011), it is unclear whether differences in premorbid cognitive 
ability in those who eventually go on to develop BD are present (Bortolato et al. 
2015; Martino et al. 2015). As highlighted in a recent review on the trajectory of 
cognitive functioning and BD (Van Rheenen et al. 2019), whilst some studies 
suggest normal (Zammit et al. 2004; Kendler et al. 2016a) or higher cognitive 
abilities and scholastic achievement in those who develop BD compared to 
controls (MacCabe et al. 2010; Gale et al. 2013), others report deficits (Meyer et 
al. 2004; Sharma et al. 2017). 
As described in previous chapters (Chapters 3 and 7), BD is a highly heritable 
disorder (Barnett and Smoller 2009), and through  genome wide association 
studies (GWAS), a number of single nucleotide polymorphism (SNP) risk alleles
(henceforth referred to as SNPs) occurring more frequently in BD cases relative 
to controls have been identified (Sklar et al. 2011; Ruderfer et al. 2018; Stahl et 
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al. 2019). When trait-associated alleles across many genetic loci are summed 
into a single polygenic risk score (PRS), it is possible to examine the effect of 
multiple disease-associated risk SNPs on phenotypes in other samples (Purcell 
et al. 2009; Cross-Disorder Group of the Psychiatric Genomics Consortium 
2013).
As identified in a recent systematic review (see Chapter 6 of this thesis), there 
is a limited understanding of how genetic risk for BD is manifest during 
childhood/adolescence in the general population (Mistry et al. 2018a). Most 
studies have relied on studying relatively small numbers of offspring of adults 
with BD to characterize genetically high-risk individuals (Nurnberger et al. 2011; 
de la Serna et al. 2017). To the best of my knowledge, only one study has 
assessed the associations between a BD-PRS and cognitive measures in 
childhood in the general population. The authors found no association between 
a BD-PRS and a measure of social cognition (emotion recognition) using the 
smaller PGC-1-BD GWAS to derive the PRS (Coleman et al. 2017). 
The objectives of the current study were: i) to examine whether genetic risk for 
BD is associated with a broad range of cognitive domains (general intelligence 
as indexed by IQ, processing speed, working memory, problem solving ability, 
executive functioning, attention, verbal learning and social cognition (emotion 
recognition)), ii) to examine whether the relationship between the BD-PRS and 
cognitive functioning is non-linear i.e. do those at high and low compared to 
average genetic risk for BD have different cognition, iii) to examine the extent to 
which any associations between the BD-PRS and cognitive domains are due to 
risk alleles shared with schizophrenia risk given the high genetic correlation 
between these two disorders (Bulik-Sullivan et al. 2015) and iv) to investigate 
the extent to which my findings might be due to selection bias (objectives 13-
16).
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8.3 Methods 
8.3.1 Participants
In the current study, I used data on individuals from the Avon Longitudinal 
Study of Parents and Children (ALSPAC) cohort. A detailed description of 
recruitment procedures and the inclusion criteria can be found in Chapter 3, 
section 3.2.1. Descriptive statistics for all outcome measures in the entire 
ALSPAC sample are shown in Table 32. 
Table 32 Descriptive statistics for cognitive measures used in the entire ALSPAC sample
ALSPAC: Avon Longitudinal Study of Parents and Children; WISC-III: Wechsler Intelligence 
Scale-III; TIQ: Total Intelligence Quotient; VIQ: Verbal Intelligence Quotient; PIQ: Performance 
Intelligence Quotient; PS: Processing Speed; WM: Working Memory; PrS: Problem Solving; EF: 
Executive Functioning; ATT: Attention; VL: Verbal Learning; ER: Emotion Recognition; TEACh: 
Test of Everyday Attention for Children; CTNWR: Children’s Test of Nonword Repetition; 
DANVA: Diagnostic Analysis of Nonverbal Accuracy
Test N Mean SD Minimum Maximum
WISC-III
PIQ 7,371 99.46 17.12 46 151
VIQ 7,379 106.96 16.80 46 155
TIQ 7,348 103.97 16.54 45 151
PS 7,405 10.50 3.05 1 19
WM 7,174 20.81 6.01 2 38
PrS 7,362 10.54 3.81 1 19
TEACh
EF 7,204 17.47 5.65 8.5 300
ATT 7,184 5.21 1.92 0.60 46.58
CTNWR
VL 7,361 7.23 2.51 0 12
DANVA
ER 6,815 4.60 2.79 0 22
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8.3.2 Cognitive assessments
When the children were aged 8 years, their cognitive functioning was assessed. 
The cognitive domains I examined in this study (general intelligence (IQ), 
processing speed, working memory, problem solving, attention, executive 
function, verbal learning, and social cognition) were selected a priori based on 
the literature of cognitive deficits in adults with BD. As highlighted in Chapter 3, 
section 3.3.3, the cognitive tasks I used cover most of the domains described in 
the Measurement and Treatment Research in Cognition in Schizophrenia 
Research Consensus Battery (MCCB), but do not map precisely onto them. 
Where required, cognitive domain scores were re-coded so that higher scores 
always reflect better cognitive performance.
Chapter 3, section 3.3.3.1 details how ALSPAC researchers derived the 
cognitive domain scores examined by the Wechsler Intelligence Scale - III 
(WISC-III) (Wechsler et al. 1992). From the WISC-III, the following domains 
were investigated:
General intelligence: I used scores for Verbal IQ (VIQ), Performance IQ (PIQ) 
and Total IQ (TIQ) (VIQ and PIQ combined). Details on the subtests which 
make up these measures can be found in Chapter 3, section 3.3.3.1. 
Processing speed: The coding subtest was used which required the children to 
place the correct symbol above each number as quickly as possible within a set 
time period. 
Working memory: This was assessed using the Freedom From Distractibility 
index score that combined scores from both the arithmetic subtest and the digit 
span task.
Problem solving: The block design subtest was used and required the children 
to copy specific patterns of blocks seen on a picture and replicate these 
patterns using real blocks. 
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From the Test of Everyday Attention in Children (TEACh), domains of executive 
functioning and attention were examined. Chapter 3, section 3.3.3.2 details how 
ALSPAC researchers derived these scores: 
Executive function: The opposite world’s task required the children to verbalise 
a number (either 1 or 2) that contradicted what they saw on a screen as quickly 
as possible.
Attention: The sky search task adjusted for motor speed was used and required 
the children to distinguish identical from non-identical spaceships and draw a 
circle around only identical spaceships. 
From the Children’s Test of Nonword Repetition, the nonword reptition task was 
used. Details on how ALSPAC researchers derived this variable can be found in 
Chapter 3, section 3.3.3.3. The task required the child to listen to 12 nonsense 
words and repeat each word back.
From the Diagnostic Analysis of Nonverbal Accuracy (DANVA), I derived a total 
emotion errors score which was the sum total of the scores for each emotion 
(happy, sad, fearful and angry). Further details can be found in Chapter 3, 
section 3.3.3.4.  
8.3.3 Genetic data in ALSPAC
In ALSPAC, 9,912 participants provided genetic data, though after quality 
control, imputation, and restriction to 1 young person per family, genetic data 
were available on 8,230 individuals. Genotyping platforms and quality control 
measures ALSPAC researchers performed can be found in section 3.5.1. 
Consent for biological samples has been collected in accordance with the 
Human Tissue Act (2004). 
8.3.4 Construction of the Polygenic Risk Scores (PRS)
I used summary statistics from the second PGC-BD GWAS (20,352 BD cases 
and 31,358 controls) (Stahl et al. 2019), second PGC SZ GWAS (n = 36,989 
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cases and 113,075 controls) (Ripke et al. 2014), and the second SZvsBD 
GWAS (33,426 SZ cases and 20,129 BD cases) (Ruderfer et al. 2018) to create 
PRSs for each individual in ALSPAC. 
To avoid repetition, the reader is guided to Chapter 7, section 7.3.7.4 for 
clumping parameters used, and Chapter 3, section 3.5.4 for a justification of the 
PT’s used. For the BD-PRS, I retained SNPs with a PT≤0.01 for my primary 
analyses, and for secondary analyses at a PT≤0.5.
For the SZ PRS, I retained SNPs with a PT≤0.05, as this is the threshold which 
maximally captures SZ liability (Ripke et al. 2014), and for the SZvsBD PRS, I 
used SNPs with a PT≤0.5 (Ruderfer et al. 2018) as this is the threshold that 
maximally captures variance for most other phenotypes (Ware et al. 2017).
To generate a PRS for each individual in ALSPAC, I used the --score command 
in PLINK. This PRS is the sum of the total number of risk alleles present for 
each SNP (0, 1, 2) weighted by the log of its odds ratio (OR) for BD/SZ/SZvsBD
from the repspective GWASs. 
8.3.5 Multiple imputation
I used multiple imputation to address the possibility of my results being affected 
by attrition bias. Chapter 3, section 3.6.1.4 provides details on the multiple 
imputation approach. 
8.3.6 Statistical analysis
For all association analyses examined in this chapter, I used STATA statistical 
software (version 14.1 SE. College Station, TX: StataCorp LP). Data for all 
cognitive tasks were standardized, and any individuals with scores >3 standard 
deviations from the mean were omitted. I used linear regression to determine 
associations between the BD-PRS and continuous outcomes, with results 
presented as beta coefficients per standard deviation (SD) increase in PRS. 
The residuals for all cognitive tasks were normally distributed. Further details on 
linear regression can be found in Chapter 3 section 3.6.1.1.1. 
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To examine whether there was a non-linear relationship between the BD-PRS 
and cognitive functioning, I included quadratic terms in the models, with p-
values derived from likelihood ratio tests comparing models with linear and 
quadratic terms to models with linear terms only. To more explicitly test whether 
both higher and lower genetic risk for BD is associated with cognitive 
performance, I also derived tertiles of the BD-PRS, and compared cognitive 
performance in those with higher/lower genetic risk tertile compared to the 
middle (reference category) tertile (see Chapter 3, section 3.6.1.1.2 for further 
details).
To examine the extent to which the strongest association(s) between genetic 
risk for BD and cognitive performance was due to risk alleles for BD that are 
also risk alleles for SZ, I used three approaches:
1. I used a multivariable model to adjust for the SZ-PRS to determine the 
extent to which the effect of the BD-PRS is due to shared effects with SZ. 
2. I conducted a principal components analysis (PCA) to obtain 2 
orthogonal factors that described: i) shared variance (i.e. what is similar 
genetically) between the BD-PRS and SZ-PRS, and ii) non-shared 
variance (what is genetically different) between the two risk scores. From 
herein, the former will be referred to as the shared component and the 
latter as the difference component.
3. My final approach was to use summary statistics from the second PGC 
GWAS of SZ cases vs BD cases to generate a PRS to determine 
whether common genetic variants associated with increased risk of being 
a SZ case relative to a BD case were associated with cognition. From 
herein, this PRS will be referred to as the SZvsBD PRS.
As mentioned in Chapter 3, section 3.4.1, genetic variation is often associated 
with geographical and historical populations. However, the ALSPAC sample 
has been shown to be homogeneous with no significant population stratification, 
and genome-wide analyses of phenotypes indicate a low genomic inflation 
factor (≈1) (Zammit et al. 2014; Martin et al. 2015). Therefore, in my analyses, 
I have not adjusted for population stratification using PCA.
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8.4 Results 
8.4.1 Sample characteristics
From the 8,230 ALSAPC individuals whose genetic data passed quality control 
checks (51.2% male), between 6,555 to 7,405 participated in cognitive 
assessments at age 8 years. When I investigated the extent of correlation 
between cognitive tests, those assessed using the WISC-III were the most 
strongly correlated measures (correlations ranged between 0.25 and 0.89), with 
other cognitive domain measures showing weaker correlations (correlations 
ranged from 0.08 to 0.38) (see Table 33). 
Table 33 Pearson correlations between cognitive tasks
TIQ: Total Intelligence Quotient; VIQ: Verbal Intelligence Quotient; PIQ: Performance 
Intelligence Quotient; PS: Processing Speed; WM: Working Memory; PrS: Problem Solving; EF: 
Executive Functioning; ATT: Attention; VL: Verbal Learning; ER: Emotion Recognition
PIQ VIQ TIQ PS WM PrS EF ATT VL ER
PIQ 1.00
VIQ 0.50 1.00
TIQ 0.84 0.89 1.00
PS 0.44 0.28 0.44 1.00
WM 0.41 0.70 0.65 0.31 1.00
PrS 0.71 0.41 0.63 0.25 0.36 1.00
EF 0.26 0.20 0.27 0.33 0.24 0.19 1.00
ATT 0.27 0.15 0.24 0.34 0.16 0.21 0.25 1.00
VL 0.23 0.38 0.36 0.12 0.41 0.21 0.13 0.08 1.00
ER 0.19 0.17 0.21 0.14 0.14 0.10 0.14 0.11 0.17 1.00
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8.4.2 BD-PRS and cognitive functioning 
Figure 7 shows the proportion of variance explained in cognition by the BD-PRS 
at both PT’s, though full results including individual effect sizes, confidence 
intervals and p-values can be found in Appendices 15 and 16, for PT≤0.01 and 
PT≤0.5 respectively. 
At my primary PT, there was evidence to suggest an association between the 
BD-PRS and poorer executive functioning (β = -0.03, 95%CI -0.06, -0.01; p = 
0.013), and more weakly with poorer processing speed (ß = -0.02, 95%CI -0.05, 
0.02; p = 0.075). There was little evidence to suggest association with other 
cognitive domains (all p >0.115). 
Using my secondary PT, I found evidence of association between increased 
genetic risk for BD and poorer executive functioning (β = -0.03, 95%CI -0.06, -
0.01; p = 0.014), poorer Performance IQ (β = -0.03, 95%CI -0.06, -0.01; p = 
0.018), and poorer processing speed (ß = -0.03, 95%CI -0.04, -0.01; p = 0.016), 
but little evidence of association to suggest the BD-PRS was associated with 
other cognitive domains examined (all p >0.115).  
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Figure 7 R2 values for associations between the BD-PRS and cognitive domains
BD-PRS: Bipolar Disorder Polygenic Risk Score; PT: P value threshold; IQ: Intelligence Quotient
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8.4.3 Investigating possible non-linear relationships  
I next investigated whether there was a non-linear relationship between genetic 
risk and cognitive domains, in which those at low and those at high compared to 
average genetic risk might have different cognitive functioning. Full results can 
be found in Appendix 17 for PT≤0.01, and Appendix 18 for PT≤0.5. 
At both primary and secondary PT’s, I found weak evidence to support non-
linear effects of genetic risk for domains of: Performance IQ (both p quadratic 
<0.065), Total IQ (both p quadratic <0.075) and executive functioning (both p 
quadratic <0.089), but not other cognitive domains examined (all p quadratic 
>0.229). 
8.4.3.1 Tertiles of genetic risk and associations with cognitive outcomes 
To further clarify the non-linear patterns of association identified, I derived 
tertiles of genetic risk for both primary (Appendix 19) and secondary (Appendix 
20) PT’s. The pattern of association was such that those in the highest genetic 
risk tertile had the poorest cognition, whereas those in the lowest genetic risk 
tertile had cognitive scores similar to those in the middle genetic risk tertile. 
8.4.4 Shared and non-shared effects of BD-PRS and SZ-PRS on cognition 
To examine the extent to which associations between the BD-PRS and 
cognition are due to risk alleles shared (or independent) of those with 
schizophrenia risk, I used three approaches. These results are presented in 
Table 34 (approaches 1 and 3) and 35 (approach 2). 
The first approach was to examine the association between the BD-PRS and 
cognition whilst adjusting for the SZ-PRS, and vice versa. In the unadjusted 
(univariable) models, associations between genetic risk for SZ and cognitive 
domains of performance IQ and processing speed were stronger than for the 
BD-PRS, whereas associations for executive function were stronger for the BD-
PRS. After adjusting the BD-PRS for the SZ-PRS in the multivariable model, 
effect sizes for the association between the BD-PRS and performance IQ and 
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processing speed weakened substantially, though the association with 
executive function remained relatively unchanged. 
Following the PCA of both risk scores (BD-PRS and SZ-PRS), I found strong 
evidence of association between the shared component and performance IQ 
(ß = -0.03, 95%CI -0.06, -0.01; p = 0.004) and processing speed (ß = -0.04, 
95%CI -0.06, -0.01; p = 0.001). There was weaker evidence of association 
between the shared component and executive function (ß = -0.03, 95%CI -0.04, 
0.00; p = 0.027), and little evidence of association between the difference 
component and these measures.
Finally, when I investigated associations using a risk score derived from SNPs 
that were more frequent in people with schizophrenia relative to those with BD, I 
found strong evidence of association between the SZvsBD PRS and 
performance IQ (ß= -0.03, 95%CI -0.06, -0.01; p=0.009), but little evidence of 
association with either processing speed or executive function (both p >0.499). 
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Table 34 Associations between genetic risk and cognitive measures when i) adjusting for the other (SZ-PRS or BD-PRS) risk score, and ii) using the SZvsBD PRS
^rounded to 2 decimal places; Associations between genetic risk for BD and cognitive domains of PIQ and PS are reported at PT0.5 and associations with EF are 
reported at PT0.01; a adjusted for the SZ-PRS; b adjusted for the BD-PRS; BD-PRS: Bipolar Disorder-Polygenic Risk Score; SZ-PRS: Schizophrenia -Polygenic 
Risk Score; PT: P-value threshold; IQ: Intelligence Quotient; CI: Confidence Intervals; PT: P-value threshold; PIQ: Performance Intelligence Quotient; PS: Processing 
Speed; SZvsBD PRS: Schizophrenia vs Bipolar Disorder Polygenic Risk Score
Exposure Outcome N ß unadjusted 95%CI P R2 ß adjusted 95%CI P R2
BD-PRS PIQ 5,911 -0.03 -0.06, -0.01 0.018 0.09 -0.02a -0.05, 0.01 0.146 0.22
SZ-PRS PIQ 5,911 -0.04 -0.07, -0.02 0.001 0.19 -0.04b -0.06, -0.01 0.006 0.22
BD-PRS PS 5,935 -0.03 -0.06 -0.01 0.016 0.10 -0.02a -0.05, 0.01 0.127 0.22
SZ-PRS PS 5,936 -0.04 -0.07, -0.02 0.001 0.18 -0.04b -0.06, -0.01 0.007 0.22
BD-PRS EF 5,788 -0.03 -0.06, -0.01 0.013 0.11 -0.03a -0.06, -0.00^ 0.022 0.11
SZ-PRS EF 5,788 -0.01 -0.04, 0.01 0.297 0.02 -0.01b -0.03, 0.02 0.695 0.11
SZvsBD PRS PIQ 5,911 -0.03 -0.06, -0.01 0.009 0.12
SZvsBD PRS PS 5,936 -0.01 -0.02, 0.12 0.499 0.01
SZvsBD PRS EF 5,788 -0.00* -0.03, 0.03 0.919 0
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Table 35 Association between the shared and difference principal components and cognitive measures  
CI: Confidence Intervals; IQ: Intelligence Quotient; PIQ: Performance IQ; PS: Processing Speed; EF: Executive Functioning 
Exposure Outcome N ß unadjusted 95%CI P R2
Shared component
PIQ 5,911
-0.04 -0.06, -0.02 <0.001 0.21
Difference component 0.01 -0.02, 0.04 0.407 0.01
Shared component
PS 5,935
-0.04 -0.06, -0.02 <0.001 0.19
Difference component 0.01 -0.02, 0.04 0.456 0.01
Shared component
EF 5,788
-0.03 -0.05, -0.00b 0.027 0.08
Difference component -0.02 0.05, 0.01 0.241 0.02
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8.4.5 Associations when using imputed data 
For domains which showed the strongest evidence of association, I also 
examined the extent to which associations might be due to selection bias. 
There was little evidence to suggest selection bias was affecting the association 
between genetic risk and cognitive domains as effect sizes in the imputed data 
were identical to those observed in the complete data (see Appendix 21).
8.5 Discussion 
8.5.1 Summary of findings
8.5.1.1 Associations between the BD-PRS and cognition
The first objective of this study was to examine associations between genetic 
risk for BD and cognitive functioning in healthy children from the general 
population. 
I found consistent evidence that increased genetic risk for BD was associated 
with poorer executive functioning (for both primary and secondary PT’s). I found 
less consistent evidence of association between the BD-PRS and poorer 
Performance IQ and poorer processing speed, and little to no evidence to 
suggest associations between the BD-PRS and other cognitive measures at 
either PT.
8.5.1.2 Modelling non-linear effects of genetic risk 
The second objective of this study was to examine whether the relationship 
between genetic risk for BD and cognition is non-linear. I found that for domains 
of performance IQ, total IQ and executive functioning a non-linear effect was 
present. The pattern was such that the association between genetic risk and 
poorer performance in these domains is driven primarily by those at the higher 
end of the genetic risk spectrum. For all other cognitive domains, poorer 
performance was observed across the entire spectrum of genetic risk. 
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8.5.1.3 Shared and non-shared effects of BD-PRS and SZ-PRS on cognition 
For the strongest associations, I examined the extent to which associations 
between genetic risk for BD and cognition were due to those alleles also shared 
with schizophrenia genetic risk. Associations between the BD-PRS and both 
performance IQ and processing speed seem to be driven primarily by the 
genetic component shared with schizophrenia risk, whereas those with 
executive functioning were primarily due to risk alleles that are BD specific. 
8.5.2 Interpreting findings in the context of previous work
Epidemiological studies examining associations between cognition and BD 
suggest that cognitive deficits occur in a substantial proportion (40-60%) of 
adults with BD (Szmulewicz et al. 2015; Bora 2018). When comparing cognitive 
deficits in adults with BD to adults with SZ, they are qualitatively similar, i.e. 
cognitive domains affected are the same, but the severity is typically less in BD 
(Bortolato et al. 2015). 
I found the BD-PRS was more strongly associated with impaired executive 
function than the SZ-PRS was, which remained even after adjusting for the SZ-
PRS. The term executive functioning is often used as a general umbrella term 
that captures 3 core domains: response inhibition, interference control, and 
cognitive flexibility (Diamond 2013). Evidence from meta-analyses and 
systematic reviews show medium to large effect size deficits in executive 
functioning in both BD (Torres et al. 2007) and schizophrenia (Fioravanti et al. 
2012) cases, as well as their first-degree relatives (Bortolato et al. 2015). The 
findings from the review describing executive functioning deficits in people with 
schizophrenia suggest deficits are mainly seen within the domain of cognitive 
flexibility, whereas the review of executive functioning deficits in those with BD 
described deficits across all 3 core domains. This may be of relevance as the 
opposite world’s task that I used to assess executive functioning primarily 
assesses response inhibition, which might explain why I found stronger 
evidence of association with the BD-PRS than the SZ-PRS. Nevertheless, 
deficits in response inhibition have been described in people with schizophrenia 
(Ettinger et al. 2018). 
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My findings for IQ implicate effects of genetic risk for BD on fluid (performance 
IQ) but not crystalised intelligence (verbal IQ), a finding similar to that in healthy 
children from the general population at high genetic risk for SZ (Hubbard et al. 
2016). Furthermore, my findings suggest genetic effects of BD on fluid 
intelligence are driven by risk SNPs shared between both the BD-PRS and SZ-
PRS, i.e. the effects are by and large a result of risk SNPs shared with those of 
schizophrenia risk, with SNPs that are specific to schizophrenia also having an 
effect on this domain. This is consistent with the observation that adults with 
schizophrenia typically have greater IQ deficits compared to adults with BD 
(Bora and Ozerdem 2017b). There are however, instances where severity of IQ 
deficits in adults with BD are quantitatively more similar to adults with 
schizophrenia, and this is often linked to the presence of psychotic symptoms 
(Tsitsipa and Fountoulakis 2015; McCarthy et al. 2016). One study examined 
individuals with BD who had manic psychosis and reported that when compared 
to adults with BD and no history of psychosis, those with manic psychosis had 
higher SZ-PRS (Markota et al. 2018). My findings, alongside these studies 
suggest that both cognitive deficits and presence of psychotic phenomena in 
people with BD are illness severity indicators that are primarily driven by risk 
SNPs that are shared across BD and schizophrenia.  
Interestingly, a previous study using the ALSPAC cohort reported that superior 
IQ was associated with reporting more hypomania symptoms assessed using 
the Hypomania Checklist-32 (HCL-32) (Smith et al. 2015). However, this finding 
does not appear to be consistent with the findings for BD genetic risk in this 
study in that I found that increased genetic risk is associated with poorer and 
not better IQ. In Chapter 5, my findings from modelling linear effects of cognitive 
performance on hypomania suggested that better performance was associated 
with higher HCL scores for domains of verbal learning, problem solving, working 
memory and more weakly with executive functioning. However, for some 
domains, a non-linear effect was detected and suggested that those with the 
poorest cognitive performance had the lowest HCL scores, whilst those with the 
highest cognitive scores had similar HCL scores to those with average cognitive 
ability. One possibility for these inconsistencies is that hypomanic features, as 
captured by measures such as the HCL-32 in community samples, do not 
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accurately index individuals with high propensity to develop full-blown or 
clinically severe BD. 
I also found some weak evidence of association between the BD-PRS and 
poorer processing speed, which was stronger at my secondary PT. However, 
when examining associations whilst adjusting for the SZ-PRS, these
associations attenuated substantially. When examining the most affected 
cognitive domains in BD, processing speed is often reported as one of the most 
impaired domains, evidenced by large effect size from meta-analyses in adults 
with BD (Bora et al. 2009; Bora 2018), and similarly in young people at high 
familial risk of BD (Bora and Ozerdem 2017a). In the current study, I used data 
from children within the general population who are at high genetic risk for BD, 
and my findings suggest that such children do not appear to be as impaired in 
processing speed as they are in executive functioning. 
To the best of my knowledge there has only been one other study which has 
investigated associations between a BD-PRS and social cognition in childhood. 
This study also used the ALSPAC sample but used the smaller PGC-1-BD 
GWAS to derive the PRS, and also found no evidence of association between 
the BD-PRS and emotion recognition (Coleman et al. 2017). Even though I 
used a larger and more powerful GWAS to derive the BD-PRS, I also found little 
evidence for such a relationship between genetic risk for BD and social 
cognition. Social cognition deficits are reported in the literature in adults with 
BD, however, these tend to be for Theory of Mind (Mitchell and Young 2016), 
whereas the measure of social cognition I used in the current study is emotion 
recognition. 
It is possible that weaker evidence of deficits in processing speed, or indeed 
lack of deficits in some domains more generally might be due to developmental 
changes in cognitive processes (Kail 1991; Luna et al. 2004; Chronaki et al. 
2015). Maturation of the brain can often be linked to the first phase of synaptic 
pruning, in which the brain removes additional weaker synapses, axons and 
dendrites (Chechik et al. 1998). This is a gradual process which begins at 
posterior (visual) regions of the brain and will work towards frontal areas over 
time. More complex functions such as response inhibition (executive 
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functioning), working memory, processing speed and attention would therefore 
be last to mature (in the late teens/early twenties) (Anderson et al. 2001; Luna 
et al. 2004). 
8.5.3 Strengths and limitations
When interpreting the findings of this study, it is important to acknowledge the 
strengths as well as the weaknesses of the measures used, and the analyses 
conducted. Firstly, this is the first and largest study of its kind to examine how 
genetic risk for BD is manifest across a broad range of cognitive domains in 
healthy children in the general population, and to examine the extent to which 
these associations are due to shared or non-shared genetic effects with 
schizophrenia. Although I was able to examine multiple domains as identified as 
impaired in adults with BD in the MCCB, I was not able to examine visual 
learning given there was no comparable measure in the ALSPAC cohort. 
Nevertheless, these tests of neurocognitive ability are well validated which 
reduces information bias. 
Second, by using the largest and most up-to-date GWAS for BD (Stahl et al. 
2019), SZ (Ripke et al. 2014) and BDvsSZ (Ruderfer et al. 2018), I have 
maximized power and minimized measurement error in the PRS. Nevertheless, 
even though I used the largest BD GWAS to date to derive the BD-PRS, the 
PRS still only explains a small proportion of variance in BD, and lack of 
evidence of association reported for some cognitive measures might result from 
my analyses being under-powered to detect smaller effect sizes. By using PRS 
in my analyses means my findings only reflect common variant influences on 
childhood neurocognitive outcomes rather than the effects of all genetic risk. A 
recent study has provided some evidence that the role of Copy Number 
Variants (CNVs) may be limited to the schizoaffective bipolar type, rather than 
treating BD as a single diagnostic entity (Charney et al. 2019). 
Third, by using a well characterized general population-based sample for 
analyzing neurocognitive phenotypes at an early age, well before onset of BD, 
this means I can be confident the associations are not biased by presence of 
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cognitive deficits arising as a result of BD (reverse causation) or treatment 
effects. 
Fourth, ALSPAC has a large degree of attrition which might have led to 
selection bias. Previous studies using the ALSPAC sample have shown that 
increased genetic risk for schizophrenia is associated with non-participation by 
both mothers and children in the ALSPAC sample (Martin et al. 2016), and that 
lower cognitive ability is also associated with higher levels of attrition (Boyd et 
al. 2013). However, the findings in this chapter suggest that for my most 
strongly associated measures, selection bias made no difference to the effect 
sizes observed in the imputed data. Though imputation was performed, there is 
still the possibility that selection bias could still be present. 
Fifth, in total, there were a number of cognitive domain outcomes examined 
which could lead to an increase in type I error. The cognitive domains examined 
were selected a priori based on prior literature, however the strength of 
evidence of the associations reported should be interpreted in the context of the 
study limitations, including the testing of multiple cognitive outcomes. Therefore, 
a replication of these findings in other large population-based samples is 
required. 
Sixth, there is no data on whether parents of the children had BD, however, 
given the low lifetime risk of bipolar disorder (1-2%) (Merikangas et al. 2011), it 
seems unlikely that this would have had any significant impact on my results.
As with previous my previous chapters, testing multiple exposure-outcome 
relationships may increase the possibility of findings being due to chance. 
Therefore, exposure and outcome measures were determined a priori in 
accordance with the literature to minimize this. Results are thus discussed 
based on the strength of evidence from statistical testing (rather than based on 
an arbitrary cut-off) within the context of this (and other) study limitations.
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8.5.4 Implications 
As highlighted in section 8.5.2, the severity of deficits for performance IQ and 
processing speed are similar to those observed in healthy children from the 
general population at high genetic risk for schizophrenia (Hubbard et al. 2016). 
The evidence reported in this chapter of cognitive deficits in genetically higher 
risk for BD children from the general population supports other evidence 
suggesting that BD, like schizophrenia, should also be considered as being on 
the neurodevelopmental spectrum (Fioravanti et al. 2012). This is predominantly 
for more severe forms of BD characterized by psychotic symptoms in childhood 
(Arango et al. 2014). 
Overall, my findings are more consistent with epidemiological studies that 
suggest an increased risk of BD in those with lower cognitive ability in childhood 
(Meyer et al. 2004; Sharma et al. 2017) than studies reporting increased BD risk 
in those with higher cognitive ability (MacCabe et al. 2010; Gale et al. 2013). A 
recent study examined risk alleles for BD, schizophrenia and intelligence with 
the findings suggesting that for BD, most risk alleles (9 of 12) were associated 
with better cognition, though 4 of the 12 risk alleles were associated with poorer
cognition. This was in comparison to 61 of 75 SZ risk alleles being associated 
with poorer cognition (Smeland et al. 2019). This might lead to low levels of 
genetic correlation between BD and cognition and hence less consistent 
evidence of association between BD genetic risk and cognition compared to 
schizophrenia genetic risk, as well as less consistent evidence of association 
between childhood cognition and BD compared to that for schizophrenia. 
8.5.5 Conclusions 
Within this study of healthy children from the ALSPAC prospective population-
based birth cohort, I found associations between the BD-PRS and poorer 
executive functioning, performance IQ and processing speed, but less 
consistent evidence of association with other cognitive domains. My results for 
performance IQ and processing speed suggest that these associations appear 
to be driven primarily by the genetic component shared between BD and 
schizophrenia, whereas those for executive functioning appear to be more 
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strongly driven by BD specific alleles. As executive functioning deficits are 
common in individuals with SZ this finding might be a consequence of the 
executive functioning domain (response inhibition) examined in this study.
Further work using both population-based longitudinal studies and clinical 
samples are required to determine the cognitive profiles of those at high genetic 
risk of BD, to inform studies of prediction, improve detection, and facilitate early 
intervention where appropriate.
The next and final chapter, Chapter 9 will be the general discussion chapter. 
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Chapter 9: General Discussion
This chapter will bring together the findings of this thesis and discuss their 
implications, the strengths and limitations of the measures, study sample and 
analytical methods used, and will conclude with possible directions for future 
research in this area. 
9.1 Overview
Bipolar Disorder (BD) is a lifelong mood disorder affecting both the individual 
and impacting on society. Its aetiology is complex and not well understood, 
though a combination of genetic and environmental factors ultimately 
determines whether an individual will go on to develop the disorder. 
Studying high-risk individuals, for example offspring of BD parents or those with 
higher polygenic risk, longitudinally, allows you to determine the temporal 
relationship between psychopathology and disorder. However, there is limited 
research investigating associations between measures of 
psychopathology/cognitive functioning and hypomania in general population 
samples. 
This thesis set out to investigate which measures of psychopathology and 
cognitive functioning are associated with hypomania, defined both categorically 
and dimensionally in children from the general population. It also sought to 
determine whether children at increased genetic risk for BD had greater levels 
of psychopathology and/or altered cognitive functioning compared to those with 
lower genetic risk for BD.
To address these aims, I used the longitudinal birth cohort study the Avon 
Longitudinal Study of Parent And Children (ALSPAC).
In Chapter 4 I examined whether measures of attention deficit hyperactivity 
disorder (ADHD), borderline personality disorder (BPD) traits, depression score
and emotional/behavioural difficulties were associated with measures of 
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hypomania assessed using the Hypomania Checklist (HCL). The results from 
these analyses highlighted that irrespective of how hypomania was defined, a
BPD traits score was consistently associated, and that these associations were 
not explained by confounding or selection bias. 
In Chapter 5 I examined whether cognitive functioning in childhood was 
associated with hypomania, and whether there was a non-linear relationship. 
Better performance on cognitive domains of working memory, problem solving 
ability, verbal learning, executive functioning and emotion recognition was 
associated with a higher HCL score. There was also evidence of non-linear 
effects of cognitive functioning on the HCL score for processing speed and 
working memory, and weaker evidence for attention and verbal learning. The 
evidence suggested that those with the poorest compared to average cognitive 
functioning on these domains had lower HCL scores. 
Chapter 6 investigated the current understanding around the phenotypic 
manifestations of increased genetic risk for BD when using the polygenic risk 
score (PRS) approach. Overall, the results highlighted that genetic risk for BD is 
associated with a broad range of phenotypes, though the greatest proportion of 
the variance explained by the BD-PRS was for psychiatric disorders such as 
schizophrenia and depression. Nevertheless, with the possible exception of one 
study that reported the variance explained in schizophrenia by the BD-PRS to 
be 23% and was a clear outlier, variance explained for other phenotypes was 
typically less than 2%. I also found that there was a sparse literature on studies 
using the PRS approach to investigate associations with childhood phenotypes 
in any population.
Chapter 7 built on the findings of Chapters 4 and 6. I investigated whether 
higher genetic risk for BD was associated with a broad range of 
psychopathology measures from childhood into early adulthood. My findings 
suggest that the BD-PRS was strongly associated with ADHD, and more 
specifically the inattentive rather than hyperactive-impulsive or combined 
subtypes. Furthermore, whilst there was little evidence of association between 
the BD-PRS and HCL score/HCL factors, there was some evidence that it was 
associated with clinically-defined hypomania.
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Finally, Chapter 8 investigated whether increased genetic risk for BD was 
associated with cognitive functioning in childhood, with cognitive domains being 
those examined in Chapter 5. The results suggested that the BD-PRS was 
associated with impaired executive functioning, and less so with poorer 
performance IQ and processing speed. When examining the extent to which 
these associations were due to risk SNPs shared or distinct from those with 
schizophrenia, I found that associations with performance IQ and processing 
speed were largely due to genetic effects shared with that for schizophrenia 
risk, but those for executive functioning appear to be due to bipolar specific 
genetic effects i.e. SNPs not shared with schizophrenia genetic risk. 
9.2 Bringing findings together
Rather than detail the interpretations of each of the findings, which are already 
discussed in previous chapters, this next section will focus on bringing together 
the findings across chapters and briefly outline what this might mean. I found
the strongest associations between measures of psychopathology and 
hypomania were for BPD traits. Given evidence from studies examining Axis II 
comorbidities with BD (Friborg et al. 2014; Bezerra et al. 2015), it is possible 
that presence of BPD traits in childhood might reflect an early manifestation of 
eventual BD. However, when examining associations between the BD-PRS and 
BPD traits, there was little evidence of an association. This suggests that 
presence of BPD traits in childhood is not a consequence of high genetic risk 
for BD, and that the association between the BPD traits score and hypomania in 
Chapter 4 is also unlikely confounded by shared genetic effects. It is more likely 
that the presence of other risk factors, and most likely childhood trauma 
(McDermid et al. 2015) such as emotional/physical abuse (Porter et al. 2020)
has a greater role than genetic risk for BD in determining the expression of 
these BPD traits in childhood. As the association between BPD traits and 
hypomania were hardly attenuated when I adjusted for confounders, including 
bullying in childhood, the most likely explanation for my findings is that 
childhood trauma (or other risk factors) lead to BPD traits which then lead to an 
increased risk of developing BD. It is possible that presence of BPD traits might 
lead someone to misuse substances to deal with how they are feeling (Trull et 
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al. 2018) which in turn might lead to further increasing risk of developing BD 
earlier (Leite et al. 2015).  
Most psychopathology measures examined were associated with the ‘risk-
taking/irritable’ but not ‘active-elated’ factor. This suggests that at a young age, 
prior to onset of clinically relevant symptoms, presence of psychopathology is 
more closely related to “dark-side” than “sunny-side” features (Hantouche et al. 
2003) i.e. presence of psychopathology is more closely aligned to the negative 
aspects of hypomania rather than the positive aspects. 
However, when examining associations between cognitive domains and the 
factor structure of hypomania, associations were with the ‘active-elated’ factor 
but not the ‘risk-taking/irritable’ factor. This suggests that whilst 
psychopathology may reflect the negative aspects of hypomania, cognitive 
functioning appears to be more closely aligned to the positive aspects of 
hypomania. Taken together, this suggests that the aetiology of both positive 
and negative aspects of hypomania may be driven by different mechanisms; 
better cognition and psychopathology respectively.
Associations between cognitive functioning and hypomania indicated that those 
who had better cognitive functioning had higher HCL scores. However, where 
evidence of a non-linear effect was detected, this appeared that this was driven 
primarily by those with the poorest cognitive ability having the lowest HCL 
scores i.e. that those with average and above average cognitive function had 
similar (higher) HCL scores than those with poorer cognitive function. When 
examining associations between genetic risk for BD and cognitive functioning, 
associations were with poorer cognitive functioning, driven by those who have 
the highest genetic risk compared to average genetic risk. Therefore, there 
seems to be some inconsistency in my findings i.e. poorer cognitive ability was 
associated with lower HCL scores, but higher genetic risk for BD was 
associated with poorer cognition and more weakly with clinically-defined 
hypomania which is difficult to explain. One possibility for this inconsistency is 
that hypomania captured using the HCL in general population samples does not 
accurately index individuals with a high propensity to develop BD.
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When examining the manifestations of genetic risk for BD I found that the 
strongest evidence was for childhood cognitive ability, and not for hypomania as 
I would have expected. One reason why genetic risk for BD might be more 
weakly associated with clinically-defined hypomania than with a diagnosis of 
BD, as discussed in Chapter 7, is that hypomania might exist as an extended 
phenotype in the population, and although those with higher genetic risk for BD 
may report more HCL symptoms, other non-genetic factors might have a 
greater influence on these symptoms which “dampens down” this association. 
This suggests that hypomania as assessed using the HCL might be less 
heritable than both BD and cognitive functioning hence the BD-PRS explaining 
less of the variance in hypomania than for BD or cognitive functioning.
Associations were also strong between genetic risk for BD and ADHD, but not 
other measures of psychopathology. This is somewhat surprising given there 
was little evidence of association between ADHD and the HCL with the possible 
exception of the ‘risk-taking/irritable’ factor. However, there is uncertainty as to 
whether ADHD is a reliable future predictor of BD in cohort studies of high-risk 
offspring of BD parents (Duffy 2012). 
Evidence of impairments in domains of performance IQ and processing speed 
appeared to be driven by risk SNPs shared between the BD-PRS and SZ-PRS. 
This might reflect a subgroup of individuals whose developmental trajectory is 
more similar to that seen in schizophrenia than pure BD; for example they may 
be more likely to experience psychotic symptoms or go on to develop a 
schizoaffective (bipolar subtype) disorder (Arango et al. 2014). 
Overall therefore, my findings suggest that there is little evidence that genetic 
risk for BD is manifest in childhood, with the possible exception for poorer 
cognitive ability and possibly inattentive ADHD. However, there is strong 
evidence that a range of childhood psychopathology measures, particularly 
BPD traits is associated with future risk of hypomania.
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9.3 Strengths and Limitations
The work presented in this thesis has a number of strengths and limitations 
which have been discussed at length in Chapters 4-8. For the strengths and 
limitations of individual measures, please see the respective chapters. This next 
section will summarise the strengths and limitations of the study sample, 
measures used and the analyses.
9.3.1 Study sample
The ALSPAC sample is one of the most comprehensive prospective birth cohort 
studies of its kind. The long duration of follow-up and availability of genotype 
data and extensive amounts of phenotypic data collected both prior to birth and 
currently ongoing represent strengths of this sample (Boyd et al. 2013; Fraser et 
al. 2013). One limitation of the ALSPAC sample is that the majority of 
participants recruited are of White ethnicity and it is therefore not clear if my 
findings will extend to other ethnic groups (Martin et al. 2017; Kim et al. 2018). 
Conversely, this homogeneity is also an advantage as it means that population 
stratification is unlikely to be biasing my genetic results. The main limitation 
however, as with most longitudinal studies, is that attrition has occurred which 
might introduce selection bias. When compared to the rest of the ALSPAC 
sample (those with no data on the HCL), the study sample had higher maternal 
social class, older mothers, a smaller proportion of mothers with depression and 
a higher proportion of mothers who were educated to degree level or above 
(see Table 5, Chapter 4). To address the issue of selection bias due to missing 
data, I used multiple imputation by chained approach as outlined in Chapter 3, 
section 3.6.1.4. Having investigated the impact of selection bias, my findings 
suggest that with the possible exception for ADHD, selection bias had little 
impact on the associations observed in the imputed data and did not drastically 
alter the interpretation of the findings.
9.3.2 Measures used
Measures of psychopathology and cognitive functioning were all examined 
using well validated measures which means I can be confident that the 
measures these tests report to assess are being assessed. Nevertheless, it is 
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unlikely these measures perfectly capture psychopathological or cognitive 
domains without error, which could bias my findings.  
Assessments of psychopathology and cognitive functioning were conducted 
between ages 7-11, long before the likely development of hypomania. This 
therefore reduces the likelihood of associations between measures of 
psychopathology/cognitive functioning and hypomania being a result of reverse 
causality i.e. presence of hypomania causing psychopathology/changes in 
cognitive functioning. 
The cognitive domains I examined were selected a priori based on their 
resemblance to the domains examined using the Measurement and Treatment 
Research to Improve Cognition in Schizophrenia Consensus Battery (MCCB). 
However, the domains examined by the MCCB reflect those most affected in 
individuals with schizophrenia. It is possible therefore that I am underestimating 
the association between genetic risk for BD and some cognitive sub-domains as 
a result of the tasks I used not adequately capturing the domains most affected 
in BD. I was also not able to examine the cognitive domain of visual learning as 
there was no comparable measure in the ALSPAC sample. A previous 
systematic review of studies using the MCCB reported deficits in visual learning 
of large effect size in those with BD compared to controls (Bo et al. 2017).
For my genetic analyses (Chapters 7 and 8), I used the largest and most up-to-
date GWASs for BD (Stahl et al. 2019), schizophrenia (Ripke et al. 2014) and 
SZvsBD (Ruderfer et al. 2018) which provides the greatest statistical power and 
predictive accuracy for the phenotypes of interest. As has been shown through 
simulations, increasing the sample size of the discovery/target dataset does 
produce greater predictive accuracy (Dudbridge 2013,2016). Therefore, further 
increases in sample size may help to support or provide evidence against the 
associations reported in this thesis. 
9.3.3 Analyses
Throughout this thesis, I have tried to adopt a thorough analytical strategy. I 
have investigated the assumptions of the statistical methods I used, and in 
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doing so can be more confident that my findings are accurate. I also 
investigated the possibility of non-linear effects of cognitive functioning on 
hypomania, and also non-linear effects of genetic risk on cognitive functioning 
to make sure that it was possible to determine whether associations between 
cognitive functioning and hypomania or genetic risk for BD and cognitive 
functioning was present across the entire spectrum of cognitive 
functions/genetic risk or confined to those with values in the extremities.
For analyses in Chapters 4 and 5, I adjusted my analyses for a range of 
sociodemographic and environmental confounders to reduce the likelihood of 
my findings being a result of confounding, and therefore strengthen inferences 
of causality. Though I adjusted for a range of potential confounders, there may 
well be some residual confounding which was not accounted for.
In Chapters 4, 5, 7 and 8, I tested associations between multiple independent 
phenotypes and various outcome measures. I did not correct for multiple testing 
in my analyses as the measures were determined a priori based on the 
literature. Furthermore, adjustment for multiple testing is built upon the 
foundation that a p-value threshold of 0.05 has a clear interpretation. Therefore, 
throughout my analyses, I have provided effect sizes and confidence intervals 
and not just p-values, and taken care to word my findings in terms of the 
strength of evidence of association rather than relating them to arbitrary 
thresholds for ‘significance’, so that the reader can interpret my findings 
appropriately (Sterne and Smith 2001; Wasserstein and Lazar 2016). However, 
as discussed in previous chapters, where weaker evidence of association is 
reported, this may well be due to chance, particularly in the context of testing 
multiple outcomes. Independent replication of these associations is therefore 
needed.
For my systematic review in Chapter 6, I followed PRISMA guidelines for 
reporting the findings in systematic reviews. In doing so, I was able to provide a 
comprehensive view of what the phenotypic manifestations of increased genetic 
risk for BD might be in different populations. However meta-analysis was not 
possible which meant I could not test for presence of publication bias. Presence 
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of publication bias might mean information on phenotypes not associated with 
increased genetic risk for BD will not have been captured.
9.4 Implications of my findings 
The findings in this thesis may have some implications for research and 
perhaps also clinically too, as highlighted in this next section. 
From my analyses in Chapter 4, there was consistent evidence that BPD traits 
were strongly associated with hypomania irrespective of how this was defined, 
and most measures of psychopathology were associated with the ‘risk-
taking/irritable’ factor. One possible research implication is that studying factor 
structure of hypomania in different populations might be more useful for 
understanding aetiological mechanisms underlying BD than examining 
hypomania as a single construct, particularly as associations with most 
psychopathology measures were often observed with the ‘risk-taking/irritable’ 
factor but not with the total HCL score. 
One potential clinical implication of these findings is that whilst a number of 
individual BPD traits were strongly associated with the HCL score, fear of 
abandonment was not. Therefore, the presence or absence of this trait might 
turn out to be a useful discriminator for clinicians to use when they are unsure 
as to whether someone has BPD or BD, or where children/adolescents show 
signs of BPD traits but have a family history of BD. A second potential clinical 
implication of the findings is that if clinicians are aware of a positive family 
history of BD, children presenting with presence of psychopathology such as 
BPD traits, ADHD and a range of behavioural difficulties are likely at higher risk 
of developing BD compared to those children presenting with no family history 
of BD. 
In Chapter 5, I found that better cognitive performance on specific domains 
rather than globally was associated with higher HCL score, and that some 
relationships were non-linear. Whilst a larger body of research exists examining 
associations between IQ and subsequent BD (Zammit et al. 2004; Mortensen et 
al. 2005; MacCabe et al. 2010; Gale et al. 2013), the findings in this thesis 
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highlight that studying specific cognitive domains that extend beyond simply IQ 
might be important to further increase understanding of the aetiology and 
prediction of BD. 
From Chapter 6, it is clear that researchers have not generally reported results 
from genetic-phenotypic association studies in a way that would allow a meta-
analysis to be conducted or results across studies to be compared. From a 
research perspective, use of the framework I suggested (Mistry et al. 2018b)
and Table 23 might improve reporting and perhaps stronger evidence of 
associations may arise from this. It was also clear that there are few studies 
which have investigated associations between the BD-PRS and 
childhood/adolescent phenotypes and therefore this might stimulate/encourage 
other research groups to investigate these associations. 
My findings from Chapter 7 suggest that overall there is little evidence that 
genetic risk for BD is manifest in childhood and therefore an implication for 
research might be to examine manifestations of increased genetic risk for BD at 
a later time point. It might also suggest that genetic risk for BD doesn’t manifest 
until onset of (or very close to onset of) clinical symptoms. 
A further research implication is that the weak evidence of association between 
the BD-PRS and hypomania outcomes calls into question the usefulness of the 
HCL in identifying individuals from the general population who have hypomania 
or are at higher risk of developing BD (see Chapter 7 section 7.5.2.1) (Lee et al. 
2016). Therefore, more studies, particularly using general population samples 
are required to determine this, particularly as there are few studies that have 
used the HCL in a general population sample.
My findings in Chapter 7 are inconsistent with studies of high-risk offspring of 
BD parents and suggest that the presence of psychopathology in high-risk 
offspring might be more likely to be due to the family environment arising from 
parental psychopathology rather than the child’s own genetic risk per se. 
Therefore, a potential clinical implication might be to offer more support to 
parents with BD, particularly as evidence from high-risk offspring studies have 
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shown that longer duration of exposure to parental BD illness is associated with 
increased risk of psychopathology in the offspring (Goodday et al. 2018).
In Chapter 8, my findings were that increased genetic risk for BD was 
associated, in a non-linear pattern, with poorer cognitive functioning in specific 
domains. Therefore, one research implication of these findings is that it might 
be important to determine whether the effect of genetic risk on phenotypes 
exists across the entire spectrum of genetic risk, or is confined to those at the 
extremities. Another potential research implication is that it might be possible to 
identify specific phenotypes that result from increased genetic risk for BD 
independent of (i.e. not due to shared effects with) schizophrenia genetic risk,
which could help with prediction. The findings from this chapter also highlight 
that where cognitive difficulties are detected during childhood, it might be 
important to closely monitor children if they have a parent with BD to improve 
early detection and provide further support mechanisms if required. 
Although I have provided some potential clinical implications of my findings,
there are a number of disadvantages to screening and monitoring which are: i) 
it can lead to worrying parents/children unnecessarily and ii) there can be 
substantial cost and difficulties in the practicality of using these tools. Thus, for 
screening to be justified, the following would be required: i) there should be 
robust evidence that it can usefully predict something in the future e.g. disorder,
ii) there should be something that can then be done about it i.e. there might be 
little point in telling someone they are at high risk for something if there is not 
something that can be offered to them to reduce the risk, and iii) it should be 
cost-efficient and practically feasible for it to happen. 
9.5 Future research 
The work in this PhD highlights the need for future studies to further investigate 
whether measures of psychopathology/cognition during childhood in general 
population samples have causal effects on BD, how any such effects are 
mediated, and whether these measures could help predict who is most likely to 
develop this disorder. 
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Ideally, well-characterised general population cohort studies are required to 
further understanding of these questions which should account for known 
confounders in the relationship between exposure and outcome. This should 
then increase the likelihood of being able to draw causal inferences between 
given exposure and outcome measures. However, as BD is an uncommon 
outcome this will undoubtedly prove difficult given the costs and time required to 
recruit large enough samples to be followed up for adequate periods of time. 
Whilst using self-report measures such as the HCL may help to capture the 
entire spectrum of (hypo)manic experiences and is likely more common in the 
general population than BD, it is not yet clear as to how valid a measure the 
HCL is in general population samples at measuring BD pathology. Therefore,
future studies may wish to investigate the ability of the HCL to distinguish true 
BD cases from controls drawn from the general population, given that 
community rates may be as high as 5-10% (Mistry et al. 2019; Richards et al. 
2019). As a screening tool, it has been well validated in clinical samples 
internationally. However, there are few studies which have examined its use in 
general population samples, and the one study where they did showed good 
sensitivity (0.82) but poor specificity (0.36) (Lee et al. 2016). Therefore, more 
studies are required to determine whether its use in general population samples 
can be justified, as its psychometric properties are not nearly as good when 
compared to use in clinical samples (see Meyer et al. (2014)) for a review on its 
psychometric properties.
Further studies are also needed to increase our understanding of how genetic 
risk for BD is manifest during childhood/adolescence. In fact, since the end date 
of the search of the systematic review described in Chapter 6, which has now 
been published (Mistry et al. 2018a), there have been a number of additional 
studies that have investigated associations between a BD-PRS and a variety 
phenotypes. These studies have reported associations between a BD-PRS and 
i) substance use/addiction (Reginsson et al. 2017; Polimanti et al. 2018a), ii) 
exposure to increased number of hours of daylight (Polimanti et al. 2018b), iii) 
higher scores of self-reported tiredness (Deary et al. 2017), iv) fewer days in a 
relationship (Hjorthoj et al. 2019), v) reduced odds of gambling, and more 
weakly with disordered gambling (Piasecki et al. 2019) and vi) a lower BD-PRS 
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was associated with reporting more severe childhood maltreatment (Aas et al. 
2020). 
Other studies have reported little or inconsistent evidence of association 
between the BD-PRS and i) telomere length (Palmos et al. 2018), ii) loneliness 
(Abdellaoui et al. 2018), iii) theory of mind in adolescence (Warrier and Baron-
Cohen 2018), iv) childhood internalising and externalising symptoms (Jansen et 
al. 2018), v) emotion recognition (Coleman et al. 2017), vi) cognitive executive 
functioning (Benca et al. 2017), vii) sleep preference (being a night owl vs being 
an early bird) (Melroy-Greif et al. 2017), viii) frequency of mood episodes 
(Smedler et al. 2019), ix) female reproductive health during adulthood (Ni et al. 
2019), x) age of onset of BD (either when treated as a continuous or binary 
(<18 years vs >18 years) outcome) (Kalman et al. 2019), xi) a range of 
cardiometabolic traits (So et al. 2019), xii) lower scores on the Mood Disorder 
Questionnaire (either self-rated or parent-rated) assessed at age 18 years 
(Taylor et al. 2019) and xiii) a range of potential cognitive endophenotypes 
(Ranlund et al. 2018). At present however, it is not known which of these 
findings are robust.
As highlighted in Chapter 1 of this thesis, there are also a range of 
environmental risk factors for BD, though investigations into these effects pale 
in comparison to a much larger literature for schizophrenia (see Marangoni et 
al. (2018) for a review of these). Associations between childhood 
abuse/maltreatment have gained more interest in recent years. However, as 
highlighted in a systematic review and meta-analysis, 19 studies examining the 
associations between childhood abuse and BD were retrospective in design. 
Nevertheless, those with BD are fourfold more likely than those with no 
psychiatric illness to have experienced emotional abuse. Therefore, clinicians
when faced with new patients exhibiting symptoms of BD may wish to consider 
enquiring about past abusive experiences and documenting the types of abuse 
e.g. physical, emotional etc. It will be difficult to establish causal links between 
abuse and BD, particularly as childhood abuse is also more frequently reported 
in those with depression and SZ compared to those with no history of 
psychiatric illness (Palmier-Claus et al. 2016). However, given that different 
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types of abuse may confer differences in BD risk, it will be important to 
investigate this further.
As mentioned throughout this thesis, chip type is being increasingly used as a 
covariate in analyses concerning PRS and future research should aim to 
include this in the analysis where possible (Choi et al. 2018). Studies may also 
begin to tease apart disorder specific effects of genetic risk on phenotype by 
using methods such as those described and conducted in Chapter 8 of this 
thesis. An often heard term in psychiatric research is to identify 
endophenotypes, and running these types of analyses may help to satisfy some 
of the proposed criteria as outlined by Gottesman and Gould (Gottesman and 
Gould 2003). Alternatively, as conducted by Hamshere and colleagues, for the 
SZ-PRS, they derived refined SZ-PRSs based on whether the direction of effect 
of risk alleles was the same or different between the BD and SZ GWAS
(Hamshere et al. 2013).
Overall, it is evident that there are still relatively few studies which are taking 
advantage of the PRS approach and investigating possible phenotypic 
manifestations of increased genetic risk for BD in childhood/adolescence. 
Furthermore, of the more recent studies mentioned in this section (section 9.5), 
few have used the 2nd PGC BD GWAS to derive the PRS.. Even in those that 
have done so, the proportion of variance explained in these phenotypes by the 
BD-PRS is small (<3%). This could indicate one of two possibilities: i) either 
discovery and/or target sample sizes need to increase substantially to increase 
the proportion of variance explained in these phenotypes, or ii) the PRS 
approach may not be useful in identifying early phenotypic signs of BD 
pathology in individuals who are at higher genetic risk of developing BD.
9.6 Concluding remarks 
BD is a complex multifactorial disease and a clear understanding of its aetiology 
remains lacking. Within this thesis, I examined whether a broad range of 
psychopathologies and cognitive domains were associated with dimensional 
and categorical measures of hypomania in the general population. I also sought 
to summarise the published literature describing the phenotypic manifestations 
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of increased genetic liability for BD, and examined the extent to which 
increased genetic risk for BD was associated with psychopathology and 
cognitive measures in childhood. 
Overall my results suggest that different aspects of hypomania may be 
expressed as specific cognitive domains and psychopathology examined in 
childhood/adolescence. My results also suggest that there is little evidence that 
genetic risk for BD is manifest in childhood/adolescence, with the possible 
exception of poorer cognitive functioning, particularly executive functioning, and 
possibly inattentive ADHD. 
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Appendices 
Appendix 1 Structure of the full Hypomania Checklist-32 (HCL-32) questionnaire
At different times in their life everyone experiences changes or swings in energy, activity and 
mood (“highs and lows” or “ups and down”). The aim of this questionnaire is to assess the 
characteristics of the “high” periods. 
1. First of all, how are you feeling today compared to your usual state: 
Much 
worse than 
usual
Worse 
than usual
A little 
worse than 
usual
Neither 
better nor 
worse than 
usual
A little 
better than 
usual
Better than 
usual
Much 
better than 
usual
2. How are you usually compared to other people? 
Independently of how you feel today, please tell us how you are normally compared to other 
people, by marking which of the following statements describes you best? 
Compared to other people my level of activity, energy and mood… 
Is always rather 
stable and even Is generally higher Is generally lower
Repeatedly shows 
periods of ups and 
downs
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Appendix 1 continued 
3. Please try to remember a period when you were in a “high” state. In such a state:
Question Yes No
Please try to remember a period of time when you were in a “high” 
state. In such a state:
1. I need less sleep
2. I feel more energetic and more active
3. I am more self-confident
4. I enjoy my work more
5. I am more sociable (make more phone calls, go out more
6. I want to travel and/or do travel more
7. I tend to drive faster or take more risks when driving
8. I spend more money/too much money
9. I take more risks in my daily life (in my work and/or other activities)
10. I am physically more active (sports etc)
11. I plan more activities or projects
12. I have more ideas, I am more creative
13. I am less shy or inhibited
14. I wear more colourful and more extravagant clothes/make up
15. I want to meet or do actually meet more people
16. I am more interested in sex
17. I am more flirtatious and/or am more sexually active
18. I talk more
19. I think faster
20. I make more jokes or puns when I am talking
21. I am more easily distracted
22. I engage in lots of new things
23. My thoughts jump from topic to topic
24. I do things more quickly and/or more easily
25. I am more impatient and/or irritable more easily
26. I can be exhausting or irritating for others
27. I get into more quarrels
28. My mood is higher, more optimistic
29. I drink more coffee
30. I smoke more cigarettes
31. I drink more alcohol
32. I take more drugs (sedatives, anxiolytics, stimulants)
If you have never experienced a “high” please stop here
4. Impact of your “highs” on various aspects of your life: 
Positive and 
negative Positive Negative No impact
Family life
Social life
Work
Leisure
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Appendix 1 continued 
5. How did people close to you react to or comment on your “highs?” 
Positively 
(encouraging or 
supportive
Neutral
Negatively 
concerned, 
annoyed, 
irritated, 
critical
Positively and 
negatively No reactions
6. Lengths of your “highs” as a rule (on average)
1 day
2-3 days
4-7 days
Longer than 1 
week
Longer than 1 
month
I can’t 
judge/don’t 
know
7. Have you experienced such “highs” in the past twelve months? 
Yes No
8. If yes, please estimate how many days you spend in “highs” during the last twelve 
months: 
Taken all together: about _________ days 
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Appendix 2 Association between BPD exposures and clinically-defined hypomania at varying 
threshold cut off scores on the HCL
BPD: Borderline Personality Disorder; HCL: Hypomania Checklist; OR: Odds Ratio; CI: 
Confidence Intervals 
Exposure Outcome N OR 95% CI P
High-risk for 
BPD HCL score 
16/28
2,543
3.72 2.25, 6.16 <0.001
BPD traits 
score 1.36 1.19, 1.55 <0.001
High-risk for 
BPD HCL score 
18/28
3.40 1.91, 6.05 <0.001
BPD traits 
score 1.32 1.13, 1.54 <0.001
High-risk for 
BPD HCL score 
20/28
4.54 2.42, 8.50 <0.001
BPD traits 
score 1.41 1.19, 1.67 <0.001
High-risk for 
BPD HCL score 
20/28
5.00 2.36, 10.58 <0.001
BPD traits 
score 1.50 1.23, 1.84 <0.001
High-risk for 
BPD HCL score 
20/28
3.39 1.16, 9.91 0.026
BPD traits 
score 1.43 1.10, 1.87 0.008
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Appendix 3 Association between individual BPD traits and a) the HCL score and b) clinically-
defined hypomania
a (% of individuals with a rating of probably present or definitely present); BPD: Borderline 
Personality Disorder; HCL: Hypomania Checklist
Exposure N (%a)  95%CI P value
Anger 2,542 (22.5%) 0.13 0.06, 0.19 <0.001
Affective 
instability
2,540 
(19.8%) 0.15 0.08, 0.23 <0.001
Emptiness 2,539 (7.72%) 0.13 0.02, 0.24 0.020
Identity 
disturbance
2,538 
(8.07%) 0.23 0.12, 0.34 <0.001
Paranoid 
ideation
2,534 
(11.9%) 0.17 0.07, 0.26 <0.001
Fear of 
abandonment
2,534 
(7.1%) 0.02 -0.10, 0.15 0.737
Suicidal 
behaviour
2,529 
(3.8%) 0.13 -0.01, 0.27 0.064
Impulsivity 2,530 (18.2%) 0.07 0.01, 0.13 0.016
Intense 
interpersonal 
relationships
2,530 
(12.9%) 0.16 0.07, 0.25 0.001
Exposure N (%a) OR 95%CI P value
Anger 2,542 (22.5%) 1.19 0.92, 1.53 0.178
Affective 
instability
2,540 
(19.8%) 1.45 1.14, 1.86 0.003
Emptiness 2,539 (7.72%) 2.00 1.48, 2.69 <0.001
Identity 
disturbance
2,538 
(8.07%) 1.71 1.24, 2.38 0.001
Paranoid 
ideation
2,534 
(11.9%) 1.41 1.03, 1.93 0.030
Fear of 
abandonment 
2,534 
(7.1%) 1.76 1.22, 2.55 0.003
Suicidal 
behaviour 
2,529 
(3.8%) 1.84 1.26, 2.69 0.002
Impulsivity 2,530 (18.2%) 1.16 0.94, 1.43 0.160
Intense 
interpersonal 
relationships 
2,530 
(12.9%) 1.57 1.17, 2.10 0.003
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Appendix 4 Association between SDQ subscales and hypomania 
^ rounded to 2 decimal places; SDQ: Strengths and Difficulties Questionnaire; HCL: Hypomania Checklist; CI: Confidence Intervals; OR: Odds Ratio
Exposure Outcome N  95% CI P value
Hyperactivity 
Problems
HCL score
2,914 -0.00^ -0.04, 0.38 0.950
Prosocial behaviour 2,917 -0.07 -0.10, -0.03 <0.001
Emotional 
difficulties 2,913 0.03 -0.01, 0.06 0.176
Conduct problems 2,918 0.00^ -0.03, 0.05 0.522
Peer relationship 
difficulties 2,913 0.02 -0.01, 0.06 0.205
Exposure Outcome N OR 95% CI P value
Hyperactivity 
Problems
Clinically-defined 
hypomania
2,914 1.04 0.89, 1.22 0.601
Prosocial behaviour 2,917 1.08 0.93, 1.25 0.317
Emotional 
difficulties 2,913 1.04 0.90, 1.20 0.595
Conduct problems 2,918 1.38 1.21, 1.58 <0.001
Peer relationship 
difficulties 2,913 1.11 0.96, 1.28 0.146
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Appendix 4 continued 
^ rounded to 2 decimal places; SDQ: Strengths and Difficulties Questionnaire; HCL: Hypomania Checklist; CI: Confidence Intervals
Exposure Outcome N  95% CI P value
Hyperactivity 
problems
Active/elated
2591
-0.05 -0.09, -0.01 0.013
Risk-taking/irritable 0.11 0.08, 0.15 <0.001
Prosocial behavior
Active/elated
2594
0.06 0.02, 0.10 0.002
Risk-taking/irritable 0.06 0.03, 0.10 <0.001
Emotional 
difficulties
Active/elated
2591
0.02 -0.02, 0.06 0.254
Risk-taking/irritable 0.03 -0.01, 0.06 0.122
Conduct problems
Active/elated
2595
-0.02 -0.06, 0.02 0.285
Risk-taking/irritable 0.08 0.04, 0.12 <0.001
Peer relationship 
difficulties
Active/elated
2592
0.02 -0.02, 0.06 0.309
Risk-taking/irritable 0.04 0.01, 0.08 0.017
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Appendix 5 Association between low and high cognitive performance and total HCL score
^rounded to 2 decimal places; HCL: Hypomania Checklist; CI: Confidence Intervals; 
*Adjusted for: gender, maternal education level, maternal age at birth, maternal social class, child being emotionally abused, child being physically abused, child 
being a victim of bullying and being left-handed
Outcome N Exposure  unadjusted 95%CI P  adjusted* 95%CI P
Processing 
speed 5,936
Lowest -0.11 -0.23, 0.00^ 0.060 -0.12 -0.24, -0.01 0.039
Highest -0.02 -0.12, 0.08 0.691 -0.02 -0.12, 0.09 0.735
Working 
memory 2,644
Lowest -0.21 -0.33, -0.00^ 0.001 -0.21 -0.33, -0.09 0.001
Highest 0.08 -0.03, 0.19 0.136 0.05 -0.06, 0.15 0.379
Attention 5,773
Lowest -0.08 -0.20, 0.04 0.174 -0.11 -0.23, 0.01 0.068
Highest -0.09 -0.20, 0.02 0.099 -0.10 -0.21, 0.00^ 0.058
Verbal 
learning 5,925
Lowest -0.19 -0.29, -0.09 <0.001 -0.16 -0.26, -0.05 0.003
Highest 0.03 -0.09, 0.14 0.659 0.02 -0.09, 0.14 0.718
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Appendix 6 Association between cognitive functioning and HCL factors 
^rounded to 2 decimal places; HCL: Hypomania Checklist; CI: Confidence Intervals 
*Adjusted for: gender, maternal education level, maternal age at birth, maternal social class, child being emotionally abused, child being physically abused, child 
being a victim of bullying and being left-handed
Exposure HCL factor N ß unadjusted 95%CI P ß adjusted* 95%CI P
Processing 
speed
Active/elated
1,642
0.05 0.00^, 0.10 0.037 0.05 0.00^, 0.10 0.039
Risk-
taking/irritable -0.01 -0.05, 0.03 0.667 0.00^ -0.04, 0.05 0.892
Working 
memory
Active/elated
1,598
0.14 0.09, 0.18 <0.001 0.11 0.07, 0.16 <0.001
Risk-
taking/irritable -0.04 -0.08, 0.00^ 0.070 -0.03 -0.07, 0.01 0.179
Problem 
Solving
Active/elated
1,631
0.14 0.10, 0.17 <0.001 0.11 0.07, 0.16 <0.001
Risk-
taking/irritable 0.00^ -0.04, 0.05 0.870 0.00^ -0.04, 0.05 0.721
Executive 
functioning
Active/elated
1,591
0.10 0.03, 0.17 0.003 0.10 0.03, 0.17 0.006
Risk-
taking/irritable -0.05 -0.11, 0.01 0.120 -0.04 -0.11, 0.03 0.232
Attention
Active/elated
1,577
0.03 -0.01, 0.09 0.230 0.02 -0.04, 0.08 0.480
Risk-
taking/irritable -0.01 -0.06, 0.04 0.724 0.04 -0.02, 0.09 0.154
Verbal learning
Active/elated
1,637
0.13 0.08, 0.17 <0.001 0.10 0.05, 0.15 <0.001
Risk-
taking/irritable -0.03 -0.07, 0.02 0.207 -0.02 -0.06, 0.03 0.448
Emotion 
recognition
Active/elated
1,530
0.08 0.03, 0.13 0.003 0.08 0.03, 0.13 0.001
Risk-
taking/irritable 0.03 -0.02, 0.07 0.298 0.03 -0.01, 0.08 0.175
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Appendix 7 Association between linear and quadratic terms for cognitive domains and clinically-defined hypomania 
Exposure N OR unadjusted 95%CI P OR adjusted* 95%CI P
Processing 
speed 1,848
Linear 0.81 0.67, 0.98 0.029 0.85 0.70, 1.03 0.091
Quadratic 0.99 0.86, 1.14 0.891 0.99 0.86, 1.15 0.927
Working 
memory 1,802
Linear 0.84 0.70, 1.01 0.061 0.88 0.73, 1.07 0.199
Quadratic 1.05 0.92, 1.20 0.457 1.04 0.90, 1.19 0.610
Problem solving 1,836
Linear 0.92 0.76, 1.11 0.388 0.94 0.77, 1.15 0.546
Quadratic 1.00 0.87, 1.14 0.957 0.99 0.77, 1.14 0.942
Executive 
functioning 1,796
Linear 0.85 0.62, 1.16 0.302 0.87 0.63, 1.20 0.400
Quadratic 0.97 0.81, 1.15 0.708 0.96 0.82, 1.13 0.638
Attention 1,782
Linear 0.82 0.62, 1.09 0.175 0.82 0.61, 1.09 0.583
Quadratic 0.94 0.83, 1.06 0.326 0.94 0.82, 1.06 0.063
Verbal learning 1,845
Linear 0.89 0.74, 1.09 0.259 0.93 0.76, 1.14 0.501
Quadratic 0.93 0.79, 1.10 0.406 0.93 0.78, 1.10 0.376
Emotion 
recognition 1,721
Linear 0.94 0.73, 1.20 0.623 0.97 0.75, 1.24 0.783
Quadratic 0.80 0.64, 1.00 0.046 0.79 0.63, 0.98 0.035
^rounded to 2 decimal places; HCL: Hypomania Checklist; CI: Confidence Intervals; OR: Odds Ratio
*Adjusted for: gender, maternal education level, maternal age at birth, maternal social class, child being emotionally abused, child being physically abused, child 
being a victim of bullying and being left-handed
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Appendix 8 Associations between childhood cognitive functioning and HCL score comparing adjusted non-imputed with adjusted imputed 
^rounded to 2 decimal places; HCL: Hypomania Checklist; CI: Confidence Intervals
*Adjusted for: gender, maternal education level, maternal age at birth, maternal social class, child being emotionally abused, child being physically abused, child 
being a victim of bullying and being left-handed
Exposure Outcome N  non-imputed 95%CI P value N  imputed* 95%CI P value
Processing 
speed
HCL score
1,848 0.04 -0.00^, 0.09 0.078
2,631
0.02 -0.02, 0.06 0.117
Working 
memory 1,802 0.09 0.04, 0.14 <0.001 0.08 0.04, 0.12 <0.001
Problem 
Solving 1,836 0.10 0.05, 0.14 <0.001 0.10 0.06, 0.14 <0.001
Executive 
functioning 1,796 0.06 0.01, 0.10 0.021 0.04 -0.00^, 0.09 0.056
Attention 1,782 0.02 -0.04, 0.08 0.480 0.02 -0.03, 0.06 0.443
Verbal 
learning 1,845 0.08 0.03, 0.13 0.001 0.07 0.03, 0.11 <0.001
Emotion 
recognition 1,721 0.07 0.02, 0.12 0.005 0.06 0.02, 0.10 0.005
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Appendix 9 Associations between childhood cognitive functioning and HCL factors comparing adjusted non-imputed with adjusted imputed 
^rounded to 2 decimal places; HCL: Hypomania Checklist; CI: Confidence Intervals
*Adjusted for: gender, maternal education level, maternal age at birth, maternal social class, child being emotionally abused, child being physically abused, child 
being a victim of bullying and being left-handed
Exposure HCL factor N ß non-imputed 95%CI P N ß imputed* 95%CI P
Processing 
speed
Active/elated 1,642 0.05 0.00^, 0.10 0.037
2,331
0.05 0.00^, 0.10 0.039
Risk-taking 0.00^ -0.04, 0.05 0.892 -0.01 -0.05, 0.02 0.479
Working 
memory
Active/elated 1,598 0.14 0.09, 0.18 <0.001 0.11 0.07, 0.16 <0.001
Risk-taking -0.04 -0.08, 0.00^ 0.070 -0.03 -0.07, 0.01 0.179
Problem 
Solving
Active/elated 1,631 0.14 0.10, 0.17 <0.001 0.11 0.07, 0.16 <0.001
Risk-taking 0.00^ -0.04, 0.05 0.870 0.00^ -0.04, 0.05 0.721
Executive 
functioning
Active/elated 1,591 0.10 0.03, 0.17 0.003 0.10 0.03, 0.17 0.006
Risk-taking -0.05 -0.11, 0.01 0.120 -0.04 -0.11, 0.03 0.232
Attention
Active/elated
1,577
0.04 -0.02, 0.09 0.154 0.03 -0.02, 0.07 0.236
Risk-taking 0.00^ -0.05, 0.05 0.979 0.00^ -0.04, 0.04 0.974
Verbal 
Learning 
Active/elated
1,637
0.10 0.05, 0.15 <0.001 0.08 0.04, 0.13 <0.001
Risk-taking -0.02 -0.06, 0.03 0.448 -0.02 -0.06, 0.02 0.351
Emotion 
recognition
Active/elated
1,530
0.08 0.03, 0.13 0.001 0.07 0.02, 0.11 0.003
Risk-taking 0.03 -0.01, 0.08 0.175 0.02 -0.02, 0.06 0.434
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Appendix 10 Associations between cognitive functioning and clinically-defined hypomania comparing adjusted non-imputed with adjusted imputed
^rounded to 2 decimal places; HCL: Hypomania Checklist; CI: Confidence Intervals; OR: Odds Ratio
*Adjusted for: gender, maternal education level, maternal age at birth, maternal social class, child being emotionally abused, child being physically abused, child 
being a victim of bullying and being left-handed
Exposure Outcome N OR non-imputed 95%CI P value N
OR 
imputed* 95%CI P value
Processing 
speed 
Clinically-defined 
hypomania 
1,848 0.83 0.70, 1.03 0.089
2,631
0.87 0.74, 1.03 0.113
Working 
memory 1,802 0.89 0.74, 1.08 0.236 0.91 0.77, 1.09 0.310
Problem 
Solving 1,836 0.94 0.77, 1.14 0.532 0.96 0.81, 1.13 0.594
Executive 
functioning 1,796 0.98 0.84, 1.15 0.827 0.99 0.85, 1.15 0.891
Attention 1,782 0.92 0.74, 1.13 0.405 0.99 0.82, 1.19 0.934
Verbal 
learning 1,845 0.91 0.75, 1.09 0.305 1.01 0.85, 1.19 0.912
Emotion 
recognition 1,721 1.08 0.88, 1.33 0.459 1.05 0.89, 1.24 0.587
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Appendix 11 Search strategy terms and delimiters used for searching Embase, Medline via 
Ovid and PsychINFO
GWAS: Genome-Wide Association Study
Key word
1. Explode Psychotic disorders
2. Explode bipolar disorder
3. mania.mp
4. manic.mp
5. Explode schizophrenia
6. Psychosis.mp
7. hypoman*.mp
8. Explode schizophren*.mp
9. depress*.mp
10. 10 or/ 1-9 
11. polygenic risk score.mp
12. risk profile score.mp
13. polygenic variation.mp
14. GWAS.mp
15. gene score.mp
16. genetic score.mp
17. allele score.mp
18. SNPb score.mp
19. explode single nucleotide polymorphism 
20. polygenic.mp
21. 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 
22. 10 and 21
23. limit 22 as follows: 
- years= ‘2009- 16th March 2016’
- English language 
- Peer reviewed journal articles
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Appendix 12 Inclusion/exclusion criteria 
Factors Assessment
Type of study
1. Has the study been peer reviewed and 
is it already published?
NB: Both must apply.
Yes           Unclear       No
Exclude
2. Does the study present data on an 
association between a risk score (derived 
from GWAS data of participants with a 
diagnosis of bipolar (either I or II) and a 
measurable phenotype?
Yes       Unclear            No
Exclude
3.  Does the study report a risk score and 
the same phenotype in both the discovery 
and target sample?
Yes         Unclear         No
Exclude
4. Does the study present an association 
between a risk score and imaging 
modalities?
Yes           Unclear      No
Exclude
5. Is the paper in English?
Yes          Unclear        No
Exclude                                      
GWAS; Genome Wide Association Studies, SNP; Single Nucleotide Polymorphism
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Appendix 13 Associations between the BD-PRS and hypomania outcomes at PT≤0.5
*Threshold score used to defined clinically-defined hypomania was a score of ≥14/28 on the HCL; BD-PRS: Bipolar Disorder-Polygenic Risk Score; HCL: 
Hypomania Checklist; OR: Odds Ratio; PT: P-value threshold
Exposure Outcome N β 95%CI P R2 (%)
BD-PRS at 
PT0.5
HCL score 2654 0.02 -0.02, 0.06 0.336 0.03
Active/elated factor
2363
0.02 -0.02, 0.06 0.292 0.05
Risk-taking/irritable
factor 0.01 -0.03, 0.05 0.572 0.01
Outcome N with outcome (%) OR 95%CI P r
2 (%)
BD-PRS at 
PT0.5
Clinically-defined 
hypomania 239 (7.1) 1.13 0.98, 1.32 0.097 0.20
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Appendix 14 Results of sensitivity analyses using different threshold cut-off scores on the HCL
Exposure Outcome
N with 
outcome if 
binary (%)
OR 95%CI P R2 (%)
BD-PRS at 
PT0.01
Threshold 
≥14/28 239 (7.1) 1.07 0.92, 1.24 0.382 0.22
Threshold 
≥16/28 198 (5.9) 1.08 0.92, 1.27 0.348 0.07
Threshold 
≥18/28 150 (4.4) 1.13 0.94, 1.36 0.193 0.17
Threshold 
≥20/28 101 (3.0) 1.32 1.06, 1.64 0.013 0.83
Threshold 
≥22/28 60 (1.8) 1.24 0.94, 1.64 0.120 0.47
Threshold 
≥24/28 34 (1.0) 1.12 0.78, 1.61 0.541 0.11
BD-PRS at 
PT0.5
Threshold 
≥14/28 239 (7.1) 1.13 0.98, 1.32 0.097 0.20
Threshold 
≥16/28 198 (5.9) 1.14 0.97, 1.34 0.105 0.22
Threshold 
≥18/28 150 (4.4) 1.20 1.00, 1.44 0.053 0.38
Threshold 
≥20/28 101 (3.0) 1.33 1.07, 1.65 0.01 0.89
Threshold 
≥22/28 60 (1.8) 1.34 1.02, 1.76 0.036 0.86
Threshold 
≥24/28 34 (1.0) 1.09 0.76, 1.56 0.645 0.06
HCL: Hypomania Checklist; BD-PRS: Bipolar Disorder-Polygenic Risk Score; PT: P-value 
threshold; CI: Confidence Interval; OR: Odds Ratio
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Appendix 15 Association between the BD-PRS and cognitive measures at PT0.01
^rounded to 2 decimal places; BD-PRS: Bipolar Disorder-Polygenic Risk Score; IQ: Intelligence 
Quotient; CI: Confidence Intervals; PT: P-value threshold
Outcome N ß 95%CI P R2
Total IQ 5,895 -0.01 -0.03, 0.02 0.485 0.01
Verbal IQ 5,921 0.00^ -0.02, 0.03 0.922 0.00
Performance IQ 5,911 -0.02 -0.04, 0.01 0.204 0.03
Processing speed 5,936 -0.02 -0.05, 0.00^ 0.075 0.05
Working memory 5,763 -0.00^ -0.03, 0.03 0.959 0.00
Problem solving 5,905 0.01 -0.02, 0.03 0.514 0.01
Executive 
functioning
5,788 -0.03 -0.06, -0.01 0.013 0.11
Attention 5,767 -0.02 -0.04, 0.01 0.146 0.04
Verbal learning 5,925 0.02 -0.01, 0.04 0.173 0.03
Emotion recognition 5,457 -0.02 -0.05, 0.01 0.134 0.04
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Appendix 16 Association between the BD-PRS and cognitive measures at PT0.5
^rounded to 2 decimal places; BD-PRS: Bipolar Disorder-Polygenic Risk Score; IQ: Intelligence 
Quotient; CI: Confidence Intervals; PT: P-value threshold 
Outcome N ß 95%CI P R2
Total IQ 5,895 -0.02 -0.04, 0.01 0.147 0.04
Verbal IQ 5,921 -0.00^ -0.03, 0.02 0.858 0.00
Performance IQ 5,911 -0.03 -0.06, -0.01 0.018 0.09
Processing speed 5,936 -0.03 -0.06 -0.01 0.016 0.10
Working memory 5,763 -0.01 -0.04, 0.01 0.329 0.02
Problem solving 5,905 -0.01 -0.03, 0.02 0.570 0.01
Executive 
functioning
5,788 -0.03 -0.06, -0.01 0.014 0.10
Attention 5,767 -0.02 -0.05, 0.01 0.115 0.04
Verbal learning 5,925 0.01 -0.02, 0.03 0.505 0.01
Emotion recognition 5,457 -0.02 -0.04, 0.01 0.250 0.02
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Appendix 17 Examining quadratic effects of the BD-PRS on cognitive domains at PT0.01
Exposure N Exposure ß 95%CI P R2
Performance IQ 5,911
Linear -0.02 -0.04, 0.01 0.204
0.08
Quadratic -0.02 -0.04, 0.00^ 0.066
Verbal IQ 5,921
Linear 0.00^ -0.02, 0.03 0.922
0.02
Quadratic 0.00^ -0.03, 0.01 0.229
Total IQ 5,895
Linear -0.01 -0.03, 0.02 0.485
0.06
Quadratic -0.02 -0.03, 0.00^ 0.077
Processing speed 5,936
Linear -0.02 -0.05, 0.02 0.075
0.05
Quadratic -0.01 -0.00^, 0.02 0.961
Working memory 5,763
Linear -0.00^ -0.03, 0.03 0.959
0.00
Quadratic -0.00^ -0.02, 0.01 0.638
Problem solving 5,905
Linear 0.01 -0.02, 0.03 0.514
0.03
Quadratic -0.01 -0.03, 0.01 0.289
Executive 
functioning 5,788
Linear -0.03 -0.06, -0.01 0.013
0.16
Quadratic -0.02 -0.04, 0.00^ 0.089
Attention
5,773 Linear -0.02 -0.04, 0.01 0.149
0.04
Quadratic 0.01 -0.01, 0.02 0.473
Verbal learning 5,925
Linear 0.02 -0.01, 0.04 0.173
0.05
Quadratic 0.01 -0.01, 0.03 0.292
Emotion recognition 5,963
Linear -0.02 -0.05, 0.01 0.134
0.04
Quadratic -0.01 -0.02, 0.01 0.773
^rounded to 2 decimal places; P-value reported for the linear model includes only the BD-PRS; P-value for the quadratic term is from likelihood ratio tests comparing 
models with linear and quadratic terms to models with linear terms only; BD-PRS: Bipolar Disorder-Polygenic Risk Score; IQ: Intelligence Quotient; CI: Confidence 
Intervals; PT: P-value threshold
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Appendix 18 Examining the non-linear effects of the BD-PRS on cognitive domains at PT0.5
^rounded to 2 decimal places; P-value reported for the linear term includes only the BD-PRS; P-value for the quadratic term is from likelihood ratio tests comparing 
models with linear and quadratic terms to models with linear terms only; BD-PRS: Bipolar Disorder-Polygenic Risk Score; IQ: Intelligence Quotient; CI: Confidence 
Intervals; PT: P-value threshold 
Exposure N Exposure ß 95%CI P R2
Performance IQ 5,911
Linear -0.03 -0.06, -0.01 0.018
0.15
Quadratic -0.02 -0.04, 0.00^ 0.063
Verbal IQ 5,921
Linear -0.00^ -0.03, 0.02 0.857
0.02
Quadratic -0.01 -0.03, 0.01 0.229
Total IQ 5,895
Linear -0.02 -0.04, 0.01 0.147
0.09
Quadratic -0.02 -0.03, 0.00^ 0.075
Processing speed 5,936
Linear -0.03 -0.06, -0.01 0.016
0.10
Quadratic -0.00^ -0.02, 0.02 0.943
Working memory 5,763
Linear -0.01 -0.04, 0.01 0.330
0.02
Quadratic -0.00^ -0.02, 0.01 0.638
Problem solving 5,905
Linear -0.01 -0.03, 0.02 0.570
0.02
Quadratic -0.01 -0.03, 0.01 0.293
Executive 
functioning 5,788
Linear -0.03 -0.06, -0.01 0.014
0.16
Quadratic -0.02 -0.04, 0.00* 0.083
Attention
5,773 Linear -0.02 -0.05, 0.15 0.123
0.05
Quadratic 0.01 -0.01, 0.01 0.466
Verbal learning 5,925
Linear 0.01 -0.02, 0.03 0.508
0.03
Quadratic 0.01 -0.01, 0.03 0.284
Emotion 
recognition 5,963
Linear -0.02 -0.04, 0.01 0.250
0.03
Quadratic -0.00^ -0.02, 0.02 0.758
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Appendix 19 Association between tertiles of the BD-PRS at PT0.01 and cognitive domains
Exposure N Exposure ß 95%CI P R2
Performance IQ 5,911
Lowest GR 0.00^ -0.06, 0.06 0.923
0.08
Highest GR -0.06 -0.12, 0.00 0.064
Verbal IQ 5,921
Lowest GR 0.01 -0.05, 0.07 0.790
0.01
Highest GR -0.02 -0.08, 0.04 0.524
Total IQ 5,895
Lowest GR 0.01 -0.06, 0.07 0.844
0.06
Highest GR -0.05 -0.11, 0.02 0.138
Processing speed 5,936
Lowest GR 0.04 -0.02, 0.10 0.228
0.07
Highest GR -0.03 -0.09, 0.04 0.415
Working memory 5,763
Lowest GR -0.00^ -0.07, 0.06 0.920
0.04
Highest GR -0.04 -0.10, 0.02 0.210
Problem solving 5,905
Lowest GR 0.01 -0.05, 0.08 0.659
0.01
Highest GR -0.01 -0.07, 0.05 0.785
Executive 
functioning 5,788
Lowest GR 0.01 -0.06, 0.07 0.852
0.06
Highest GR -0.05 -0.12, 0.01 0.120
Attention
5,773 Lowest GR 0.02 -0.04, 0.08 0.209
0.03
Highest GR -0.02 -0.08, 0.04 0.527
Verbal learning 5,925
Lowest GR -0.02 -0.08, 0.04 0.518
0.02
Highest GR 0.01 -0.05, 0.07 0.736
Emotion 
recognition 5,963
Lowest GR 0.04 -0.02, 0.11 0.185
0.08
Highest GR -0.02 -0.09, 0.04 0.459
^rounded to two decimal places BD-PRS: Bipolar Disorder-Polygenic Risk Score; IQ: Intelligence Quotient; CI: Confidence Intervals; PT: P-value threshold; GR: 
Genetic Risk
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Appendix 20 Association between tertiles of the BD-PRS at PT0.5 and cognitive domains 
Exposure N Exposure β 95%CI P R2
Performance IQ 5,911
Lowest GR -0.01 -0.07, 0.05 0.725
0.18
Highest GR -0.10 -0.16, -0.03 0.003
Verbal IQ 5,921
Lowest GR 0.02 -0.04, 0.08 0.509
0.02
Highest GR -0.01 -0.07, 0.05 0.763
Total IQ 5,895
Lowest GR 0.01 -0.05, 0.07 0.695
0.09
Highest GR -0.06 -0.12, 0.01 0.073
Processing 
speed 5,936
Lowest GR 0.06 -0.00^, 0.12 0.055
0.14
Highest GR -0.03 -0.09, 0.03 0.360
Working 
memory 5,763
Lowest GR 0.03 -0.03, 0.09 0.358
0.02
Highest GR -0.00^ -0.07, 0.06 0.964
Problem 
solving 5,905
Lowest GR 0.01 -0.05, 0.07 0.719
0.04
Highest GR -0.03 -0.10, 0.03 0.270
Executive 
functioning 5,788
Lowest GR 0.00^ -0.06, 0.07 0.883
0.07
Highest GR -0.06 -0.12, 0.01 0.084
Attention
5,773 Lowest GR 0.04 -0.02, 0.10 0.209
0.06
Highest GR -0.02 -0.08, 0.05 0.608
Verbal learning 5,925
Lowest GR 0.02 -0.04, 0.08 0.564
0.06
Highest GR 0.06 -0.00^, 0.12 0.061
Emotion 
recognition 5,963
Lowest GR -0.07 -0.13, -0.00^ 0.046
0.14
Highest GR -0.09 -0.15, -0.02 0.007
^rounded to two decimal places BD-PRS: Bipolar Disorder-Polygenic Risk Score; IQ: Intelligence Quotient; CI: Confidence Intervals; PT: P-value threshold; GR: 
Genetic Risk
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Appendix 21 Associations between genetic risk and cognitive domains comparing non-imputed with imputed data 
^rounded to 2 decimal places; Associations between genetic risk for BD and cognitive domains of PIQ and PS are reported at PT0.5 and associations with EF are 
reported at PT0.01; a adjusted for the SZ-PRS; b adjusted for the BD-PRS; BD-PRS: Bipolar Disorder-Polygenic Risk Score; SZ-PRS: Schizophrenia -Polygenic 
Risk Score; PT: P-value threshold; IQ: Intelligence Quotient; CI: Confidence Intervals; PIQ: Performance Intelligence Quotient; PS: Processing Speed; SZvsBD PRS: 
Schizophrenia vs Bipolar Disorder Polygenic Risk Score
Exposure Outcome N ß non-imputed 95%CI P N ß imputed 95%CI P
BD-PRS PIQ 5,911 -0.02a -0.05, 0.01 0.146
7,370
-0.02a -0.05, 0.01 0.176
SZ-PRS PIQ 5,911 -0.04b -0.06, -0.01 0.006 -0.04b -0.06, -0.01 0.006
BD-PRS PS 5,935 -0.02a -0.05, 0.01 0.127
7,403
-0.02a -0.05, 0.01 0.208
SZ-PRS PS 5,936 -0.04b -0.06, -0.01 0.007 -0.04b -0.06, -0.01 0.009
BD-PRS EF 5,788 -0.03a -0.06, -0.00^ 0.022
7,202
-0.03a -0.05, -0.00^ 0.027
SZ-PRS EF 5,788 -0.01b -0.03, 0.02 0.695 -0.01b -0.03, 0.02 0.661
SZvsBD PRS PIQ 5,911 -0.03 -0.06, -0.01 0.009 7,370 -0.03 -0.06, -0.01 0.009
SZvsBD PRS PS 5,936 -0.01 -0.03, 0.02 0.499 7,403 -0.01 -0.04, 0.02 0.400
SZvsBD PRS EF 5,788 -0.00^ -0.03, 0.03 0.919 7,202 -0.00^ -0.03, 0.02 0.845
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